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ABSTRACT 
 Perinatal depression is a complex mood disorder often treated with Selective 
Serotonin Reuptake Inhibitor (SSRI) antidepressants, which block the serotonin 
transporter (SERT) and alter synaptic serotonin concentrations. The serotonergic 
system is highly plastic and serotonin regulates the growth and maturation of neurons 
and signaling systems from conception through end of life. Notably, interference with 
serotonin levels during an SSRI sensitive window (SSW) of development in humans and 
rodents has been linked to neurovegetative effects which increase susceptibility for the 
manifestation of anxiety- and depressive-like behaviors and can be persistent 
throughout life. We hypothesize the persistent behavioral perturbations resulting from 
acute SSRI challenge during the SSW are the culmination of gene expression changes 
altering epigenetic modifications in the genome. Historically, inferences have been 
drawn from comparing postnatal SSRI treated wild-type (WT) mice to those that lack a 
functioning SERT. This model is problematic, as SERT knock-out (KO) mice display 
numerous physiological deficits prior to the SSW due to the trophic developmental role 
of serotonin. In this study, we attempt to characterize a more appropriate mouse model 
by utilizing RNA-Seq analysis to compare midbrain and hippocampus transcriptomes of 
WT and KO mice to the transgenic SERT I172M mouse that harbors a fully functioning 
transporter while rendering SERT resistant to many SSRIs. We further characterized 
pertinent metabolites to determine brain levels, and if I172M selectivity was maintained 
and revealed, desmethylcitalopram accumulates in the brain over time and not all SSRI 
metabolites maintain I172M selectivity. The primary focus of this study was the 
transcriptomic characterization of the I172M mouse, which is necessary before 
xvi
beginning postnatal SSRI treatment studies. Overall our findings unveil KO mice have 
significant aberrant neuronal signaling and neurotransmitter metabolism. Moreover, KO 
mice display dysregulated protein and RNA processing due to midbrain aggregation of 
misfolded truncated SERT protein and ectopic hippocampal Sert mRNA expression, 
respectively. Interestingly, comparison of differentially expressed genes in the midbrain 
and hippocampus of WT/I172M and WT/KO revealed that the Sert locus may share 
expression quantitative trait loci with Neurexin 1 (Nrxn1) and the transcription factor D-
Box Binding PAR BZIP (Dbp), which is independent of Sert expression. Collectively, our 
data demonstrate WT and I172M mice share similar transcriptomes and validate the 
ability of the I172M model, over SERT KO, to appropriately detect SERT-SSRI mediated 




Depression and Anxiety Disorders 
Anxiety disorders which include separation anxiety, phobias, social anxiety, 
selective mutism, panic disorder and generalized anxiety disorder (GAD)[1] and 
depressive disorders which include disruptive mood dysregulation, major 
depressive disorder (MDD), persistent depressive disorder (dysthymia), 
premenstrual dysphoric disorder and unspecified depressive disorders[1] 
comprise a global mental health burden affecting approximately 7.2% of the 
world's population[2, 3]. Today that percentage equates to 558 million people 
suffering from either excessive fear and worry (anxiety) or feelings of sadness, 
emptiness, irritability and lack of self-worth (depression). It has been estimated 
that depression and anxiety are comorbid in 133 million affected individuals[1, 4, 5]. 
Anxiety and depression are the two most prevalent mental health concerns in the 
world and cause significant socioeconomic burdens associated with in- and 
outpatient medical services, pharmaceuticals, work absenteeism, workplace 
productivity loss, and depression-related suicide[3, 6]. In the late 1990’s, the 
estimated annual cost of anxiety and depressive disorders in the United States 
was $45 billion and $49 billion dollars, respectively[7-10]. These numbers 
increased to $173.2 billion in 2005 and $210.5 billion by 2010 with depression 
prevalence rates among adults of 6.4% and 6.8%, respectively during those 
1
years[6, 11]. As world population increases, so too will the incidence rate of anxiety 
and depression (A&D) along with the burden of these mental health disorders.  
In 2017, the National Institute of Mental Health (NIMH) reported the 
percentage of U.S. population aged 18 and older with anxiety at 19.1% and 
depression at 7.1%[12] (Table 1.1). Females exhibit higher prevalence rates 
among females with 23.4% for anxiety and 8.7% for depression, whereas in 
males the rates are 14.3% and 5.3%, respectively. Alarmingly, the 2017 study 
reported prevalence rates amongst 12-17 year old adolescents, 31.9% with 
anxiety and 13.3% with depression[12]. The incidence of both mental health 
disorders in the U.S. is significantly higher in female adolescents, 38% with 
anxiety and 20% with depression, in comparison to adolescent males with 26.1% 
and 6.8%, respectively. These trends are not unique to the United States, as 
European reports for 2010 identified 14.0% of the population suffered from some 
form of anxiety, with 6.9% affected by a depressive disorder[13]. In Canada in 
2013, the lifetime prevalence rate for depression was estimated at 8% for the 
adult population[14]. For Canadian youth aged 12-19, the prevalence was 17%, 
again with a higher percent of the female population 12.0% having depression in 
comparison to male youth at 5%[14]. In China, the lifetime prevalence of A&D was 
7.6% and 6.8% respectively for the years 2013-2015[15]. In India in 2017, 
documentation from clinical visits estimated 3.3% of the population suffered from 
anxiety or depressive disorders, and again the prevalence rates were higher in 
females 3.9% than males 2.7%[16]. Moreover, for women the perinatal period is a 
time of increased susceptibility for developing depressive disorders[17-22]. 
Worldwide, an estimated 11.9% of expecting women are diagnosed with a form 
of depression at some point throughout their pregnancy[22]. The prevalence rate 
of perinatal depression (PD) in low- to mid-income countries is 15.6%[23], and the 
2
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Females Males Overall Females Males Overall
18 ≤ 8.7% 5.3% 7.1% 23.4% 14.3% 19.1%
12 – 17 20.0% 6.8% 13.3% 38.0% 26.1% 31.9%
Gender based statistics reported by the National Institute of Mental Health (NIMH) for adults 
aged 18 and older versus adolescents aged 12-17. Major Depression: https://www.nimh.nih.gov/
health/statistics/major-depression)
United States ranges from 14-23%[20]. An international consortium study 
evaluating PD onset identified 48% of the sample population with first trimester 
onset had severe anxious depression, which dropped to 38% for second 
trimester onset, 20% for third trimester onset, and 12% for 0-4 weeks post-
partum onset, in the sample population with 4-8 weeks post-partum onset, 28% 
of the women had severe anxious depression and the percentage rose to 46% 
for post-partum onset beyond 8 weeks[21].  
Although the morbidity of these mental health disorders may vary with 
age, race, gender, culture, religion, location, and socioeconomic status, they are 
nonetheless the most burdensome diseases worldwide[13, 16, 24]. And while anxiety 
may affect a larger portion of the population overall, depression has a greater 
impact on society as the leading cause of disability[5, 6] and is projected by the 
World Health Organization to be the single most contributing factor to the global 
disease burden by the year 2030[25]. The disabling effects of depression are often 
a result of long-term feelings of inadequacy, sadness and despair. Many 
individuals do not seek help for fear of the stigma that will follow them[26], while 
other individuals take antidepressants (AD) without relief of depressive 
symptoms[27]. The incapacitating nature of MDD can leave people feeling there is 
no escape, often leading to suicidal ideation[28] and suicide attempts[28, 29]. It 
should not be surprising that roughly 50% of the world’s suicides are linked to 
depressive disorders[6]. Furthermore, suicide is the world’s second leading cause 
of death amongst 15-29 year-olds[24], which incidentally overlaps with the typical 
age of onset or initial diagnoses for A&D, which is 12-25 years of age[30, 31].  
It is important to note here that while the formation of neurons and glial 
cells, as well as the migration and differentiation of neurons involved in brain 
development is mostly complete by 5 months of age[32, 33], the maturation of cells 
4
continues well beyond this age and in some regions the formation of synapses, 
myelination of axons, apoptosis, and synaptic pruning continues through early 
adulthood (18-25 years of age)[34, 35] (Table 1.2). Moreover, these processes are 
associated with lifelong neuroplasticity which can positively or negatively impact 
brain function in response to experiences[32, 36-38]. Components of neuroplasticity 
involved in the structural reorganization of neurological connections can occur in 
any region of the brain throughout life[36, 37], whereas neurogenesis in the fully 
developed human brain is only known to occur in the hippocampus (HPC)[39-41]. 
Mechanisms of neuroplasticity make the brain highly susceptible to aberrant 
sculpting from negative external stimuli or traumatic events, especially in 
individuals under the age of 25[34, 35]. External stimuli are processed in the brain 
as electrochemical signals involving intra-cellular signaling cascades that 
produce post-translational modifications of proteins, alterations in gene 
expression, protein synthesis and the release of neurotrophins and 
neurotransmitters resulting in the migration, maturation, pruning and myelination 
of neurons (Figure 1.1), thus altering synaptic connections culminating in 
memory consolidation, re-consolidation and recall[32, 38, 42]. Ultimately these 
mechanisms of cellular plasticity mediate unconscious physiological responses 
that are interpreted as feelings or emotions about situations and our 
environment, shaping our view of the world and how we behave in it[43]. 
Execution of emotionally driven behaviors occur due to the highly diverse 
neural circuitry of limbic system components and their integration with motor 
control centers of the cerebral cortex and cerebellum[32, 43]. More specifically, 
processes of memory consolidation and behavioral sculpting occurs via 
communication between the frontal lobes of the brain and limbic system 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































complex cognitive behaviors, decision making, impulse control, reward 
processing, for carrying out expressions of personalities and emotions, and the 
execution of voluntary muscle movements[43-45]. Whereas the limbic system 
impacts how we respond psychologically and behaviorally to external stimuli 
through memory encoding and retrieval, processes which are influenced by the 
interpretation and regulation of complex processes such as learning, cognition, 
motivation, attention, and emotion[42-45]. The neural organization that exists 
between the frontal lobes and structures of the limbic system allows emotions to 
influence cognitive and motor functions, and as a result A&D are capable of 
negatively impacting the performance of daily routine tasks and ability to function 
in a normal capacity. 
Pathological neural connections and defective neuronal signaling in the 
brain are associated with abnormal behavioral, emotional and mental health 
disturbances. For anxiety disorders, these disturbances include excessive fear 
and worry, muscle tension, hypervigilance and increased avoidance, all of which 
can lead to panic attacks[1]. The disturbances attributable to depressive disorders 
are changes in affect and cognition that are characterized by depressed (low) 
mood, loss of interest or pleasure in activities, changes in weight, irregular 
circadian rhythms, psychomotor agitation, fatigue, diminished energy, reduced 
concentration, feelings of helplessness, worthlessness or guilt and sometimes 
recurrent thoughts of death or suicide[1]. Unfortunately, the consequences of A&D 
can persist for years and if left untreated or is of the treatment-resistant kind, can 
exacerbate the neurovegetative effects responsible for the psychological 
disturbances implicated in these disorders. Neurovegetative effects vary amongst 
different forms of stress, anxiety and depressive disorders, are region-dependent 
and may include irregularities in brain metabolism[46, 47], cerebral blood flow[44, 47], 
7
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GABAergic interneurons including those expressing parvalbumin 
(PV), somatostatin (SOM), and vasoactive intestinal peptide (VIP) drive 
cortical osscilations, maintain excitatory-inhibitory balance in cortical 
circuits, and regulate activiy-dependent plasticity through inhibition.
Peri-neuronal nets (PNN) are components of the extracellular matrix 
that densely surround neurons, particularly PV+ cells, and provide a 
physical barrier to plasticity by stabilizing synapses.
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Neuromodulatory inputs and neuromodulators are critical for many 
forms of cortical plasticity in the mature barin and mediate plasticity 
thorugh the recruitment of neural pathways associated with states of 
cognition including motivation, attention, and emotion.
l i l l i i
i
i i l i i l i l
Myelin and myelin associated proteins play an important rold in 
neuronal connectivity and inhibit large-scale plasticity by limiting axonal 
growth and regenergation, especially after injury in adult animals. 
fpsyg-08-01657 September 28, 2017 Time: 16:2 # 3
Voss et al. The Changing Rules of Neuroplasticity
FIGURE 1 | Continued
Frontiers in Psychology | www.frontiersin.org 3 October 2017 | Volume 8 | Article 1657
Glial cells including astrocytes and microglia are being increasingly 
understood to contribute to synaptic plasticity through monitoring the 
extracellular milieu and absorbing and releasing synaptically active 
molecules. Astrocytes are known to communicate with neurons by 
releasing gliotransmitters, especially glutamate. Microglia are involved 
in neuroimmune responsees following brain injury and are capable of 
physically remodeling synapses. 
Neurotrophins such as Brain-Derived Neurotrophic Factor (BDNF) 
promote plasticity during adulthood through mediating local protein 
synthesis, dendritic arborization and synaptic growth.
A.
B.
Figure adatpted from Voss et al., 2017. Frontiers in Psychology.
Figure 1.1. Regulato s of Plasticity. (A) Some of the major regulators of plasticity 
in the auditory cortex. Plasticity regulators limit plasticity in the mature brain by 
controlling the activity of excitatory cells, primarily pyramidal (Pyr) neurons. They 
include cells such as inhibitory interneurons and glia, structural molecules like 
PNNs and myelin associated proteins, neuromodulatory control from other brain 
regions, and neurotrophic factors. (B) Table of regulators of plasticity. Altered 
neuroplasticity has been implicated in a variety of neurological disorders including 































Figure 1.2. Cortical and Limbic Structures of the Human Brain. Cortical structures of the 
brain include the frontal, parietal, occipital and temporal lobes, as well as the prefrontal (PFC), 
entorhinal and cerebellar cortices, and cingulate and parahippocampal gyri. Subcortical 
structures include the corpus callosum, striatum, fornix, thalamus, hypothalamus, hippocampus 
(HPC), amygdala (AMY), and pituitary and pineal glands. The brainstem includes the midbrain, 
pons and medulla oblongata. Structures of the limbic system include the HPC, AMY, thalamus, 
hypothalamus, fornix, basal ganglia (not depicted), raphe nuclei of the midbrain, pituitary and 
pineal glands, the cingulate and parahippocampal gyri and the entorhinal and prefrontal 
cortices. The HPC is associated with long-term episodic memory formation and memory 
consolidation via long-term synaptic plasticity. The AMY is involved in stimulating hormone 
release, encoding implicit memories and processing emotional learning such as fear-
conditioning and the positive-reward pathway. The thalamus functions as a relay center 
between the spinal cord, cerebrum and cerebellum interpreting sensory perceptions to 
modulate motor function. The hypothalamus modulates the release of hormones from the 
pituitary and adrenal glands. The fornix is a neural tract connecting the HPC to the 
hypothalamus. The pituitary gland regulates physiological responses to stress, growth, 
reproduction and lactation through its synthesis, storage and secretion of hormones and its 
ability to influence other hormone-secreting glands. The pineal gland is responsible for 
synthesizing and secreting melatonin and serves as a limbic system connection center. The 
basal ganglia and raphe nuclei are groups of subcortical nuclei containing the cell bodies of 
glutamatergic, dopaminergic, GABAergic, cholinergic, nitrergic and serotonergic neurons which 
project afferently to multiple regions of the brain. The cingulate gyrus is a regulator of emotion 
and cognition. The PFC is the processing center for higher reasoning, executive functioning and 
emotions. Reference: Kandel et al., 2013 (Book).
glucose uptake[44, 46], signaling of serotonergic[46], dopaminergic[48], 
noradrenergic[48], gamma-aminobutyric acid (GABAergic)[44], glutamatergic[48], 
and cholinergic[48] neurotransmitter systems, levels of brain-derived neurotrophic 
factor (BDNF)[48, 49], serotonin transporter (SERT) expression and function[49, 50], 
neuronal atrophy of the HPC[47, 48, 51, 52], amygdala (AMY)[47, 53], prefrontal cortex 
(PFC)[44], thalamus[47] and cingulate cortex[53], and inflammation of corticolimbic 
circuitry and structures[54]. 
Monoamines – Discovery and Physiological Roles 
 Monoamines are derived from aromatic amino acids and when 
synthesized in the adrenal medulla act as hormones for the peripheral nervous 
system (PNS) and when synthesized in the brain act as neurotransmitters for 
specific neural circuitry pathways in the brain and sympathetic nervous 
system[55-57]. Monoamines are involved in the regulation of blood pressure, heart 
rate, smooth muscle function, corporal homeostasis, diurnal and nocturnal 
cycles, gut motility, immune and inflammatory responses, learning, memory, 
emotions, reward processing, and stress and fear responses, as well as multiple 
other physiological and psychological processes[43, 55-58]. The three main 
classifications of monoamines are catecholamine, indoleamine and 
imidazoleamine. The catecholamines are dopamine (DA), norepinephrine (NE) 
also known as noradrenaline, and epinephrine (EPI) also known as adrenaline. 
The indoleamines are serotonin (5-hydroxytryptamine, 5-HT) and N-Acetyl-5-
methoxytryptamine (melatonin), and the imidazoleamine is histamine[43, 55]. Here 
we will focus on the 3 catecholamines and the indoleamine 5-HT.  
 The catecholamines and indoleamines are structurally similar and are 
derived from three hydrophobic, aromatic amino acids phenylalanine (Phe), 
tyrosine (Tyr), and tryptophan (Trp). Catecholamines can be derived from the 
10
conversion of Phe to Tyr, or directly from Tyr, whereas indoleamines are derived 
strictly from Trp. Hydroxylation of Tyr and Trp is followed by subsequent 
decarboxylation to form DA and 5-HT, respectively (Figure 1.3)[43, 55, 57]. DA 
serves as the precursor molecule to NE, which is the precursor for EPI[56]. 
Likewise, 5-HT is the precursor molecule to melatonin[57]. Catabolism of DA, NE 
and 5-HT (Figure 1.3B) to their major metabolites occurs by the enzymes 
monoamine oxidase (MOA) and aldehyde dehydrogenase (AD), whereas DA and 
EPI are also catabolized by catechol-o-methyltransferase (COMT)[43, 55, 57].  
 The knowledge of monoamines, their metabolic and catabolic pathways, 
the involvement of transporters and receptors, as well as their physiological roles 
as hormones and neurotransmitters began with the discovery of the 
catecholamine EPI in 1860 by Henry Hyde Salter[56]. At that time however, EPI 
was simply known as an adrenal medulla substance with the ability to 
instantaneously cease asthmatic attacks[56]. During that same year, Alfred 
Vulpian demonstrated that EPI entered the blood stream by way of the adrenal 
veins, however, the adrenal gland was not classified as an endocrine organ until 
the early 1890’s by Carl Jacobj. Furthermore, EPI was neither named nor termed 
a hormone until George Oliver and Edward Schafer extracted it from calf and 
sheep suprarenal glands in 1893/1894, whereby they subsequently 
demonstrated that EPI had an effect on blood pressure, heart rate and splenic 
muscle contraction[56, 59]. In 1895, Wladyslaw Szymonowicz and Napoleon 
Cybulski came to similar conclusions as Oliver and Schafer, however they 
determined that blood from the adrenal veins (and no other veins) resulted in 
hypertension when intravenously injected into dogs[56]. The proof that EPI acted 
directly on the heart and blood vessels came from Rudolf Gotlieb in 1896[56]. 
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 Jokichi Takamine isolated EPI it in its pure form in 1901 and subsequently 
marketed it under the name Adrenalin[56]. In 1903, Oliver was the first to use 
Adrenalin in the treatment of asthma to counteract constricted airways, as it was 
known that Adrenalin causes the smooth muscle lining the bronchi to dilate, 
although the mechanism of action was still unknown[56]. All of these 
groundbreaking findings along with the observation that sympathetic ganglia 
were only excited with direct application of nicotine, but not Adrenalin, combined 
with smooth muscle electrical stimulation experiments, led Thomas Renton Elliot 
to publish the first hypothesis of chemical neurotransmission in 1904[56, 59]. Elliot 
hypothesized that a chemical stimulus is received and by an unknown 
mechanism is transferred through the cell to synapse at sympathetic fibers, 
whereby the message is received and transformed in order to carry nerve 
impulses to muscle fibers[56, 59]. Unfortunately, at that time Elliot’s hypothesis was 
not well recognized amongst the scientific community except by Henry Dale, who 
from 1904-1914 carried out pharmacological investigations on ergot of rye, a 
fungus which was used medicinally at the time to induce labor[59]. Dale’s work 
with ergot allowed him to discover and isolate (1) ergotoxine, one of the first 
adrenergic receptor blockers, (2) the monoamine histamine, (3) acetylcholine 
(ACh), a central nervous system (CNS) and PNS neurotransmitter, and (4) 
tyramine, a trace amine derivative of Tyr[56, 59-61]. Additional breakthrough 
discoveries that would ultimately lead scientists to revisit Elliot’s hypothesis of 
chemical neurotransmission were (1) the elucidation of the chemical structure of 
EPI by Ernst Joseph Friedmann in 1906[56], (2) the discovery of NE as a 
precursor of EPI by Farbwerke Hoechst in 1907[62], (3) the discovery and 
synthesis of DA by George Barger and James Ewens in 1910, (4) the chemical 
synthesis of L-dihydroxyphenylalanine (L-DOPA) which is a derivative of Tyr and 
immediate precursor molecule to DA by Casimir Funk in 1911 (Figure 1.3A), and 
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(5) the isolation of L-DOPA from fava beans by Marcus Guggenheim in 1913[63].  
 Elliot’s hypothesis of chemical neurotransmission regained traction 
between 1921-1936 when Otto Leowi began investigating the physiological 
effects of EPI on the sympathetic nervous system to elucidate the underlying 
mechanisms of action for EPI and ACh[56, 59]. Leowi was able to demonstrate the 
transferability of cardiac nerve impulses by immersing a denervated beating frog 
heart in fluids from an innervated heart which responded to vagus nerve 
stimulation[56, 59]. The findings of these experiments led Leowi to hypothesize that 
EPI produced effects on the sympathetic nervous system causing an increase in 
ACh concentrations and thus had an effect on the parasympathetic nervous 
system[56]. Importantly, Dale’s research from 1904-1914 and Leowi’s from 
1921-1936 resulted in the culmination of two major concepts finally being 
accepted by the scientific community, (1) that EPI was a transmitter for the 
sympathetic nervous system and (2) that nerve impulses were indeed 
electrochemically transmitted[56, 59]. 
 The suggestion that NE was also a sympathetic system transmitter was 
proposed by Zenon Bacq in 1934, however enough proof did not exist for this 
hypothesis to become widely accepted until 1945[56]. The discovery of MAO and 
its ability to oxidize DA, NE and EPI in vivo came from Hermann Blaschko in 
1937[56]. Two years later, Peter Holtz obtained dopa decarboxylase from the 
kidneys of guinea pigs and further demonstrated that this enzyme was 
responsible for catalyzing the conversion of L-DOPA to DA[56, 63], which is the 
second enzyme in the Tyr to EPI pathway. These data led both Blaschko and 
Holtz to simultaneously predict the catecholamine metabolic sequence starting 
with Tyr and ending with EPI[56, 58], although several enzymes in the pathway 




Figure 1.3. Pathways of Monoamine Biosynthesis. (A) The biosynthetic pathway of all 3 
catecholamines begins with the conversion of the amino acid (aa) phenylalanine (Phe) to L-
Tyrosine (Tyr) by Phe hydroxylase (not shown). The aa Tyr which is the second precursor to all 
catecholamines is then converted to L-Dihydroxyphenylalanine (L-DOPA) by Tyr hydroxylase. 
The carboxyl group of L-DOPA is removed by DOPA decarboxylase to produce dopamine (DA), 
the first synthesized catecholamine in the pathway. Norepinephrine (NE) is the second 
synthesized catecholamine in the pathway and is formed by the addition of a hydroxyl group to 
DA by the enzyme DA β-hydroxylase. The third and final catecholamine epinephrine (EPI) is 
synthesized from NE by the addition of a methyl group by phenylethanolamine-N-
methyltransferase. (B) The biosynthetic pathway for serotonin (5-HT) begins with the 
conversion of aa L-Tryptophan (Trp) to 5-hydroxy-L-tryptophan (5-HTP). The carboxyl group of 
5-HTP is removed by 5-HTP decarboxylase to produce 5-HT. One mechanism of 5-HT 
catabolism is removal of the amine group via oxidative deamination by monoamine oxidase 
(MAO), resulting in the intermediate 5-hydroxyindoleacetaldehyde (not shown) which is then 
oxidized by aldehyde dehydrogenase (AD) to produce the 5-HT metabolite 5-
hydroxyindoleacetic acid (5-HIAA). Although not shown, the catecholamines are similarly 
catabolized by MAO and AD or through the addition of a methyl group by catechol-o-methyl 
transferase (COMT). 
NE as a neurotransmitter came from the work of Ulf von Euler in 1945, whereby 
biochemical assays demonstrated the natural occurrence of NE in the extracts of 
mammalian bodily organs including the brain[56]. Further proof was published by 
the Holtz group in 1947 which identified all three catecholamines in the urine of 
humans, in addition to further characterizing NE as the second hormone 
produced by the adrenal medulla[56]. In 1949 Edith Bulbring showed that NE in 
adrenal tissue was converted to EPI by methylation[56, 62], although the specific 
enzyme responsible for this had not yet been discovered. Moreover, in 1954 
Marthe Vogt utilized a filter paper chromatography method on the purified 
extracts of dog cortical, thalamic, hypothalamic, midbrain and brainstem regions 
and determined NE and EPI had distinct patterns of region-specific 
concentrations in the mammalian brain which was different than what she had 
previously identified for ACh[64]. These data led the scientific community to begin 
thinking that neurotransmitters in the brain not only served different functions in 
the central and peripheral nervous systems, but also that they likely had distinct 
neuronal patterns of expression and distribution.  
 Further significant breakthroughs in the catecholamine pathway came 
after 1957, when Julius Axelrod discovered the enzyme catechol-O-
methyltransferase (COMT) in the mammalian brain and showed it was 
responsible for the O-methylation and hence second degradation pathway of DA, 
NE and EPI[56]. Additionally, between 1957-1959, Arvid Carlsson and his group 
developed a method to measure DA in the brain and demonstrated region-
specificity of DA concentrations, which were different than NE, EPI and ACh, thus 
proving DA was more than just the precursor molecule for NE and highlighting 
the importance of DA as a neurotransmitter[56, 65-67]. In 1960 dopamine β-
hydroxylase, the the third enzyme in the Tyr to EPI pathway responsible for 
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converting DA to NE was isolated and characterized by Ephraim Levin and the 
Seymour Kaufman group[68]. The fourth enzyme in the catecholamine 
biosynthesis pathway phenylethanolamine-N-methyltransferase (PNMT) was 
discovered by the Axelrod group in 1962[56], and the first enzyme in the pathway, 
tyrosine hydroxylase (TH) responsible for converting Tyr to L-DOPA was finally 
discovered, isolated, purified and characterized in 1964 by Toshiharu Nagatsu 
and the Sidney Udenfriend group[69]. 
 While the process of discovering and classifying catecholamines as 
neurotransmitters along with identifying and understanding their complete 
biosynthetic pathway took a total of 104 years (1860-1964), that of the 
indoleamine 5-HT took only 27 years (1937-1964) as a result of previous and 
coinciding technological advancements associated with catecholaminergic 
molecular biochemistry and pharmacology. The discovery of 5-HT began in 1937 
when Erspamer and Vialli isolated an indoleamine compound from 
enterochromaffin cells from multiple species which could elicit contractions in 
intestines and termed it enteramine[70]. In 1948, a vasoconstrictive and clotting 
factor molecule which is readily available in the platelets of beef serum[71] was 
identified and termed serotonin. Importantly enteramine and serotonin were the 
same compound and these data indicated 5-HT was present in multiple body 
systems and practically all animal species. The precursor amino acid for 5-HT 
was identified as Trp by Udenfriend in 1953, along with the conversion 
mechanisms of the biosynthetic pathway being oxidation of Trp to yield 5-
hydroxytryptophan (5-HTP), which gets decarboxylated to produce 5-HT[72] 
(Figure 1.3B). The first 5-HT metabolic enzyme to be discovered was the second 
enzyme in the pathway 5-hydroxytryptophan decarboxylase (5-HTPD) which was 
purified from the kidneys of hogs and guinea pigs by Carroll Clark of the 
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Udenfriend group in 1954[72]. It was not until 1964 that David Grahame-Smith 
identified the first enzyme in the pathway tryptophan hydroxylase (TPH) in brain 
tissue and characterized it as the rate-limiting step in 5-HT biosynthesis[73], 
however purification of TPH proved to be a difficult task and was not successfully 
carried out until 1975 by Jeffrey Tong and Seymour Kaufman[74]. 
 Prior to the complete characterization and purification of molecules and 
enzymes in the indoleamine biosynthetic pathway, 5-HT was synthesized in 1952 
by Erspamer and Asero to use as a tool for investigating the physiological and 
pharmacological properties of 5-HT[75]. The synthesis of 5-HT led to a vast array 
of investigative studies and ground breaking discoveries about the multifaceted 
roles of 5-HT in living organisms. The first scientific evidence of 5-HT as a CNS 
active molecule came in 1953, when Twarog and Page injected brain tissue 
extract from dogs, rats and rabbits into a perfusion bath containing a suspended 
Venus mercenaria (clam) heart, in which the heart could be excited by the 
presence of 5-HT in the perfusion bath and the heart beat recorded[76]. The 
amplitude of muscle contractions of the Venus heart consistently increased in the 
of presence brain extract, and urine extract from dogs and humans[76]. Further 
characterization of the indoleamine was by Gaddum et al in 1953, when the 
mechanism of the broncho- and vasoconstrictor properties of serotonin was 
determined to act directly on the smooth muscle lining the walls of lung blood 
vessels in an anesthetized feline model using lysergic acid diethylamide (LSD) as 
a 5-HT antagonist[77]. Due to the structural similarities between LSD and 5-HT[78] 
(Figure 1.4), as well as the understanding that LSD caused hallucinations, 
delusions and disordered thinking, similar to symptoms of schizophrenia[79], it 
was proposed that 5-HT had psychotropic properties and may play a role in 
mental health disturbances. Woolley and Shaw consolidated these data with the 
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pharmacological discovery that LSD acts on serotonin receptors in the brain 
(Figure 1.5) and PNS and inferred that suppression of brain 5-HT actions may 
play a causative role in the formation of disorders of the mind, especially in 
schizophrenia[80].  
In addition to the above findings, multiple clinical drug trials led to the idea 
that mood could be altered via biochemical modulation. For instance in 1952, 
iproniazid, an antimycobacterial agent, was used to treat tuberculosis and 
serendipitously showed improved mood in patients comorbid with mild 
depression[81, 82]. Ironically, iproniazid treatment at high doses in severely 
depressed tuberculosis patients provoked psychoses and agitation, which was 
reversible upon discontinuation of the drug[83, 84]. Also in 1952, iproniazid was 
identified as an inhibitor of MAO, the presynaptic enzyme responsible for the 
degradation of free monoamines[85] (Figure 1.5). Moreover, iproniazid prevented 
the breakdown of 5-HT, NE[83, 84], and DA[66] thereby increasing their available 
concentrations in the brain, providing the first supporting data that elevating 
endogenous monoamine levels had a therapeutic effect in the treatment of 
depression.  
Further evidence that drugs could be psychotomimetic emerged in 1955 
with the development of the antihypertensive compound reserpine, which 
serendipitously precipitated anxiety and depressive symptoms in a subset of 
hypertensive patients[86]. Furthermore it was identified that administration of 
reserpine to dogs depleted 5-HT stores and increased the breakdown of 5-HT 
into one of its major metabolites 5-hydroxyindoleacetic acid (5HIAA) (Figure 1.3, 
Figure 1.5), which was elevated in the excreted urine of reserpine-treated 
canines[87]. Investigations on the effects of reserpine identified that administration 



















Figure 1.4. Structural Similarities of LSD and 5-HT. (A) Chemical structure of LSD mimics 
that of (B) 5-HT in that both share an indole ring (highlighted in blue). 
depressive episodes in both animals and humans[65, 88]. These data suggested 
the catecholamines DA and NE, in addition to the indoleamine 5-HT had a role in 
the pathophysiology of mental health disorders and the maintenance of healthy 
brain function.  
Based on the multitude of data indicating a monoaminergic role in mental 
health disturbances and the findings that iproniazid at low doses improved the 
mood of mildly depressed tuberculosis patients, iproniazid went on to become 
one of the first antidepressants (AD) marketed for use in humans in 1957[89-91]. 
That same year, the tricyclic AD drug imipramine was under the trade name 
Tofranil. The thymoleptic properties of imipramine were serendipitously identified 
in 1956[92] during its use as an antipsychotic to treat schizophrenia and whereas 
imipramine was ineffective in treating schizophrenia patients with co-morbid 
depression, saw anti-depressive outcomes. Unraveling the mode of action of 
imipramine started in 1959 when it was discovered to potentiate the effects of NE 
by prolonging its vasopressor response[93], supporting its effect on the central 
adrenergic system. Supporting studies in the early 1960’s revealed that 
imipramine treatment in cats increased plasma NE levels within 5 minutes of 
treatment[94]; however, the complete mechanism conferring the AD activity of 
imipramine was not elucidated until 1969, when Lapin and Oxenkrug showed 
imipramine blocked the presynaptic reuptake of both 5-HT and NE[95]. 
Monoamine Hypothesis 
The monoamine hypothesis attempts to explain the neurovegetative 
functions underlying mood disorder pathophysiology and antidepressant (AD) 
efficacy, by positing that depressed patients have reduced basal brain 
concentrations in one or more of the monoamines 5-HT, DA and NE[96-98]. The 






Figure 1.5. Graphical Representation of the Actions of 5-HT, Iproniazid, Reserpine and 
LSD on the Serotonergic System. Intracellular 5-HT is packaged into synaptic vesicles by way 
of the vesicular monoamine transporter (VMAT). Upon an action potential, the synaptic vesicles 
are transported to and fuse with the synaptic membrane, releasing a quantal amount of 5-HT 
into the synapse whereby 5-HT can (1) diffuse across the synaptic cleft to bind to any one of the 
postsynaptic neuron or astrocyte (not depicted) 5-HT receptor subtypes thus further propagating 
the signal, (2) can diffuse out of the synaptic cleft, (3) can be degraded by MAO, (4) can bind to 
presynaptic neuron 5-HT autoreceptors creating an autoinhibitory feedback loop, or (5) can be 
recycled back into the presynaptic neuron by the serotonin transporter (SERT) for vesicular 
repackaging or degradation by monoamine oxidase (MAO). SERT acts as the primary 
mechanism for clearing 5-HT from the synapse. Free presynaptic intracellular 5-HT can also be 
catabolized to 5-hydroxyindoleacetaldehyde (5-HIAL) by MAO, a process halted by the 
monoamine oxidase inhibitor (MAOI) compound Iproniazid. 5-HIAL is catabolized by aldehyde 
dehydrogenase to the 5-HT major metabolite 5-hydroxyindoleacetic acid (5-HIAA), whereby 5-
HIAA is then excreted by the kidneys. The compound Reserpine increases 5-HT catabolism to 
5-HIAA. LSD in the synaptic cleft can bind any of the postsynaptic 5-HT receptor subtypes, 
however its hallucinogenic properties mainly act via binding the 5-HT2 receptors whereby it 
activates the β-arrestin pathway. Additionally, LSD dissociates significantly slower from 5-HT 
receptors than does 5-HT. References: Kristensen et al., 2011; Zeller et al., 1952; Shore et al., 
1955; Berridge MJ, & Prince WT, 1974. 
status and that metabolic 5-HT deficiency may contribute to psychological illness 
was first proposed by Woolley and Shaw in 1954 by critical comparison of 
multiple published findings on the physiological role, abundance, and 
pharmacological properties of 5-HT[80]. The catecholamine hypothesis of 
depression was introduced in 1965 by Schildkraut, which suggested that DA and 
NE deficiencies were responsible for the pathological state of depression[99]. 
Then in 1967, the importance of 5-HT in the maintenance of mental health was 
highlighted by Coppen[100] and in 1969 the monoamine hypothesis of depression 
which focused on 5-HT as the primary underlying deficiency, was proposed by 
Lapin and Oxenkrug, paving the way for marked advancements in thymoleptic 
pharmacotherapy[95]. 
Following FDA approval of iproniazid (1958) and imipramine (1983), 
numerous clinical trials were carried out in order to determine their efficacy in 
treating subtypes of depression. Interestingly, clinical trials for both compounds 
were consistently reporting a 2-4 week delay in the alleviation of depressive 
symptoms[90, 101-103], even though clinically relevant doses of iproniazid 
significantly increased blood platelet 5-HT within 24 hours of drug 
administration[104]. Even as new ADs with alternate mechanisms of action on the 
monoaminergic system were developed, the delayed onset of symptom 
improvement remained a constant factor. It soon became evident that the 
monoamine hypothesis alone was not sufficient to explain the cause, 
maintenance or treatment efficacy of depression. If low monoaminergic levels 
were the only contributing factor to depression pathophysiology, then there would 
be an expectation of mood improvement soon after monoamine levels were 
elevated by the AD. This inconsistency led to the search for alternative 
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hypotheses to explain the neurovegetative functions underlying mood disorder 
pathophysiology and the delay in AD efficacy. 
An Integrated Hypothesis of Depression: Brain-Derived Neurotrophic Factor, 
Neuroplasticity, Neurotransmitters and Cytokines 
	 Brain-derived neurotrophic factor (BDNF) is widely known as a regulator of 
neuroplasticity in the developing and adult brain, and also serves as a 
neuroprotectant promoting the survival of neurons[97, 105, 106]. Transcription of the 
BDNF gene is regulated by 5-HT receptor activation, which subsequently 
increases intracellular Ca2+ levels resulting in Ca2+/calmodulin kinase (CaMK) 
phosphorylation of cAMP Response Element-Binding Protein (CREB) thus 
stimulating BDNF gene expression[105, 106]. Moreover, BDNF binding and 
activation of presynaptic tyrosine or tropomyosin receptor kinase B (TrkB) 
enhances SERT reuptake of 5-HT to ultimately reduce the transcription of BDNF 
(Figure 1.6A)[106]. Reduced expression of BDNF[97] and 5-HT[95] in the HPC have 
both been implicated in the pathophysiology of depression and anxiety, which is 
consistent with BDNF and the serotonergic pathway being physiologically linked 
to one another. 

 Identification of the BDNF Val66Met polymorphism associated with 
reduced mRNA and protein trafficking as well as reduced secretion has further 
demonstrated the involvement of BDNF in the neurovegetative roles associated 
with depression[97, 107]. Studies in humans and rodents have shown that 
heterozygous and homozygous carriers of the Val66Met mutation have impaired 
episodic memory, volumetric reductions in the HPC, AMY and PFC, along with 
reductions in cortical thickness of the frontal, temporal, cingulate and insular 
cortices[98, 107]. Importantly the majority of these regions are not only part of the 
limbic system (Figure 1.2) but are also innervated by serotonergic neurons[43] 
(Figure 1.7). These data support the combined hypotheses that monoamines and 
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BDNF are intricately involved in the pathophysiology of depression, however the 
mechanisms by which BDNF and 5-HT dysregulation occurs has still not been 
explained 
 It remains unclear whether reduced BDNF and 5-HT levels in an otherwise 
healthy child, adolescent or adult brings about depressive or anxious states in 
the brain. A multitude of studies over several decades have been dedicated to 
answering this very problem, and a common finding is that exposure to chronic 
stress resulting from one or more traumatic events in early developmental stages 
or at any point during adulthood can bring about significant neurological, 
physiological, and structural changes in the brain[97, 98, 105, 106, 108-111]. In fact, 
chronic stress has been determined to be one of the most significant contributors 
to the neurovegetative effects characterized in MDD[98] and likely results from 
dysregulation of various neurotransmitter systems. Chronic stress stimulates the 
production and secretion of glucocorticoids (GC), such as cortisol (Figure 1.8) 
from the hypothalamic-pituitary-adrenal (HPA) axis, subsequently rendering the 
homeostatic negative feedback loop ineffective, which ultimately exacerbates the 
release of GC and results in down regulation of 5-HT receptors, decreased BDNF 
expression, neuronal death, and reduced HPC volume[97, 98, 105, 110]. Additionally, 
chronic stress increases the release of glutamate (GLU)[97, 98, 105, 106, 110] (Figure 
1.8) causing overstimulation of glutamatergic receptors N-methyl-D-aspartate 
(NMDARs) and ɑ-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPARs) resulting in their down regulation, and ultimately, impairment of 
memory consolidation due to aberrant structural changes to the HPC and 
PFC[108]. Furthermore, stress results in anomalous modulation of the GABAergic 
system which appears to be region-specific, however a reduction in GABA 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































dysfunction of the HPC, AMY and PFC in MDD and bipolar disorder[109, 111]. In 
addition to the negative impacts that chronic stress has on neurotransmitter 
systems, it is also detrimental to microglia and neurons through activation and 
increased production of pro-inflammatory cytokines that cause brain 
inflammation[106]. Prolonged and aberrant immune system activation leads to 
reduction in microglia of the HPC, depletion of the amino acid  Trp, enhanced 
SERT activity via the p38 mitogen-activated protein kinase (MAPK) pathway, and 
inhibition of neurogenesis through reduced transcription of the BDNF gene 
(Figure 1.6B)[106]. In addition to BDNF and 5-HT, these data clearly highlight a 
significant role for the integration of neurotransmitters and cytokines as 
responsible contributors in the pathophysiology of depression and anxiety 
disorders. 
  If the above components are involved in the development of depressive 
and anxious brain states, suppression of these aberrant molecular processes 
and symptom amelioration would be expected with AD treatment. Classical and 
atypical AD’s have been shown to reverse several of the above discussed 
dysregulated biochemical, physiological and structural anomalies[106] in 
approximately 60% of the treated population[27], however, as noted above there is 
a 2-4 week delay in the onset of symptom relief. It is hypothesized that the 
mechanism of actions of classical and atypical AD is the reason it takes 
approximately 2-4 weeks to therapeutically reverse the damage and 
subsequently increase BDNF transcription leading to neurogenesis in the HPC 
and thus begin feeling the positive effects of the AD. Interestingly, the drug 
ketamine which acts through a completely different mechanism of action by way 
of NMDA and AMPA receptors (Figure 1.6C) not only results in reversal of the 
neurovegetative effects of depression and anxiety within hours of administration, 
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Figure 1.7. Serotonergic Pathway Innervation. (A) Serotonergic innervation of the human 
brain is depicted by black arrows arising from the raphe nuclei (fluorescent green oval) of the 
midbrain (shaded in green). (B) Serotonergic innervation of murine brain is depicted by purple 
arrows arising from the raphe nuclei (purple oval) of the midbrain (shaded in blue). Olfactory 
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Figure 1.8. Chemical Structures of Neurotransmitters.
but also results in almost immediate relief of negative symptoms[98, 106, 110]. These 
data not only provide support for the integration of neurotransmitters, BDNF, 
neuroplasticity and cytokines as contributors to the pathological state of 
depression and anxiety, but also provide a more thorough understanding of the 
underlying mechanisms. Albeit, several gaps in knowledge still exist.  
Impact of Gestational Antidepressants on Fetal Development 
 Selective serotonin (5-HT) reuptake inhibitor (SSRI) antidepressants (AD) 
are a first line treatment for 6-8% of pregnant women that clinically present with 
depression or anxiety disorders[112-115]. Unfortunately, short and long-term effects 
of developmental SSRI exposure in humans is poorly understood. Human and 
rodent studies have shown that exposure to SSRIs during early mammalian 
development alters neurocircuitry and confers risk for affective disorders later in 
life[115-126]. These findings are physiologically consistent with the critical role of 5-
HT as a signaling molecule during central nervous system (CNS) development 
where it regulates establishment of the serotonergic system and directs neural 
plasticity through processes such as cell differentiation, migration, dendritic 
growth, and synaptogenesis[105, 127-129]. Developmental plasticity renders the brain 
vulnerable to environmental changes which may underlie an identified SSRI-
sensitive window (SSW) starting at the end of second trimester and extending 
through the third trimester in humans. In rodents, the SSW corresponds to the 
first three weeks of postnatal (P2-21) rodent neurodevelopment with one study 
indicating the SSW may be as narrow as 10 days (P2-11)[117, 119, 121, 130, 131]. The 
SSW coincides with the rise of transient spatiotemporal expression of the 
serotonin transporter (SERT) and 5-HT receptors in serotonergic and non-
serotonergic cells which aides in maturation of neural connections[123, 132-134] 
providing a mechanism by which other pathways could be impacted by SSRI-
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mediated disruption in developmental 5-HT homeostasis. Importantly, abnormal 
5-HT levels during the SSW are known to alter neural plasticity in the 
hippocampus (HPC), midbrain (MdB) raphe nuclei, and pyramidal neurons of the 
medial prefrontal cortex (mPFC)[118, 120, 121, 125, 135], regions which are associated 
with modulating mood, emotion and behavior[136].  
Physiologically, 5-HT homeostasis can be disrupted by SSRIs which 
readily cross the placental and fetal blood-brain barriers[137, 138]. SSRIs bind to 
SERT, antagonize 5-HT reuptake and increase synaptic 5-HT levels[139]. 
Exposure of the developing brain to SSRIs could initiate pathophysiologies 
through disruption of 5-HT-mediated neurotrophic effects on temporal signaling 
pathways and modulating cues important for normal brain development. For 
example, mRNA levels of brain-derived neurotrophic factor (BDNF) and its 
receptor TrKB significantly decrease in the HPC during neurodevelopmental 
SSRI challenge but return to normal levels upon discontinuation of chronic drug 
treatment[140]. Whereas reductions in immunoreactivity of hippocampal 
tryptophan hydroxylase (TPH), the rate-limiting enzyme involved in 5-HT 
synthesis, and MB SERT are present immediately after chronic SSRI treatment 
and persist throughout adulthood[118, 120, 135]. Such variations in the expression of 
critical 5-HT signaling pathway molecules demonstrates that the effects of 
developmental SSRI exposure can be temporary or persistent, setting up a 
predisposed state for developing affective disorders later in life.  
The manifestation of psychiatric disorders is complex and while 
pharmacological intervention may play a formative role, other factors have also 
been implicated. Heritable genetics, adverse early-life experiences and 
environmental influences, such as maternal mental health and mood contribute 
to the emergence of these disorders[141-146]. For example, adolescents born to 
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mothers with affective disorders exhibit an increased risk for depression, 
nevertheless the risk increases significantly with in utero SSRI exposure and the 
risk is enhanced with 2nd to 3rd trimester SSRI use[115, 126]. Notably, the potential 
for developing anxiety, autism spectrum, attention deficit hyperactivity, 
somatoform, and behavioral disorders or mental retardation was unchanged 
independent of maternal SSRI treatment. Therefore, whereas offspring 
susceptibility to multiple mental illnesses may materialize independent of 
perinatal SSRI exposure, these studies collectively identify a correlation between 
fetal SSRI vulnerability and an increased prevalence of depression with greatest 
risk occurring during mid- to- late gestation SSRI exposure. 
Rodent Models of Depression 
Rodent models support the correlation between increased risk of 
psychiatric-like disorders and late gestation SSRI vulnerability, identifying P2-21 
neurodevelopment as the SSW when SSRI actions may result in an increase in 
persistent abnormal emotional behaviors[117-119, 121, 124, 125, 147-149]. The SSW is 
characterized by heightened brain plasticity, whereby environmental influences 
can affect genome-wide expression profiles and epigenetic modifications leading 
to phenotypic changes in physiology, cognition, and behavior[150]. Epigenetic 
reprogramming during early development can be chronic altering susceptibility 
and resilience to psychopathological dysfunction[151, 152]. In rat models, postnatal 
treatment with the SSRI fluoxetine (FLX), induced significant changes in 
hippocampal gene regulation of epigenetic modifiers HDAC4, DNMT3a and 
MeCP at P21 and 18-months of age, however, these genes remain unchanged 
with adult chronic FLX treatment[148], further supporting differential outcomes for 
SSRI exposure during the SSW compared to non-developmental time frames. 
Consequently, these SSRI-mediated changes in gene expression are associated 
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with a rise in hippocampal HDAC4 promoter acetylation and reduction in global 
methylation[148]. Altogether, these data correlate postnatal SSRI exposure with 
epigenetic reprogramming and the onset and persistence of depressive-like 
behaviors in rodents.  
While it is understood that exposure to SSRIs during the SSW can 
modulate emotional behavior, the mechanism by which this occurs remains to be 
elucidated. Currently the underlying mechanisms have been investigated using a 
mouse lacking a functional transporter (SERT-KO), which is representative of 
lifelong genetic SERT blockade[153] (Figure1.9-1.10). Unfortunately, because 
SERT-KO animals begin development lacking SERTs, they have substantial 
neurological deficits that occur prior to the SSW[122, 154-156], indicating their 
emotional and behavioral abnormalities may not be consistent with postnatal 
mice treated during the SSW[122]. We therefore propose a novel transgenic 
mouse harboring a mutant SERT I172M that is fully functional for 5-HT transport 
and maintains wild type (I172) (Figure1.9-1.10) levels of protein surface 
expression[157, 158] as a more advantageous mouse model for investigating the 
actions of SSW exposure. Importantly, the isoleucine to methionine substitution 
in the I172M mouse renders the mutant transporter pharmacologically insensitive 
to blockade by the SSRIs escitalopram (S-CIT) and FLX, yet has no effect on the 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Rationale for Dissertation Studies 
In this study we aim to validate the I172M mouse for its appropriateness in 
investigating developmental SSRI-mediated effects through genome-wide mRNA 
sequencing. The insensitivity of the I172M mouse to S-CIT and FLX will be 
leveraged against sensitive I172 and insensitive SERT-KO animals to identify 
potential targets involved in SSRI-mediated transcriptomic adaptations which 
may have a causative role in the altered, persistent behavioral outcomes. Our 
paradigm includes evaluation of MdB and HPC tissues to identify region-specific 
transcriptomic profiles, since each of these brain regions has been implicated in 
affective disorders and receives differential serotonergic innervation, they may 
selectively contribute to aberrant emotional behavior. Validation of the I172M 
mouse is important for future studies to adequately distinguish between SERT-
mediated and SERT-independent effects to identify potential therapeutic targets 
which may reduce susceptibility to the onset and persistence of affective-like 
disorders during SSW exposure. 
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CHAPTER II 
INHIBITION OF SEROTONIN TRANSPORT IS ALTERED BY METABOLITES 
OF SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE 
INHIBITORS AND REPRESENTS A CAUTION TO ACUTE OR CHRONIC 
TREATMENT PARADIGMS 
 Previous studies of transgenic mice carrying a single isoleucine to 
methionine substitution (I172M) in the serotonin transporter (SERT) 
(chr11:77,013,236) demonstrated a loss of sensitivity to multiple antidepressants 
(ADs) at SERT. However, the ability of AD metabolites to antagonize SERT was 
not assessed. Here, we evaluated the selectivity and potency of these 
metabolites for inhibition of SERT in mouse brain-derived synaptosomes and 
blood platelets from wild-type (I172 mSERT) and the antidepressant-insensitive 
mouse M172 mSERT. The metabolites norfluoxetine and desmethylsertraline lost 
the selectivity demonstrated by the parent compounds for inhibition of wild type 
mSERT over M172 mSERT, whereas desvenlafaxine and desmethylcitalopram 
reta ined select iv i ty. Fur thermore, we show that the metabol i te 
desmethylcitalopram accumulates in the brain and that the metabolites 
desmethylcitalopram, norfluoxetine, and desvenlafaxine inhibit serotonin uptake 
in wild-type mSERT at potencies similar to those of their parent compounds, 
suggesting that metabolites may play a role in effects observed following AD 
administration in wild-type and M172 mice.  
Introduction 
The serotonin transporter (SERT) is a member of the solute carrier 6 
(SLC6) family of neurotransmitter transporters. SERT is expressed in the brain 
and periphery[159, 160], where it is the primary mechanism for termination of 
serotonergic signaling following vesicular release of serotonin (5-
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hydroxytryptamine, 5-HT). Altered activity of SERT has been implicated in 
multiple neurobehavioral disorders, including major depression, autism spectrum 
disorder, anxiety, post-traumatic stress disorder, and obsessive-compulsive 
disorder[161, 162]. Antidepressants (ADs) such as tricyclic antidepressants (TCAs), 
selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine 
reuptake inhibitors (SNRIs) effectively block 5-HT and/or norepinephrine (NE) 
reuptake, thereby increasing synaptic levels of those neurotransmitters. Of these 
drugs, SSRIs and SNRIs are prescribed most often due to their superior safety 
profile in comparison to TCAs, which have multiple secondary targets[163, 164]. 
Although treatment with SSRIs and SNRIs effectively block 5-HT and/or NE 
almost immediately upon administration, chronic blockade is required for 
efficacy[165, 166]. The mechanisms underlying the delay in symptom amelioration 
with AD treatment and the distinct roles of both the norepinephrine transporter 
(NET) and SERT as primary targets in depression are areas that remain poorly 
understood[167, 168]. 
 Structurally, SERT and the related NET and dopamine transporters 
contain 12 transmembrane domains (TMs), of which TMs 1, 3, 6, and 8 form the 
majority of the substrate permeation pathway as well as key interactions with 
ions, substrates, and antagonists[169-172]. Species scanning mutagenesis studies 
of SERT TMs have identified the well-conserved Ile172 (I172) residue as an 
important molecular determinant responsible for high-affinity AD binding in 
human and mouse SERT (hSERT and mSERT, respectively) as substitution to 
methionine (M172) resulted in a dramatic loss in inhibitory potencies for many 
SERT antagonists, such as citalopram, fluoxetine, sertraline, and cocaine, in both 
hSERT and mSERT[157, 158, 173-176]. Importantly, the M172 substitution does not 
alter normal 5-HT transport or SERT surface expression. The unique properties 
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Inhibition of the Serotonin Transporter Is Altered by Metabolites of
Selective Serotonin and Norepinephrine Reuptake Inhibitors and
Represents a Caution to Acute or Chronic Treatment Paradigms
Danielle Krout,† Meghan Rodriquez,† Stephen A. Brose,† Mikhail Y. Golovko,† L. Keith Henry,*,†
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ABSTRACT: Previous studies of transgenic mice carrying a single isoleucine
to methionine substitution (I172M) in the serotonin transporter (SERT)
demonstrated a loss of sensitivity to multiple antidepressants (ADs) at SERT.
However, the ability of AD metabolites to antagonize SERT was not assessed.
Here, we evaluated the selectivity and potency of these metabolites for
inhibition of SERT in mouse brain-derived synaptosomes and blood platelets
from wild-type (I172 mSERT) and the antidepressant-insensitive mouse M172
mSERT. The metabolites nor!uoxetine and desmethylsertraline lost the
selectivity demonstrated by the parent compounds for inhibition of wild-type
mSERT over M172 mSERT, whereas desvenlafaxine and desmethylcitalopram
retained selectivity. Furthermore, we show that the metabolite desmethylcita-
lopram accumulates in the brain and that the metabolites desmethylcitalopram,
nor!uoxetine, and desvenlafaxine inhibit serotonin uptake in wild-type mSERT
at potencies similar to those of their parent compounds, suggesting that
metabolites may play a role in e"ects observed following AD administration in wild-type and M172 mice.
KEYWORDS: Serotonin transporter, SSRI, antidepressants, metabolites, M172 mouse, mass spectrometry
The serotonin transporter (SERT) is a member of thesolute carrier 6 (SLC6) family of neurotransmitter
transporters. SERT is expressed in the brain and periphery,1,2
where it is the primary mechanism for termination of
serotonergic signaling following vesicular release of serotonin
(5-hydroxytryptamine, 5-HT). Altered activity of SERT has
been implicated in multiple neurobehavioral disorders,
including major depression, autism spectrum disorder, anxiety,
post-traumatic stress disorder, and obsessive-compulsive
disorder.3,4 Antidepressants (ADs) such as tricyclic antidepres-
sants (TCAs), selective serotonin reuptake inhibitors (SSRIs),
and serotonin-norepinephrine reuptake inhibitors (SNRIs)
e"ectively block 5-HT and/or norepinephrine (NE) reuptake,
thereby increasing synaptic levels of those neurotransmitters.
Of these drugs, SSRIs and SNRIs are prescribed most often due
to their superior safety pro#le in comparison to TCAs, which
have multiple secondary targets.5,6 Although treatment with
SSRIs and SNRIs e"ectively block 5-HT and/or NE reuptake
almost immediately upon administration, chronic blockade is
required for clinical e$cacy.7,8 The mechanisms underlying the
delay in symptom amelioration with AD treatment and the
distinct roles of both the norepinephrine transporter (NET)
and SERT as primary targets in depression are areas that
remain poorly understood.9,10
Structurally, SERT and the related NET and dopamine
transporters contain 12 transmembrane domains (TMs), of
which TMs 1, 3, 6, and 8 form the majority of the substrate
permeation pathway as well as key interactions with ions,
substrates, and antagonists.11!14 Species scanning mutagenesis
studies of SERT TMs have identi#ed the well-conserved Ile172
(I172) residue as an important molecular determinant
responsible for high-a$nity AD binding in human and mouse
SERT (hSERT and mSERT, respectively) as substitution to
methionine (M172) resulted in a dramatic loss in inhibitory
potencies for many SERT antagonists, such as citalopram,
!uoxetine, sertraline, and cocaine, in both hSERT and
mSERT.15!20 Importantly, the M172 substitution does not
alter normal 5-HT transport or SERT surface expression. The
unique properties of this mutation allow for the generation of
an M172 SERT mouse that is virtually pharmacologically
invisible to many ADs supported by studies showing M172
transgenic mice lose sensitivity to multiple SSRIs without
altering 5-HT transport or extracellular levels of 5-HT.15,20 This
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Figure2.1. Proposed Action of Antidepressant Metabolites in Serotonergic Neurons.
of this mutation allow for the generation of an M172 SERT mouse that is virtually 
pharmacologically invisible to many ADs supported by studies showing M172 
transgenic mice lose sensitivity to multiple SSRIs without altering 5-HT transport 
or extracellular levels of 5-HT[158, 176]. This is notable, considering that the actions 
of SSRIs are often evaluated and characterized in studies by comparison to the 
SERT null mouse[153], which is generally inappropriate due to the effect of SERT 
loss on 5-HT levels and how this disruption of 5-HT homeostasis can impact 
development of both serotonergic and non-serotonergic systems[119]. Chronic 
loss of appropriate serotonergic tone caused by the SERT null genotype results 
in alteration of multiple physiological and behavioral phenotypes that make any 
comparisons to the wild-type mouse during SSRI treatment confounding and 
problematic at best[177]. The SERT M172 AD-insensitive mouse represents a 
significant step forward and a powerful new tool to define the role of SERT and 5-
HT signaling following AD administration as this model, unlike the SERT null 
mouse, has normal 5-HT transport and no known phenotypic changes other than 
loss of SSRI sensitivity. Therefore, the utility of the SERT M172 mouse to serve 
as a better control in AD studies will likely result in its increased use making more 
detailed characterizations of this mouse model of interest to the field. 
 Whereas many SSRIs have been evaluated for inhibition of the mSERT 
M172 mutant[157, 158], there exists no analysis of SSRI metabolites in regards to 
potency and selectivity between the native and M172 SERT proteins. In humans 
and rodents, most SSRIs and SNRIs are metabolized to demethylated forms by 
cytochrome P450 enzymes, found primarily in the liver[178]. Many of these 
demethylated metabolites are active antagonists of SERT mediated 5-HT 
transport[179]. However, the selectivity and potency of these metabolites for wild-
type mSERT (I172) versus M172 mSERT has not been evaluated. This is an 
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important consideration for chronic drug studies using this model (or similar 
animal models)[180-182], as some of these metabolites have very long half-lives 
leading to bioaccumulation of the compounds. If the M172 mSERT mouse were 
to retain sensitivity to these relatively long-lasting drug metabolites despite being 
insensitive to the parent compound, it could confound experimental outcomes. In 
this study, we investigate the sensitivity of M172 mSERT in brain-derived 
synaptosomes and platelets to antagonism by multiple SSRIs, SNRIs, and their 
metabolites. Furthermore, we measure the generation of the citalopram 
metabolite desmethylcitalopram in serum and brain tissue at 45 min and 2 h 
following intraperitoneal injections to determine if SSRI chronic treatment 
regimens could be impacted by bioactive metabolites that have equivalent or 
biologically relevant potencies at wild type mSERT and M172 mSERT. This 
information is critical to ensuring that the physiological and behavioral effects 
observed with AD administration are due to the action of the parent compound 
and not to metabolites.  
Methodology 
Animals 
 Serotonin transporter (SERT) M172 knock-in mice were previously 
generated on a 129S6 background[158]. The M172 knock-in and I172 wild-type 
littermates (8−12 weeks old) from heterozygous breeding litters were used for the 
ex vivo serotonin transport inhibition assays. Age-matched I172 wild-type C57BL/
6J (Jackson Laboratory) mice from homozygous breeding litters were used for 
mass spectrometry (MS) analysis. Food and water were provided ad libitum, and 
mice were maintained on a 12 h light/dark schedule. All animal procedures follow 
protocols approved by the UTHSCSA and/ or UND IACUC animal use and care 
committees.  
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Synaptosome and Platelet-rich Plasma Preparations 
 Samples were prepared as previously described[158], but adapted to obtain 
both synaptosomes and PRP from the same animal to minimize the number of 
animals used. Briefly, mice were deeply anesthetized using Euthasol (500 µL/
animal) (Virbac AH, TX) and effectiveness assessed using foot pinch. Following 
ophthalmectomy for PRP preparation, orbital blood was collected with 
heparinized capillary tubes and the brain (forebrain and midbrain) dissected on 
ice for synaptosome preparation.  
Brain blocks were homogenized in a buffer solution (containing 0.32 M 
sucrose and 4.2 mM HEPES, pH 7.4). Synaptosomal pellets were obtained 
through two-stage centrifugation: the homogenate was spun at 1500 rpm for 15 
min at 4 °C and then the supernatant at 1.5 × 10 000g for 15 min at 4 °C. 
Synaptosomal pellets were resuspended with Krebs-Ringer HEPES buffer (KRH; 
130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 
1.8 g/L D-glucose, 10 mM HEPES, pH 7.4, 100 mM pargyline, and 100 mM 
ascorbic acid). Synaptosomal suspensions were assessed for protein content 
using a spectrophotometer (Thermo Scientific) and then diluted to 667 µg/mL 
with KRH buffer. The prepared synaptosomes were maintained on ice until 
dispensed for serotonin transport assays. 
Blood was collected as described above and anticoagulated with Acid 
Citrate Dextrose Solution A (BD Franklin Lakes, NJ) at a ratio of 100 µL per 500 
µL and then centrifuged at 150g for 20 min at 22 °C to obtain PRP (the upper, 
clear supernatant). The PRP was collected and platelet counts/µL were 
determined using a hemocytometer. Platelets were diluted to achieve a final 
concentration of 3 × 106 platelets/assay. To prevent platelet activation, PRP was 
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maintained at room temperature until use in competition 5-HT uptake assays as 
described below.  
5-HT Competition Uptake Assays 
 Transport of 5-HT was assayed as described previously[183]. Briefly, [3H]5-
HT (100 nM) and serial dilutions of SERT inhibitors were prepared separately in 
KRH for synaptosomes or a platelet buffer solution (150 mM NaCl, 50 mM Tris 
HCl, 25 mM EDTA, pH 7.4, 100 mM pargyline, and 100 mM ascorbic acid) for 
platelets. The assays were set up on ice in a final volume of 250 µL (150 µL 
synaptosome or PRP, 50 µL [3H]5-HT, and 50 µL antagonist). The assay was 
initiated by incubation in a water bath for 10 min at 37 °C followed by immediate 
filtration over 0.3% polyethylenimine-coated glass fiber filters (Brandel) using a 
cell harvester (Brandel). Filter-bound radioactivity was quantified by a Beckman 
LS 6000 liquid scintillation counter. All transport assays were performed in 
duplicate. Radioactivity was normalized as a percentage of inhibition and plotted 
to determine the IC50 of the tested antagonist.  
Drugs 
 Antidepressants and metabolites used for 5-HT competition uptake assays 
were purchased as follows: citalopram (cat # C7861), fluoxetine (cat #F132), and 
norfluoxetine (cat #F133) from Sigma- Aldrich; venlafaxine (cat #sc-201102), 
desvenlafaxine (cat #sc- 255071), sertraline (cat #sc-201104), S-
desmethylcitalopram (cat #sc-220017), and rac-trans-N-desmethylsertraline (cat 
#sc-219920) from Santa Cruz Biotechnology.  
Animal Injections and Measurement of Brain and Serum Drug Concentrations 
 VK05-19. Oxalate S-Citalopram, a gift from Amy Newman (NIH-NIDA), 
and the metabolite (S)-N-desmethylcitalopram (Toronto Research Chemicals 
Inc., cat #D291571) were administered via intraperitoneal injection in 0.9% NaCl 
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at 10 mg/kg, 5 mL/kg, respectively. For mass spectrometry analysis, imipramine 
(Sigma-Aldrich, cat #I7379) was used as an internal standard while citalopram 
and desmethylcitalopram were used as positive controls and were reconstituted 
in 100% methanol with a final concentration of 5 ng.  
Brain Tissue and Serum Preparations 
 At 45 min and 2 h post injection, mice were decapitated. Whole brains 
were frozen and stored in liquid nitrogen (N2). Trunk blood was collected and 
centrifuged for 10 min at 4 °C, 10 000 rpm, and then the supernatant transferred 
to cryovials for storage in N2. Brain tissue was pulverized to a fine powder under 
N2 temperatures to allow for a homogeneous mixing of different brain 
compartments and extracted using a one-step protocol[184]. For extraction, 10 mg 
of brain tissue or 10 µL of plasma was spiked with the internal standard 
imipramine and then mixed with 90 µL of 100% methanol. Samples were briefly 
sonicated on ice, vortexed, and centrifuged for 10 min at 4 °C, 10 000 rpm. 
Collected supernatant was diluted 100-fold with 90% methanol in water.  
UPLC-MS/MS Analysis for Citalopram and Desmethylcitalopram 
 Compounds were resolved on a Waters ACUITY UPLC HSS T3 column 
(1.8 µM, 100 Å pore diameter, 2.1 × 150 mm, Waters, Milford, MA) with an 
ACUITY UPLC HSS T3 precolumn (1.8 µM, 100 Å pore diameter, 2.1 × 5 mm, 
Waters) at a temperature of 55 °C. Analytes were eluted using a Waters ACUITY 
UPLC pump with a well plate autosampler at 8 °C. A volume of 10 µL of sample 
was injected on the column.  
 The separation was based on the previously described method[184-186]. 
Solvent A was water containing 0.1% formic acid and solvent B was acetonitrile 
with 0.1% formic acid. The flow rate was maintained at 0.45 mL/min. The initial 
conditions of 39% B were held for 0.5 min. Solvent B was increased to 40.5% 
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over 6.88 min, followed by an increase to 70% over 1.62 min, then increased to 
75% over 3 min, and further increased to 98 over 1.5 min where it was held for 
5.3 min to elute hydrophobic molecules from the column. At 20 min, solvent B 
was returned to initial conditions over 0.2 min to re-equilibrate the column for 2 
min. 
 Compounds were analyzed using a triple quadrupole mass spectrometer 
(Xevo TQ-S, Waters) with electrospray ionization optimized in a positive mode. 
The capillary voltage was 3.29 kV and cone voltage was 14 V. The desolvation 
temperature was 500 °C and the source temperature 150 °C. The desolvation 
gas flow was 1000 L/ h, the cone gas flow was 150 L/h, and the nebulizer gas 
was at 5.0 bar. The collision gas was set at 0.18 mL/min. MassLynx V4.1 
software (Waters) was used for instrument control, acquisition, and sample 
analysis. 
 Citalopram and desmethylcitalopram were quantified using imipramine as 
an internal standard. Each compound’s MS/MS parameters were optimized for 
multiple reactions monitoring (MRM) mode by direct infusion of a standard 
solution of each analyte. Citalopram was quantified using 325.18/109.04 mass 
transition (collision energy (CE) 14 V) with 325.18/234.14 conformational ion (CE 
24 V); desmethylcitalopram was quantified using 311.16/109.04 mass transition 
(CE 14 V) with 311.16/262.15 conformational ion (CE 16 V); and imipramine was 
quantified using 281.20/86.09 mass transition (CE 14 V) with 281.20/208.11 
conformational ion (CE 36 V). The mass transitions for analytes and the selection 
of internal standard were consistent with previous reports[187]. The data are 
represented as the log of the concentration. This log scaling is used to reduce 
the impact of scaling for metabolite intensity differences during MS/MS 
analysis[188].  
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Results and Discussion 
 Our previous study revealed that in comparison to wild-type mice, the 
SSRIs citalopram and fluoxetine display significantly reduced potencies for 
inhibition of SERT mediated 5-HT uptake in brain-derived synaptosomes from 
M172 SERT mice[158]. Similarly, in this study, the SSRIs citalopram, fluoxetine, 
and sertraline as well as the SNRI venlafaxine showed significant losses in 
potency for antagonism of M172 synaptosomes, reductions ranging from 16-fold 
(fluoxetine) to 633-fold (citalopram) (Figure 2.2, Table 2.1). As multiple SSRIs and 
SNRIs have active metabolites with half-lives long enough to make them 
biologically relevant[158, 179], we also characterized the potency of the correlate 
metabolites desmethylcitalopram, norfluoxetine, desmethylsertraline, and 
desvenla fax ine. Compar ison of potenc ies o f nor f luoxet ine and 
desmethylsertraline to inhibit 5-HT uptake in wild-type mSERT and M172 mSERT 
derived synaptosomes revealed that the demethylated compounds no longer 
exhibited strong selectivity for inhibition of wild-type mSERT over M172 mSERT 
as the fold-change differentials between the IC50 values was reduced to 3.1- and 
2.5-fold, respectively. However, desvenlafaxine and desmethylcitalopram 
retained selectivity for wild-type mSERT over M172 mSERT (49- and 80-fold, 
respectively) (Figure 2.2, Table 2.1). It is important to note that whereas the 
selectivity of desmethylsertraline between wild-type mSERT and M172 mSERT is 
2.5- fold, the potency of the drug to inhibit wild-type mSERT is 39- fold less than 
the parent drug sertraline. Conversely, metabolites norfluoxetine, desvenlafaxine, 
and desmethylcitalopram inhibit 5-HT uptake in wild-type mSERT at potencies 
similar to their parent compounds (≤2.5-fold-change). For this reason, it is 
plausible that these metabolites in particular contribute to physiological blockade 
of transport and have a role in the effects observed following chronic AD 
administration. 
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 NET and SERT are both significant targets of SNRIs. Although our 5-HT 
uptake assays should not be affected by the presence of NET, we also tested the 
potency of these drugs in platelets, which eliminates any contribution of NET. 
Platelets isolated from whole blood are often used as peripheral markers[189] in 
human studies of SERT as they are easily obtained from subjects[190]. In addition, 
platelets cannot synthesize 5-HT and are therefore entirely dependent on SERT-
mediated uptake to accumulate 5-HT[159, 190, 191]. Our inhibitory data from platelets 
are consistent with the synaptosomal results in that all drugs lose potency for the 
M172 mutant (Table 2.1). However, there were some differences in the 
magnitude of the fold-change of drug potencies between platelets and 
synaptosomes (Table 2.1, Figures 2.2 and 2.3). In addition, some compounds 
showed higher potency in platelets versus synaptosomes while other compounds 
were more potent in synaptosomes. This is not entirely unexpected as platelets 
likely lack some of the SERT interacting proteins present in neurons whose 
interactions can affect conformational states of the transporter and thereby 
selectively impact binding of each antagonist. Similarly, post-translational 
modifications of SERT such as phosphorylation status could be altered in 
synaptosomes versus platelets and these changes are known to impact potency 
of some inhibitors[192]. These factors could account for changes in magnitude and 
cell-type specific potency differences for each drug. Nevertheless, the identical 
trends in potency loss from WT to M172 in each condition support our 
conclusions. Notably, we are primarily focused on metabolite action in the brain; 
the following analyses are from synaptosome assays unless specifically noted. 
 Analysis of SERT activity in brain synaptosomes derived from the M172 
mouse reveals that the fluoxetine metabolite norfluoxetine shows a slight 
decrease in antagonist potency for wild-type mSERT, but gains potency for 
47
48
is notable considering that the actions of SSRIs are often
evaluated and characterized in studies by comparison to the
SERT null mouse,21 which is generally inappropriate due to the
e!ect of SERT loss on 5-HT levels and how this disruption of
5-HT homeostasis can impact development of both serotoner-
gic and nonserotonergic systems.22 Chronic loss of appropriate
serotonergic tone caused by the SERT null genotype results in
alteration of multiple physiological and behavioral phenotypes
that make any comparisons to the wild-type mouse during SSRI
treatment confounding and problematic at best.23 The SERT
M172 AD-insensitive mouse represents a signi"cant step
forward and a powerful new tool to de"ne the role of SERT
and 5-HT signaling following AD administration as this model,
unlike the SERT null mouse, has normal 5-HT transport and
no known phenotypic changes other than loss of SSRI
sensitivity. Therefore, the utility of the SERT M172 mouse to
serve as a better control in AD studies will likely result in its
increased use making more detailed characterizations of this
mouse model of interest to the "eld.
Whereas many SSRIs have been evaluated for inhibition of
the mSERT M172 mutant,15,16 there exists no analysis of SSRI
metabolites in regards to potency and selectivity between the
native and M172 SERT proteins. In humans and rodents, most
SSRIs and SNRIs are metabolized to demethylated forms by
cytochrome P450 enzymes, found primarily in the liver.24 Many
of these demethylated metabolites are active antagonists of
SERT mediated 5-HT transport.25 However, the selectivity and
potency of these metabolites for wild-type mSERT (I172)
Figure 1. Competition 5-HT uptake analysis in brain-derived synaptosomes. Brain-derived synaptosomes were prepared from wild-type ("lled
circles, !) and M172 (open boxes, ") mice and utilized to assess the ability of multiple SSRI class drugs and their metabolites to compete for [3H]5-
HT uptake. All SSRIs showed decreased potency in the M172 synaptosomes, while some metabolites showed similar potency in both wild-type and
M172 synaptosomes (n = 4!8 per drug; values represent the mean ± SE).
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Figure 2.2. Competition 5-HT uptake analysis in brain-derived 
synaptosomes. Brain-derived synaptosomes were prepared from wild-type (filled 
circles, ●) and M172 (open boxes, □) mice and utilized to assess the ability of 
multiple SSRI class drugs and their metabolites to compete for [3H]5- HT uptake. 
All SSRIs showed decreased potency in the M172 synaptosomes, while some 
metabolites showed similar potency in both wild-type and M172 synaptosomes (n 
= 4−8 per drug; values represent the mean ± SE).  
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versus M172 mSERT has not been evaluated. This is an
important consideration for chronic drug studies using this
model (or similar animal models),26!28 as some of these
metabolites have very long half-lives leading to bioaccumulation
of the compounds. If the M172 mSERT mouse were to retain
sensitivity to these relatively long-lasting drug metabolites
despite being insensitive to the parent compound, it could
confound experimental outcomes. In this study, we investigate
the sensitivity of M172 mSERT in brain-derived synaptosomes
and platelets to antagonism by multiple SSRIs, SNRIs, and their
metabolites. Furthermore, we measure the generation of the
citalopram metabolite desmethylcitalopram in serum and brain
tissue at 45 min and 2 h following intraperitoneal injections to
determine if SSRI chronic treatment regimens could be
impacted by bioactive metabolites that have equivalent or
biologically relevant potencies at wild-type mSERT and M172
mSERT. This information is critical to ensuring that the
physiological and behavioral e!ects observed with AD
administration are due to the action of the parent compound
and not to metabolites.
! RESULTS AND DISCUSSION
Our previous study revealed that in comparison to wild-type
mice, the SSRIs citalopram and "uoxetine display signi#cantly
reduced potencies for inhibition of SERT mediated 5-HT
uptake in brain-derived synaptosomes from M172 SERT
mice.15 Similarly, in this study, the SSRIs citalopram, "uoxetine,
and sertraline as well as the SNRI venlafaxine showed
signi#cant losses in potency for antagonism of M172
synaptosomes, reductions ranging from 16-fold ("uoxetine)
to 633-fold (citalopram) (Figure 1, Table 1). As multiple SSRIs
and SNRIs have active metabolites with half-lives long enough
to make them biologically relevant,25 we also characterized the
potency of the correlate metabolites desmethylcitalopram,
nor"uoxetine, desmethylsertraline, and desvenlafaxine. Com-
parison of potencies of nor"uoxetine and desmethylsertraline to
inhibit 5-HT uptake in wild-type mSERT and M172 mSERT
derived synaptosomes revealed that the demethylated com-
pounds no longer exhibited strong selectivity for inhibition of
wild-type mSERT over M172 mSERT as the fold-change
di!erentials between the IC50 values was reduced to 3.1- and
2.5-fold, respectively. However, desvenlafaxine and desmethyl-
citalopram retained selectivity for wild-type mSERT over M172
mSERT (49- and 80-fold, respectively) (Figure 1, Table 1). It is
important to note that whereas the selectivity of desmethylser-
traline between wild-type mSERT and M172 mSERT is 2.5-
fold, the potency of the drug to inhibit wild-type mSERT is 39-
fold less than the parent drug sertraline. Conversely,
metabolites nor"uoxetine, desvenlafaxine, and desmethylcitalo-
pram inhibit 5-HT uptake in wild-type mSERT at potencies
similar to their parent compounds ("2.5-fold-change). For this
reason, it is plausible that these metabolites in particular
contribute to physiological blockade of transport and have a
role in the e!ects observed following chronic AD admin-
istration.
NET and SERT are both signi#cant targets of SNRIs.
Although our 5-HT uptake assays should not be a!ected by the
presence of NET, we also tested the potency of these drugs in
platelets, which eliminates any contribution of NET. Platelets
isolated from whole blood are often used as peripheral
markers29 in human studies of SERT as they are easily
obtained from subjects.30 In addition, platelets cannot
synthesize 5-HT and are therefore entirely dependent on
SERT-mediated uptake to accumulate 5-HT.2,31 Our inhibitory
data from platelets are consistent with the synaptosomal results
in that all drugs lose potency for the M172 mutant (Table 1).
However, there were some di!erences in the magnitude of the
fold-change of drug potencies between platelets and
synaptosomes (Table 1, Figures 1 and 2). In addition, some
compounds showed higher potency in platelets versus
synaptosomes while other compounds were more potent in
synaptosomes. This is not entirely unexpected as platelets likely
lack some of the SERT interacting proteins present in neurons
whose interactions can a!ect conformational states of the
transporter and thereby selectively impact binding of each
antagonist. Similarly, post-translational modi#cations of SERT
such as phosphorylation status could be altered in synapto-
somes versus platelets and these changes are known to impact
potency of some inhibitors.32 These factors could account for
changes in magnitude and cell-type speci#c potency di!erences
for each drug. Nevertheless, the identical trends in potency loss
from WT to M172 in each condition support our conclusions.
Notably, we are primarily focused on metabolite action in the
brain; the following analyses are from synaptosome assays
unless speci#cally noted.
Analysis of SERT activity in brain synaptosomes derived
from the M172 mouse reveals that the "uoxetine metabolite
nor"uoxetine shows a slight decrease in antagonist potency for
wild-type mSERT, but gains potency for inhibiting M172
mSERT resulting in a signi#cant reduction in selective
inhibition of wild-type mSERT versus M172 mSERT from
Table 1. IC50 Values for Inhibition of [
3H]5-HT Uptakea
platelets synaptosomes
IC50 (!M) IC50 (!M)
WT M172 fold shift WT M172 fold shift
"uoxetine 0.040 [0.02, 0.12] 0.63 [0.18, 2.75] 16 0.10 [0.03, 0.24] 1.6 [1.19, 3.12] 16
nor"uoxetine 0.10 [0.07, 0.13] 0.20 [0.10, 0.49] 2 0.16 [0.10, 0.21] 0.50 [0.43, 0.58] 3.1
sertraline 0.010 [0.01, 0.02] 0.79 [0.28, 3.01] 79 0.016 [0.003, 0.07] 1.3 [1.04, 1.76] 81
desmethylsertraline 0.050 [0.04, 0.07] 0.40 [0.26, 0.95] 8 0.63 [0.25, 1.91] 1.6 [1.12, 3.52] 2.5
venlafaxine 0.40 [0.23, 1.07] 126 [49.43, 381.07] 315 0.16 [0.09, 0.29] 7.9 [2.44, 13.74] 49
desvenlafaxine 0.50 [0.17, 2.55] 50 [24.10, 72.78] 100 0.16 [0.09, 0.25] 7.9 [3.91, 13.30] 49
citalopram 0.016 [0.01, 0.03] 10 [8.34, 16.18] 625 0.0079 [0.004, 0.02] 5.0 [3.42, 6.65] 633
desmethylcitalopram 0.025 [0.01, 0.15] 10 [6.87, 13.09] 400 0.020 [0.02, 0.03] 1.6 [0.92, 3.06] 80
aCompetition uptake analysis of platelet rich plasma (PRP) and brain synaptosomes derived from wild-type and M172 mice was performed to
calculate the IC50 for multiple SSRIs and their active metabolites (mean with range given in brackets). Fold shift compares the rightward shift in
potency for inhibiting SERT activity in M172 compared to wild-type.
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aCompetitio  uptake analysis f platelet rich plasma (PRP) and brain synaptosomes derived 
from wild-type and M172 mice was performed to calculate the IC50 for multiple SSRIs and their 
active metabolites (mean with rang  given in brackets). Fold shift compares the rightward shift 
in potency fo  inhibiting SERT activity in M172 compared to wild-type.  
Table 2.1 IC50 Values f r Inhibition of [
3H]5-HT Uptakea  
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16-fold to 3.1-fold (Figure 1, Table 1). In addition,
nor!uoxetine has been reported to return to the mouse brain
where signi"cant levels can accumulate due to its longer half-life
(12.3 h) compared to !uoxetine (6.8 h).22,33,34 As a result,
nor!uoxetine is likely the major antagonist of 5-HT uptake by
SERT in both wild-type mSERT and M172 mSERT following
chronic administration of !uoxetine. Desmethylsertraline, the
breakdown product of sertraline, also displays reduced
selectivity for wild-type mSERT over M172 mSERT (81-fold
to 2.5-fold) in synaptosomes but importantly is 39-fold less
potent than sertraline for inhibiting wild-type mSERT and is
therefore unlikely to signi"cantly contribute to inhibition of 5-
HT uptake. Venlafaxine and its metabolite desvenlafaxine
maintain their selective potencies for inhibition of wild-type
mSERT versus M172 mSERT in synaptosomes, as both exhibit
a 49-fold selectivity for wild-type mSERT over M172 mSERT
(Figure 1, Table 1). Therefore, if desvenlafaxine is capable of
entering the brain, it would have the same antagonistic e#ect as
venlafaxine in both wild-type mSERT and M172 mSERT.
Desmethylcitalopram, the primary metabolite of citalopram,
exhibits reduced potency compared to citalopram but retains
robust selectivity for inhibition of wild-type mSERT over M172
mSERT (633-fold selectivity for citalopram versus 80-fold for
desmethylcitalopram).
Having established that AD metabolites are capable of
antagonizing SERT mediated 5-HT transport in ex vivo assays,
we determined whether the metabolite desmethylcitalopram is
capable of crossing the blood brain barrier, because re-entry
Figure 2. Competition 5-HT uptake analysis in isolated platelets. Isolated platelet rich plasma (PRP), from wild-type ("lled circles, !) and M172
(open boxes, ") mice, was utilized to assess the ability of multiple SSRI class drugs and their metabolites to compete for [3H]5-HT uptake. All SSRIs
showed decreased potency in the M172 platelets, while some metabolites showed similar potency in both wild-type and M172 platelets, comparable
to what was seen in synaptosomes (n = 5!7 per drug; values represent the mean ± SE).
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Figure 2.3. Competition 5-HT uptake analysis in isolated platelets. Isolated 
platelet rich plasma (PRP), from wild-type (filled circles, ●) and M172 (open 
boxes, □) mice, was utilized to assess the ability of multiple SSRI class drugs 
and their metabolites to compete for [3H]5-HT uptake. All SSRIs showed 
decreased potency in the M172 platelets, while some metabolites showed similar 
potency in both wild-type and M172 platelets, comparable to what was seen in 
synaptosomes (n = 5−7 per drug; values represent the mean ± SE).  
inhibiting M172 mSERT resulting in a significant reduction in selective inhibition 
of wild-type mSERT versus M172 mSERT from 16-fold to 3.1-fold (Figure 2.2, 
Table 2.1). In addition, norfluoxetine has been reported to return to the mouse 
brain where significant levels can accumulate due to its longer half-life (12.3 h) 
compared to fluoxetine (6.8 h)[119, 193, 194]. As a result, norfluoxetine is likely the 
major antagonist of 5-HT uptake by SERT in both wild-type mSERT and M172 
mSERT following chronic administration of fluoxetine. Desmethylsertraline, the 
breakdown product of sertraline, also displays reduced selectivity for wild-type 
mSERT over M172 mSERT (81-fold to 2.5-fold) in synaptosomes but importantly 
is 39-fold less potent than sertraline for inhibiting wild-type mSERT and is 
therefore unlikely to significantly contribute to inhibition of 5- HT uptake. 
Venlafaxine and its metabolite desvenlafaxine maintain their selective potencies 
for inhibition of wild-type mSERT versus M172 mSERT in synaptosomes, as both 
exhibit a 49-fold selectivity for wild-type mSERT over M172 mSERT (Figure 2.2, 
Table 2.1). Therefore, if desvenlafaxine is capable of entering the brain, it would 
have the same antagonistic effect as venlafaxine in both wild type mSERT and 
M172 mSERT. Desmethylcitalopram, the primary metabolite of citalopram, 
exhibits reduced potency compared to citalopram but retains robust selectivity for 
inhibition of wild-type mSERT over M172 mSERT (633-fold selectivity for 
citalopram versus 80-fold for desmethylcitalopram). 
 Having established that AD metabolites are capable of antagonizing SERT 
mediated 5-HT transport in ex vivo assays, we determined whether the 
metabolite desmethylcitalopram is capable of crossing the blood brain barrier, 
because re-entry into the brain following first-pass metabolism could contribute to 
the behav iora l e f fec ts observed wi th chron ic SSRI t rea tment . 
Desmethylcitalopram was selected due to its importance in our ongoing studies. 
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Wild-type mice injected intraperitoneally with citalopram or its metabolite 
desmethylcitalopram were sacrificed after 45 min or 2 h then blood serum and 
brain tissue extracts were analyzed by liquid chromatography and mass 
spectrometry to quantify the levels of parent compounds and metabolites. 
Comparison of the 45 min and 2 h time points revealed that brain and serum 
citalopram levels decrease over time whereas desmethylcitalopram levels, 
metabolized from citalopram, increased in the brain (Figure 2.4, Table 2.2). In 
contrast, the concentration of desmethylcitalopram was not significantly altered in 
the serum of mice injected with citalopram consistent with the injected citalopram 
being metabolized over the 45 min to 2 h time period. Likewise, mice directly 
injected with desmethylcitalopram show an accumulation in the brain over time 
though there was a time dependent reduction in serum levels, which can be 
attributed to elimination. Importantly, desmethylcitalopram, unlike norfluoxetine 
and desmethylsertraline, maintains selectivity for wild- type SERT over M172 
SERT, and therefore, its accumulation in the brain is not expected to interfere 
with chronic citalopram treatment studies in the M172 mouse. 
 In conclusion, synaptosomes and platelets derived from M172 SERT mice 
show a reduced sensitivity to multiple SERT antagonists, as was previously 
demonstrated[158]. However, the ability of bioactive metabolites to antagonize 5-
HT uptake by the M172 mSERT substitution had not previously been studied. 
Here, we explored the potency of these drugs for antagonism of wild type 
mSERT versus M172 mSERT. In chronic drug administration studies, it is 
important to maintain selective inhibition of wild-type mSERT over M172 mSERT. 
In addition, our results suggest chronic drug administration studies need to 
account for active metabolites and determine if there are changes in selectivity, 
inhibitory potency, and blood brain barrier passage, as retention of these effects 
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could lead to misinterpretation of the results. Over the course of days or weeks of 
treatment, metabolites could play a significant, if not, primary role in the blockade 
of SERT. Therefore, this study suggests that the levels of both parent drugs and 
their metabolites be assessed over the duration of the experimental paradigm to 
determine the potential contribution of each compound. Thus, compounds whose 
metabolites lose selectivity for wild-type mSERT versus M172 mSERT, but retain 
potencies comparable to the parent compound are problematic and should not 
be used in M172 mouse studies requiring differential inhibition of wild-type 
mSERT over M172 mSERT.  
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into the brain following !rst-pass metabolism could contribute
to the behavioral e"ects observed with chronic SSRI treatment.
Desmethylcitalopram was selected due to its importance in our
ongoing studies. Wild-type mice injected intraperitoneally with
citalopram or its metabolite desmethylcitalopram were
sacri!ced after 45 min or 2 h then blood serum and brain
tissue extracts were analyzed by liquid chromatography and
mass spectrometry to quantify the levels of parent compounds
and metabolites. Comparison of the 45 min and 2 h time points
revealed that brain and serum citalopram levels decrease over
time whereas desmethylcitalopram levels, metabolized from
citalopram, increased in the brain (Figure 3, Table 2). In
contrast, the concentration of desmethylcitalopram was not
signi!cantly altered in the serum of mice injected with
citalopram consistent with the injected citalopram being
metabolized over the 45 min to 2 h time period. Likewise,
mice directly injected with desmethylcitalopram show an
accumulation in the brain over time though there was a time
dependent reduction in serum levels, which can be attributed to
elimination. Importantly, desmethylcitalopram, unlike nor#uox-
etine and desmethylsertraline, maintains selectivity for wild-
type SERT over M172 SERT, and therefore, its accumulation in
the brain is not expected to interfere with chronic citalopram
treatment studies in the M172 mouse.
In conclusion, synaptosomes and platelets derived from
M172 SERT mice show a reduced sensitivity to multiple SERT
antagonists, as was previously demonstrated.15 However, the
ability of bioactive metabolites to antagonize 5-HT uptake by
the M172 mSERT substitution had not previously been
studied. Here, we explored the potency of these drugs for
antagonism of wild-type mSERT versus M172 mSERT. Our
results suggest that chronic drug administration studies, where
it is important to maintain selective inhibition of wild-type
mSERT over M172 mSERT, need to account for active
metabolites and determine if there are changes in selectivity,
inhibitory potency, and blood brain barrier passage and
retention as these e"ects could lead to misinterpretation of
the results. Over the course of days or weeks of treatment,
metabolites could play a signi!cant, if not, primary role in the
blockade of SERT. Therefore, this study suggests that the levels
of both parent drugs and their metabolites be assessed over the
duration of the experimental paradigm to determine the
potential contribution of each compound. Thus, compounds
whose metabolites lose selectivity for wild-type mSERT versus
M172 mSERT, but retain potencies comparable to the parent
compound are problematic and should not be used in M172
mouse studies requiring di"erential inhibition of wild-type
mSERT over M172 mSERT.
! METHODS
Animals. Serotonin transporter (SERT) M172 knock-in mice were
previously generated on a 129S6 background.15 The M172 knock-in
and I172 wild-type littermates (8!12 weeks old) from heterozygous
breeding litters were used for the ex vivo serotonin transport inhibition
assays. Age-matched I172 wild-type C57BL/6J (Jackson Laboratory)
mice from homozygous breeding litters were used for mass
spectrometry (MS) analysis. Food and water were provided ad
libitum, and mice were maintained on a 12 h light/dark schedule. All
animal procedures follow protocols approved by the UTHSCSA and/
or UND IACUC animal use and care committees.
Synaptosome and Platelet-Rich Plasma (PRP) Preparations.
Samples were prepared as previously described,15 but adapted to
obtain both synaptosomes and PRP from the same animal to minimize
the number of animals used. Brie#y, mice were deeply anesthetized
using Euthasol (500 !L/animal) (Virbac AH, TX) and e"ectiveness
assessed using foot pinch. Following ophthalmectomy for PRP
preparation, orbital blood was collected with heparinized capillary
tubes and the brain (forebrain and midbrain) dissected on ice for
synaptosome preparation.
Brain blocks were homogenized in a bu"er solution (containing
0.32 M sucrose and 4.2 mM HEPES, pH 7.4). Synaptosomal pellets
were obtained through two-stage centrifugation: the homogenate was
Figure 3. Time course analysis of brain and serum levels of citalopram
and the metabolite desmethylcitalopram. Age-matched C57BL/6J
mice were injected with either citalopram or desmethylcitalopram and
sacri!ced at 45 min or 2 h postinjection. The analytes were isolated
from whole brain or serum and detected by LC-MS/MS. In the brain
and serum, citalopram levels (!lled circles, !, Cit) decrease from 45
min to 2 h, whereas the metabolite desmethylcitalopram (open
triangles, ", dCit from Cit) levels increase only in the brain over time.
As a control, mice injected with the metabolite desmethylcitalopram
(open boxes, #, dCit) show an accumulation of the metabolite in the
brain, when comparing 45 min and 2 h, but a decreased concentration
in the serum. (n " 2 mice; values represent mean ± SE; one-way
ANOVA with posthoc Holm!S!i "da "k multiple comparison test was
used to compare 45 min to 2 h for each compound, *, p < 0.05, **, p <
0.01).
Table 2. LC-MS/MS Quanti!cation of Citalopram and the Metabolite Desmethylcitalopram in Brain and Seruma
brain (!M) serum (!M)
45 min 2 h ANOVA 45 min 2 h ANOVA
citalopram 5.52 ± 0.54 2.85 ± 0.38 * 0.76 ± 0.04 0.42 ± 0.05 *
desmethylcitalopram 0.38 ± 0.03 0.73 ± 0.12 ** 1.03 ± 0.04 0.51 ± 0.10 *
desmethylcitalopram from citalopram 0.14 ± 0.01 0.37 ± 0.05 * 0.33 ± 0.01 0.46 ± 0.09 n.s.
aAge-matched C57BL/6J mice were injected with either citalopram or desmethylcitalopram and sacri!ced at 45 min or 2 h post-injection. The
analytes were isolated from whole brain or serum and detected by LC-MS/MS (n " 2 mice; values represent mean ± S.E.; one-way ANOVA with
post-hoc Holm-S!i "da "k multiple comparison test was used to compare 45 min to 2 h, *p < 0.05, **p < 0.01; n.s. not signi!cant).
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Figure 2.4. Time course analysis of brain and 
serum levels of citalopram and the metabolite 
desmethylcitalopram. Age-matched C57BL/6J 
mice were injected with either citalopram or 
desmethylcitalopram and sacrificed at 45 min or 2 h 
postinjection. The analytes were isolated from 
whole brain or serum and det cted by LC-MS/MS. 
In the brain and s rum, italopram levels (filled 
circles, ●, Cit) decrease from 45 min to 2 h, 
whereas the metabolite des ethylcitalopra  (open 
tria gles, △, dCit from Cit) levels increase only in 
the brain over ti e. As a control, mice injected with 
the metabolite desmethylcitalopram (open boxes, □, 
dCit) show an accumulation of the metabolite in the 
brain, when comparing 45 min and 2 h, but a 
decreased concentration in the serum. (n ≥ 2 mice; 
v a l u e s r e p r e s e n t m e a n ± S E ; o n e - w a y 
ANOVAwithposthocHolm−Šid́aḱmultiplecomparisont
estwas used to compare 45 min to 2 h for each 
compound, *, p < 0.05, **, p < 0.01).  
into the brain following !rst-pass metabolism could contribute
to the behavioral e"ects observed with chronic SSRI treatment.
Desmethylcitalopram was selected due to its importance in our
ongoing studies. Wild-type mice injected intraperitoneally with
citalopram or its metabolite desmethylcitalopram were
sacri!ced after 45 min or 2 h then blood serum and brain
tissue extracts were analyzed by liquid chromatography and
mass spectrometry to quantify the levels of parent compounds
and metabolites. Comparison of the 45 min and 2 h time points
revealed that brain and serum citalopram levels decrease over
time whereas desmethylcitalopram levels, metabolized from
citalopram, increased in the brain (Figure 3, Table 2). In
contrast, the concentration of desmethylcitalopram was not
signi!cantly altered in the serum of mice injected with
citalopram consistent with the injected citalopram being
metabolized over the 45 min to 2 h time p riod. Likewis ,
mice directly injected with desmethylcitalopram show an
accumulation in the brain over time though there was a time
dependent reduction in serum levels, which can be attributed to
elimination. Importantly, desmethylcitalopram, unlike nor#uox-
etine and desmethylsertraline, maintains selectivity for wild-
type SERT over M172 SERT, and therefore, its accumulation in
the brain is not expected to interfere with chronic citalopram
treatment studies in the M172 mouse.
In conclusion, synaptosomes and platelets derived from
M172 SERT mice show a reduced sensitivity to multiple SERT
antagonists, as was previously demonstrated.15 However, the
ability of bioactive metabolites to antagonize 5-HT uptake by
the M172 mSERT substitution had not previously been
studied. Here, we explored the potency of these drugs for
antagonism of wild-type mSERT versus M172 mSERT. Our
results suggest that chronic drug administration studies, where
it is important to maintain selective inhibition of wild-type
mSERT over M172 mSERT, need to account for active
metabolites and determine if there are changes in selectivity,
inhibitory potency, and blood brain barrier passage and
retention as these e"ects could lead to misinterpretation of
the results. Over the course of days or weeks of treatment,
metabolites could play a signi!cant, if not, primary role in the
blockade of SERT. Therefore, this study suggests that the levels
of both parent drugs and their metabolites be assessed over the
duration of the experimental paradigm to deter ine the
potential contribution of each compound. Thus, compounds
whose metabolites lose selectivity for wild-type mSERT versus
M172 mSERT, but retain potencies comparable to the parent
compound are problematic and should not be used in M172
mouse studies requiring di"erential inhibition of wild-type
mSERT over M172 mSERT.
! METHODS
Animals. Serotonin transporter (SERT) M172 knock-in mice were
previously generated on a 129S6 background.15 The M172 knock-in
and I172 wild-type littermates (8!12 weeks old) from heterozygous
breeding litters were used for the ex vivo serotonin transport inhibition
assays. Age-matched I172 wild-type C57BL/6J (Jackson Laboratory)
mice from homozygous breeding litters were used for mass
spectrometry (MS) analysis. Food and water were provided ad
libitum, and mice were maintained on a 12 h light/dark schedule. All
animal procedures follow protocols approved by the UTHSCSA and/
or UND IACUC animal use and care committees.
Synaptosome and Platelet-Rich Plasma (PRP) Preparations.
Sa ples were prepared as previously described,15 but adapted to
obtain both synaptosomes and PRP from the same animal to minimize
the number of animals used. Brie#y, mice were deeply anesthetized
using Euthasol (500 !L/animal) (Virbac AH, TX) and e"ectiveness
assessed using foot pinch. Following ophthalmectomy for PRP
preparation, orbital blood was collected with heparinized capillary
tubes and the brain (forebrain and midbrain) dissected on ice for
synaptosome preparation.
Brain blocks were homogenized in a bu"er solution (containing
0.32 M sucrose and 4.2 mM HEPES, pH 7.4). Synaptosomal pellets
were obtained through tw -stage centrifugation: the homogenate was
Figure 3. Time course analysis of brain and serum levels of citalopram
and the metabolite desmethylcitalopram. Age-matched C57BL/6J
mice were injected with either citalopram or desmethylcitalopram and
sacri!ced at 45 min or 2 h postinjection. The analytes were isolated
from whole brain or serum and detected by LC-MS/MS. In the brain
and serum, citalopram levels (!lled circles, !, Cit) decrease from 45
min to 2 h, whereas the metabolite desmethylcitalopram (open
triangles, ", dCit from Cit) levels incr ase only in the brain ver time.
As a control, mice injected with the metabolite desmethylcitalopram
(open boxes, #, dCit) show an accumulation of the metabolite in the
brain, when comparing 45 min and 2 h, but a decreased concentration
in the serum. (n " 2 mice; values represent mean ± SE; one-way
ANOVA with posthoc Holm!S!i "da "k multiple comparison test was
used to compare 45 min to 2 h f r each compound, *, p < 0.05, **, p <
0.01).
Table 2. LC-MS/MS Quanti!cation of Citalopram and the Metabolite Desmethylcitalopram in Brain and Seruma
brain (!M) serum (!M)
45 min 2 h ANOVA 45 min 2 h ANOVA
citalopram 5.52 ± 0.54 2.85 ± 0.38 * 0.76 ± 0.04 0.42 ± 0.05 *
desmethylcitalopram 0.38 ± 0.03 0.73 ± 0.12 ** 1.03 ± 0.04 0.51 ± 0.10 *
desmethylcitalopram from citalopram 0.14 ± 0.01 0.37 ± 0.05 * 0.33 ± 0.01 0.46 ± 0.09 n.s.
aAge-matched C57BL/6J mice were injected with either citalopram or desmethylcitalopram and sacri!ced at 45 min or 2 h post-injection. The
analytes were isolated from whole brain or serum and detected by LC-MS/MS (n " 2 mice; values represent mean ± S.E.; one-way ANOVA with
post-hoc Holm-S!i "da "k multiple comparison test was used to compare 45 min to 2 h, *p < 0.05, **p < 0.01; n.s. not signi!cant).
ACS Chemical Neuroscience Letter
DOI: 10.1021/acschemneuro.6b00343
ACS Chem. Neurosci. 2017, 8, 1011!1018
1015
aAge-matched C57BL/6J mice were injected with either citalopram or desmethylcitalopram and 
sacrificed at 45 min or 2 h post-injection. The analytes were isolated from whole brain or serum 
and detected by LC-MS/MS (n ≥ 2 mice; values represent mean ± S.E.; one-way ANOVA with 
post-hocHolm-Šid́aḱ multiple comparison test was used to compare 45 min to 
2h,*p<0.05,**p<0.01;n.s.not significant).  
Table 2.2. LC-MS/MS Quantification of Citalopram and the Metabolite 
Desmethylcitalopram in Brain and Seruma  
CHAPTER III 
TRANSCRIPTOMIC COMPARISON OF THE MIDBRAIN AND HIPPOCAMPUS 
OF WILD-TYPE MICE TO MICE LACKING THE SEROTONIN TRANSPORTER 
OR HARBORING AN ANTIDEPRESSANT INSENSITIVE SEROTONIN 
TRANSPORTER MUTANT (I172M) 
Abstract 
 Anxiety and depression are complex mood disorders that are often treated 
with antidepressants that target the serotonergic system. Biochemical and 
behavioral insight into antidepressant actions and the role the serotonergic 
system plays in depression and anxiety-like behaviors has traditionally been 
informed by comparisons of normal mice to those that lack the serotonin 
transporter (SERT; Slc6a4) (knock-out; KO). However, SERT KO animals exhibit 
numerous behavioral and physiological changes that make interpretation of 
results problematic. In an attempt to characterize a more appropriate animal 
model for such studies, we use RNA-Seq analysis to compare transcriptomic 
changes in the midbrain and hippocampus of wild-type and SERT knock-out mice 
to a SERT I172M transgenic mouse line which harbors a SERT that is virtually 
insensitive to many SERT-directed antidepressants while maintaining full 
functionality for serotonin transport. Our findings reveal similar transcription 
profiles between the wild-type and I172M mice in contrast to the KO animal 
which displays numerous expression changes in genes involved in neuronal 
genesis, organization, locomotion, signaling, and protein and RNA processing. In 
addition, we observed ectopic expression of a truncated SERT transcript in the 
hippocampus of knock-out animals and pathway analysis suggests this transcript 
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or the partial protein product may impact neuronal survival suggesting further 
caution for use of the SERT knock-out animal as a model system. Collectively, 
these findings support the advantage of the I172M mouse line over SERT 
knockout mice for evaluating the role and action of SERT-directed 
antidepressants.  
Introduction 
 Dysregulation in serotonergic neurotransmission has long been 
associated with depression[96, 136, 141, 195-198], anxiety[136, 141, 196, 197], stress[196, 199, 
200] and autism spectrum disorders[196, 201-204]. Neurologically, the serotonergic 
system is involved in the regulation of cognition[205-207], learning[208, 209], 
memory[207, 210], sensorimotor activities[211, 212], circadian rhythm[211, 212], 
appetite[213], sexual behaviors[214-216], aggressions[214-216], stress[199, 200, 217] and 
mood[96, 141, 196, 206, 217] while systemically the serotonergic system is involved in 
the regulation of cardiovascular function[218-220], respiration[221, 222], and 
gastrointestinal motility[159, 223]. In fact, serotonergic signaling is widespread 
throughout the body with the serotonergic system being one of the first neuronal 
networks to develop during embryogenesis where it is critical to the development 
and life-long neuroplastic maintenance of brain structures[105, 123, 129, 133, 159, 162, 205, 
224]. Several key components for the regulation of serotonergic signaling are the 
neurotransmitter serotonin (5-hydroxytryptamine; 5-HT), the serotonin transporter 
(SERT; Slc6a4) which is the primary mechanism for clearing 5-HT from 
synapses[139, 162], and 15 distinct serotonin receptor subtypes involved in auto-
regulation and signal propagation[105, 159, 225, 226], including the receptor-mediated 
morphogenic effects of 5-HT[128, 224, 227]. The neurotrophic role of 5-HT is constant 
throughout life[36, 37], but it is especially crucial for the evolvement of neural 
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networks and neurotransmitter systems[105, 128, 205, 228]. Disruption of these 
developmental processes by genetic variations of the serotonergic system[141, 195, 
196, 229, 230] or by drugs that target the serotonergic system, such as selective 
serotonin reuptake inhibitor (SSRI) antidepressants may contribute to the 
etiology of depressive disorders[115, 126, 136, 162, 197, 198, 231]. 
 Historically, behavioral, biochemical, and physiological comparisons of 
SERT knock-out (KO) mice to wild-type (WT) has served as a primary murine 
model for understanding depression and anxiety-like behaviors[117, 122, 232-235] and 
drugs such as SSRIs[117, 119, 122, 236]. Studies with these SERT knock-out animals 
have shown that constitutive loss of functional SERT results in profound 
behavioral consequences, such as hypo-locomotion[215], reduced exploration[117, 
122, 232, 234] and social interactions[234, 235], increased helplessness[233], altered 
socio-emotional ultrasonic communication[235], maladaptive stress responses[117, 
233], and increased depressive and anxiety-like behaviors[117, 122, 232]. While these 
data support the role of SERT in behavior it also clearly displays that the 
disruption of 5-HT regulation especially during development has significant 
physiological ramifications. In the serotonergically innervated brain regions of KO 
mice, 5-HT concentrations are atypical[122, 153, 236-238], with a significant increase in 
5-HT metabolism[237], reduced 5-HT receptor 1A (5-HT1AR) binding and 
function[232], as well as a reduction in postnatal apoptotic cells[239]. In the dorsal 
raphe nuclei (DRN) of the midbrain (MB), KO mice have a significant reduction in 
serotonergic cells and their associated firing rate[233]. Additionally, KO mice 
display abnormal thermoregulation[122, 232] and increased rapid eye movement 
sleep[240]. As a result of the aberrant biological consequences, interpreting 
experimental outcomes from these SERT null mice would be highly problematic. 
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 Previous efforts to elucidate antidepressant binding sites on SERT 
identified a single point mutation in SERT (Ile172Met, I172M) through species-
scanning mutagenesis that makes the transporter virtually insensitive to many 
SERT-blocking antidepressants and cocaine while maintaining full functionality 
for 5-HT transport[157, 158, 241, 242]. Generation of a mouse line harboring this I172M 
SERT resulted in an antidepressant-resistant animal with an intact serotonergic 
system with appropriate monoaminergic homeostasis and development[158]. 
Biochemical analyses comparing WT to I172M mice found no changes in SERT 
protein expression[158, 176, 241, 242], SERT-mediated 5-HT clearance[158, 176], 
extracellular 5-HT concentrations[158, 241, 243], extracellular dopamine or 
norepinephrine concentrations[176], DRN serotonergic firing rates[158], 5-HT 
receptor activity[244] and levels of neurogenesis[176, 243]. Moreover, I172M mice 
display the same novel  object activity[176, 243], mobility[158, 243], and locomotive[241] 
behaviors, as well as circadian rhythm patterns[244] as WT animals. For these 
reasons, the I172M animal should provide a more appropriate murine model for 
prospective investigations into antidepressant action. 
 In this study, we performed RNA-Seq transcriptomic analysis on the MB 
and hippocampus (HPC) of age-matched 9-week-old male SERT WT, I172M, and 
KO mice to gain high-resolution, comprehensive gene expression data allowing 
assessment of the baseline variance in gene expression between the mouse 
strains and provide insight regarding the utility of the I172M model in future 
epigenetic studies. Such studies would allow us to understand the impact of 
antidepressant exposure during developmental programming as multiple studies 
have identified a link between early SSRI exposure and increased risk of mood 





 All animal housing and procedures complied with the National Institute of 
Health Guide for the Care and Use of Laboratory Animals and followed protocols 
approved by the University of North Dakota’s Institutional Animal Care and Use 
Committees (IACUC). Food and water were provided ad libitum, and mice were 
maintained on a 12 h light/dark schedule. The SERT I172M knock-in mice 
previously generated on a 129S6 background were backcrossed with C57BL/6J 
wild type mice and were a kind gift from Dr. Randy Blakely (Vanderbilt University, 
currently at Florida Atlantic University)[158]. SERT-KO B6.129(Cg)-Slc6a4tm1Kpl/J 
mice were obtained from Jackson Laboratory[153, 232, 245], then backcrossed with 
C57BL/6J wild type mice. All genotypes were maintained on the C57BL/6J 
background. Homozygous breeding pairs were used to obtain experimental 
offspring. To increase pup survival, breeder males were removed from breeding 
cages once females were confirmed pregnant, male and female offspring were 
included in experiments. 
Genotyping and Identification 
 For identification purposes tail tattoos were administered to weaned pups 
and ear snips were collected to genotype mice using the REDExtract-N-Amp 
Tissue PCR Kit (Sigma-Aldrich, CAT# XNAT-1000RXN) and protocol, which 
allows for DNA extraction from tissue and provides the enzyme and buffer for 
polymerase chain reaction (PCR). Two distinct primer sets were used to amplify 
specific regions of Slc6a4 that identify the presence or absence of I172M or KO 
recombinant remnants. Primers that anneal in intron 4 of Slc6a4 were used to 
confirm WT or I172M genotypes (Table 3.1). Primer 2830 anneals 493 base pairs 
(bp) downstream from exon 4 and primer 2872 anneals 453 bp upstream from 
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exon 5, amplifying a region that captures if present, the two 13 base pair bp lox-P 
sites, and the 8 bp asymmetric core spacer sequence that remains from 
generation of the transgenic mouse line[158]. Primers that anneal in intron 1 of 
Slc6a4 were used to confirm WT or KO genotypes (Table 3.1). Primer oIMR8899 
anneals 48 bp upstream of the BamH1 restriction site, a sequence present in 
both WT and KO. Primer oIMR8899 anneals 224 bp downstream from the 
BamH1 restriction site in WT, whereas, primer oIMR7415 anneals 116 bp 
downstream from the BamH1 restriction site in KO. PCR cycling parameters: (1) 
5 min at 94°C for initial denaturation, (2) 30 sec at 94°C for denaturation, (3) 45 
sec at 61-63°C (Table 3.1) for annealing, (4)  1 min at 72°C for extension, (5) 
steps 2-4 repeated for 35 cycles, and (6) 10 min at 72°C for final extension. PCR 
product was visualized using 0.75% agarose gel and ethidium bromide on the 
Omega Lum C Gel Imaging System (Aplegen, Pleasanton, CA).  
Brain Tissue Collection 
 Age-matched 9-wk old mice (3 per genotype) were gently placed in 
decapicones and decapitated using a rodent guillotine without anesthesia. Brains 
were quickly removed and dissected on a clean ice cold surface. Right and left 
hemispheres of the cortex, MB and HPC were collected and stored in RNAlater™ 
(Ambion, #AM7021) at 4°C for 48 hours to allow stabilization buffer to permeate 
lipid rich brain tissue, and then stored at -80°C until used. 
RNA/DNA Extraction 
 RNA and DNA were extracted using the AllPrep DNA/RNA Mini Kit 
(Qiagen #80204) and eluted in RNase free water. RNA integrity was quantified 
using a fluorometric based method of gel electrophoresis on the Agilent 2100 




 RNA samples were sequenced on Illumina HiSeq 3000 with TruSeq 
stranded library prep and 50 bp paired end reads at the University of Minnesota 
Genomics Center. Data analysis performed by UND-EBC. Reads were aligned to 
mouse genome (mm10) using Hierarchical Indexing for Spliced Alignment of 
Transcripts (HISAT)[246] and fragments were assigned to genes using 
FeatureCounts v1.4.6[247]. Differential gene expression analysis was performed 
with R/Bioconductor package DESeq2 v1.22.2[248]. Statistical significance was 
determined by the Wald test with the false discovery rate set at 0.05 to control for 
multiple comparisons. MB and HPC samples were sequenced on different runs, 
therefore, datasets were analyzed separately for each brain region. As a second 
pass statistical analysis to compare MB Slc6a4 expression to that of the HPC, 2-
Way ANOVA with Newman-Keuls multiple comparisons test was performed 
(Prism, GraphPad Software, Inc., La Jolla, CA). Column statistics (Prism, 
GraphPad Software, Inc., La Jolla, CA) were used to calculate the average and 
standard deviations of mRNA fragment counts for Slc6a4, B2m, and Gapdh 
within each genotype and brain region. 
Quantitative Real-time PCR Validation 
 To validate RNA-Seq expression data for the subset of DEGs listed in 
Table 3.2, qPCR was performed on MB (N=2-3) and HPC (N=3) RNA. cDNA was 
synthesized from 100-200 ng of RNA using iScript cDNA Synthesis Kit (BioRad, 
Cat#170-8890). Control reactions without cDNA were performed in parallel with 
cDNA synthesis. cDNA synthesis cycling parameters: (1) 5 min at 25°C for 
efficient random priming, (2) 20 min at 46°C for reverse transcription and (3) 1 
min at 95°C for enzyme inactivation. qPCR was performed using SSo 
Advanced™ Universal SYBR® Green Supermix (BioRad, #172-5274) and the 
primers listed in Table 3.2. cDNA was diluted 4-fold, biological replicates were run 
61
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a Dr. Brent Thompson Lab, Oakland University William Beaumont School of Medicine, Auburn Hills, MI 
b The Jackson Laboratory, Bar Harbor, ME
Table 3.2. qPCR Oligonucleotides Used in the Validation of Select RNA-Seq Genes.





Gapdh Gapdh 104 0.996 16.13 86.5
Slc6a4 SLC6A4ex6-8F 103 0.994 22.25 86.5 Eton BioSLC6A4ex6-8R
Pclo Mm_Pclo_1_SG (QT00168567) 107 0.996 20.36 78.5 Qiagen
Mal Mm_Mal_1_SG (QT00125468) 107 0.993 18.92 83.0 Qiagen
Calr Mm_Calr_1_SG (QT00101206) 109 0.994 18.78 88.5 Qiagen
Rbm3 Mm_Rbms_1_SG (QT00174419) 108 0.997 22.19 84.0 Qiagen
Lrp1 qMmuCID0013464 113 0.988 19.86 84.5 Bio-Rad
Dbp Mm_Dbp_1_SG (QT00103089) 103 0.996 23.49 81.5 Qiagen
Hsph1 Mm_Hsph1_1_SG (QT00157367) 110 0.989 20.95 78.0 Qiagen
Nrxn1 Mm_Nrxn1_1_SG (QT00166159) 103 0.997 21.19 84.0 Qiagen
Data for our qPCR validation of oligonucleotides.
in triplicates, and no polymerase controls were included. qPCR cycling 
parameters on CFX96 Touch Deep Well Real-Time PCR Detection System 
(BioRad, Cat#1854096): (1) 30 sec at 95°C for initial denaturation and 
polymerase activation, (2) 10 sec at 95-98°C for denaturation, (3) 15 sec at 60°C 
for combined annealing and extension, (4) steps 2 and 3 repeated for 40 cycles, 
(5) melt curve analysis ran at 5 sec per step at 65-95°C with 0.5°C increments. 
CFX Maestro™ 2.0 Software (BioRad, Hercules, CA) was utilized for the plate 
setup, data collection, and graphing of results. The geometric mean and 2-ΔΔCt 
methods were used to determine fold change from WT, with significance set at P 
< 0.05). 
Transcript Analysis 
 Integrative Genomics Viewer (IGV) (Broad Institute, Cambridge, MA) was 
used to visualize RNA-Seq mRNA transcript reads for the Slc6a4 gene loci, for 
the MB and HPC of all samples. Exons 2 and 4 were evaluated in all Slc6a4 
gene transcripts to confirm WT, I172M and KO genotypes.  
Functional Gene Set Enrichment Analyses 
 Functional analyses with Gene Ontology (GO)[249, 250] term and Kyoto 
Encyclopedia of Genes and Genomes (KEGG)[251-253] pathway enrichments were 
performed to compare differential gene expression (DGE) clusters for annotated 
genes related to biological processes (BP), cellular components (CC), molecular 
functions (MF) and pathways. For each pairwise comparison, DGE expression 
and statistical data was uploaded to the R/Bioconductor clusterProfiler v3.14.1 
package with the strict cutoff of P values <0.01 and FDR <0.05[254].  
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Results 
Quality of RNA-Sequencing Data 
 Quantification of mappable reads obtained an average RNA-Sequencing 
depth of 26.3M and 33.3M for the MB and HPC, respectively. Normalization of 
data was performed as these depths surpassed the Encyclopedia of DNA 
Elements (ENCODE) project standards of 20-25M mappable reads for studies 
evaluating differential expression (DE) of transcriptomic profiles[255]. The 
dispersion of the majority of genes (Table 3.3) in these datasets fit within the 
Differential Expression Sequencing 2 (DESeq2) packages parametrized 
generalized linear model and gene-wise estimates for the dispersion of these 
genes were adjusted towards the fitted curve (Figure 3.1, A-B) to reduce the 
possibility of false positives being identified as differentially expressed genes 
(DEGs). A subset of genes in both datasets had low transcript counts (Table 3.3) 
with gene-wise estimates more than two standard deviations above the curve 
and were considered as dispersion outliers (Figure 3.1, A-B). For this subset, 
dispersions were not fitted to the curve, and initial gene-wise estimates were 
used as the final dispersion values for subsequent analyses. Nine genes within 
the MB dataset and 2 genes within the HPC dataset had a Cook’s distance 
greater than the 0.99 quantile of the F distribution[248] and were excluded (Table 
3.3) from the logarithmic fold change (LFC) estimations and downstream 
analyses. 
Identification of Genomic Similarities and Differences 
 Three independent pairwise comparisons, WT/172M, WT/KO, and I172M/
KO were used to determine LFC estimations for each brain region. Genes with a 
significant LFC are visually represented by plotting the difference in log 
intensities ‘M’, against the average log intensity ‘A’, (MA scatter plot) to easily 
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identify genomic disparities between two conditions. MA scatter plots show 
minimal differential expression (DE) in the MB (Figure 3.2 A) and HPC (Figure 
3.2 B) of WT/I172M comparisons. In contrast, the MB (Figure 3.2 C) and HPC 
(Figure 3.2 D) of WT/KO results in significant DE much greater than that 
identified when comparing WT/I172M. Comparisons of the MB (Figure 3.2 E) and 
HPC (Figure 3.2 F) of I172M/KO demonstrates the most significant DE of all 
comparisons. Overall these data indicate that WT and I172M mice are similar, 
whereas KO mice are significantly different from WT and I172M mice.  
Variance Between Datasets 
Independent Midbrain and Hippocampus Comparisons 
Similarities between two conditions are easily identified by looking at 
principal component analysis (PCA) scatter plots of the top 500 most variable 
genes. Independent PCA of the MB (Figure 3.3 A) and HPC datasets (Figure 3.3 
B) reveal that WT and I172M animals cluster together, and KO animals form a 
separate and distinct cluster. These data demonstrate that genotype is the first 
component and greatest contributing factor to the variance in gene expression, 
accounting for 48% of variance in MB (Figure 3.3 A) samples, and 40% in the 
HPC (Figure 3.3 B). Moreover, these data support the transcriptomic similarities 
between WT and I172M in contrast to the large expression differences in KO 
mice when compared to WT and I172M. All biological biological replicates have 
an N of 3. The number of biological replicates has a direct effect of the second 
component[256, 257] contributing to sample variance, which is biological variation 
within replicates of the same genotype, and accounts for 21% of sample variance 
in the MB (Figure 3.3 A) and 28% in the HPC (Figure 3.3 B). Variance among 
biological replicates is expected when performing differential expression analysis 
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Figure 3.1. Graphical Representation for the Generalized Linear Model of Gene 
Dispersion in the Midbrain and Hippocampus of 9-Week-Old SERT WT, I172M and KO 
Mice. Initial gene estimates are depicted in black, the parametric fitted curve in red and the 
overall final dispersion of differentially expressed genes in blue. This figure is a graphical 
representation of the values reported in Table3.3.
Table 3.3. Differential Gene Expression Statistics.
Midbrain	-	19,216	Total	Genes Hippocampus	-	19,389	Total	Genes
WT	vs	I172M WT	vs	KO I172M	vs	KO WT	vs	I172M WT	vs	KO I172M	vs	KO
Genes # % # % # % # % # % # %
Fit	to	
Curve 17736 92.30 14797 77.00 11129 57.92 8255 42.58 13821 71.28 13079 67.46
Low	
Counts 1471 7.70 4410 23.00 8078 42.00 11132 57.00 5566 29.00 6308 33.00
Excluded	
Outliers 9 0.05 9 1.05 9 0.05 2 0.01 2 0.01 2 0.01
Statistical breakdown of differentially expressed gene dispersion estimates of each pairwise 
comparison. Dispersion estimates were either adjusted toward the fitted curve, determined from 
initial gene-wise estimates (Low Counts), or excluded from downstream analyses based off the 
parametrized generalized linear model from DESeq2.
replicates for each condition[256, 257]; Two to three biological replicates per 
condition is an acceptable number when working with animals[255] and is common 
practice for RNA-Seq studies. Moreover, the level of biological variance identified 
among the replicates are within the suggested parameters based on the number 
of biological replicates and the sequencing depth obtained with our samples[248, 
255, 257].  
Midbrain Versus Hippocampus 
Due to the contrasting functional nature of these two brain regions as the 
MB is a control center for serotonergic innervation, and the HPC as a receiver of 
serotonergic input[258, 259], tissue-specific expression changes in our experimental 
paradigm were anticipated. PCA of the 500 most variable genes between the MB 
and HPC (Figure 3.3 C) datasets, identify “brain region” as the first component 
accounting for 95% of sample variance and biological replicates as the second 
component accounting for 21% of variance. The clear separation of MB and HPC 
gene expression in Figure 3.3 C, combined with the minimal variance observed 
within brain regions for the second component, supports that the reproducibility in 
tissue isolation performed in this study was consistent across samples. 
Differential Expression Analysis 
In line with MA scatter plots discussed above, DE between WT and I172M 
mice is minimal with 28 and 17 DEGs in MB and HPC respectively (Table 3.4). 
This is in contrast to the >20-fold increase in the number of genes differentially 
expressed when comparing WT to KO which rises to >77-fold when comparing 
I172M/KO (Table 3.4). The comparative expression of DEGs are displayed in 
heat maps comparing normalized expression values for 1442 genes in the MB 
(Figure 3.4 A) and 1662 genes in the HPC (Figure 3.4 B). The heat maps for the 
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Figure 3.2
Figure 3.2. Log Fold Change Estimations of Differentially Expressed Genes in SERT 
Genotype Pairwise Comparisons. Log fold changes were determined from the mean of 
normalized mRNA fragment counts.
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Ch3 Fig7 (A-C). RNA-Seq PCA Plots for Midbrain and Hippocampus of 9-wk 
















































































































Figure 3.3. Genetic Variance Separates KO from WT and I172M, and Tissue-
Specific Gene Expression Separates Midbrain from Hippocampus. Principal 
component (PC) analyses to evaluate variance within and between replicates and brain 
regions.
KO mice and WT or I172M. Notably, for the WT/I172M comparisons only 28 
(Figure 3.4 A) and 17 (Figure 3.4 B) of all mapped genes reach a level of 
significance for DE as determined by Wald statistics performed on LFC 
estimations with a false discovery rate (FDR) set at 0.05. 
Genes Most Affected by Genotype  
To identify genes that are sensitive to loss of Slc6a4 (KO) or the single 
point substitution (I172M), the genes with the most significant DE for each 
comparison were evaluated and compared to the genes with the greatest fold 
change (FC) in expression. Several genes of interest were identified after further 
evaluation of DE in multiple comparisons, as well as relation to the serotonergic 
system, signal transduction, brain development, behavior, and diseases or 
disorders of the brain. All differentially expressed genes for each comparison are 
listed in Appendices A-F and includes gene ID’s and names, as well as DE data. 
Moreover, many of the genes with the greatest differential expression are 
neurologically relevant.  
Midbrain 
Comparison of DEGs in the MB of WT/I172M mice with significance 
ranges from 4.94E-02 to 4.48E-13 are given in Appendix A. The following is a brief 
description of some of those genes. Nrxn1 (up regulated) encodes a Ca2+-
dependent cell-surface receptor important in cell differentiation, synaptic 
formation and maturation, and is required for effective neurotransmission[260]. 
Ppp1r17 (down regulated) encodes a protein phosphatase inhibitor, which is a 
substrate for cGMP-dependent protein kinase, important for neurodevelopment, 
signaling cascades and synaptic long-term depression (LTD)[260]. Arhgef33 (down 
regulated) is a Rho guanine nucleotide exchange factor that encodes a protein 
involved in G-protein-coupled receptor (GPCR), p75 neurotrophin receptor-
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mediated signaling and cell death[260]. Neurod1 (down regulated) is a basic helix-
loop-helix (bHLH) transcription factor (TF) which activates genes that contain an 
enhancer box (E-box) consensus sequence and is known to be involved in 
neuronal cell differentiation[260]. Lrp1 (up regulated) encodes a low-density 
lipoprotein receptor which aids in lipid homeostasis, intracellular signaling, 
clearance of apoptotic cells, and vesicle endocytosis[260]. Dbp (down regulated) 
encodes a proline and acidic amino acid-rich (PAR) basic leucine zipper (bZip) 
TF involved in regulating circadian rhythm clock genes and plays a significant 
role during development[260]. Car8 (down regulated) is a carbonic anhydrase 
protein that lacks anhydrase functions and mediates GTPase/ATPase activities, 
as well as Ca2+-dependent receptor interactions at the plasma membrane (PM)
[260]. Sspo (up regulated) encodes a protein known to modulate neuronal 
aggregation and is involved in CNS development[260]. Fam45a (down regulated) 
encodes a guanine nucleotide exchange factor (GEF) that regulates various 
aspects of the endocytic pathway[260]. Dync1h1 (up regulated) encodes a 
microtubule-activated ATPase dynein which performs as an intracellular axonal 
retrograde motor that removes vesicles from the PM[260]. Hes3 (down regulated) 
encodes a TF that represses bHLH genes[260]. Gm15800 (up regulated) encodes 
a ubiquitin ligase that marks proteins for degradation[260]. It is worth noting, that 
the FDR-adjusted P values (P Adj) for the majority of genes in this list are 
marginally significant (P > 10E-3) when compared to genes like Nrxn1 (P < 4E-13) 
and given the limited number of replicates the marginal genes may represent 
genes that are not differentially expressed.  
The list of significant DEGs in the MB of WT/KO are given in Appendix B. 
In contrast to the WT/I172M comparison, the P Adj values for these genes range 




Comparison Up Down Total Up Down Total
WT vs I172M 6 22 28 14 3 17
WT vs KO 453 559 1012 155 169 324
I172M vs KO 635 807 1442 882 780 1662
Table 3.4. Minimal Differential Expression Exists Between WT vs I172M, and KO Differ 
Significantly from both WT and I172M. 
Differentially expressed genes determined by RNA-Seq. FDR 0.05.
Table 3.4. Differentially Expressed Genes Identified in the MB and HPC of WT vs I172M, 






















































































































































Figure 3.4. Gene Expression is Differentially Regulated in the Midbrain and 
Hippocampus of KO Mice. Heat maps were generated from DEGs and significance 
values are provided by the color scale with arbitrary numbers. Visual representation of (A) 
1442 DEGs in the MB of I172M/KO, (B) the 1662 DEGs in the HPC of I172M/KO, (C) the 
28 DEGs in the MB of WT/I172M, (D) the 1012 DEGs in the MB of WT/KO, and (E) the 
1442 DEGs in the MB of I172M/KO.
are differentially expressed between the two mouse lines. Similar to the MB of 
WT/I172M, Nrxn1 is up-regulated and Ppp1r17 is down-regulated. Notably, 
Slc6a4 is shown to be down regulated with great confidence 1.52E-10.  
The DE of many genes in the KO are involved in regulating transcription, 
differentiation, proliferation, synaptic plasticity, Ca2+ flux, vesicle trafficking, cell 
adhesion, protein processing, cell death, signal transduction and development. 
Notably, in the KO MB there is also an enrichment of DEGs involved in RNA 
processing, regulation of cell projections, myelination and responses to cellular 
stress.  
The list of significant DEGs in the MB of I172M/KO are shown in Appendix 
C and has an enrichment of DEGs consistent with the same biological processes 
as the WT/KO comparison, and 675 of the 1442 DEGs are shared with the WT/
KO DEGs (Figure 3.9), with 767 genes that differ. Similar to the WT/KO outcome, 
the significance of DEGs in this table ranges from 5.00E-02 to 1.87E-247. 
Hippocampus 
The 17 DEGs identified in the HPC comparison of WT/I172M are detailed 
in Appendix D, whereby their P adj values range from 4.88E-02 to 8.51E-11. The 
Nrxn1 and Dbp transcripts are up and down-regulated, respectively, to similar 
levels observed in the respective analysis of the MB. All other DEGs in the HPC 
of WT/I172M are different than genes differentially expressed in the MB 
comparison, yet they are involved in similar biological processes. Fourteen of the 
17 DEGs have P adj values that are borderline significant and are therefore of 
less interest in the current goal to identify clear key targets. However, the genes 
and their functions are given here. Cox7a2l (up regulated) encodes an enzyme 
that catalyzes electron transfer of cytochrome c to oxygen and is required for 
mitochondrial respiration. Pclo (up regulated) encodes a presynaptic cytoskeletal 
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scaffolding protein that is important for active synaptic zone formation and 
regulating vesicular trafficking[260]. Tspan2 (up regulated) encodes a 
transmembrane cell-surface receptor, involved in signal transduction, cell 
development, activation, growth and motility, along with stabilizing mature myelin 
sheaths[260]. Sorbs1 (up regulated) encodes a protein associated with tyrosine 
phosphorylation, the formation of actin stress fibers, focal adhesions and insulin-
stimulated glucose transport[260]. Ccng1 (up regulated) encodes a cyclin-
dependent kinase that regulates cell growth, division and proliferation, and is 
responsible for the second growth phase mitotic (G2/M phase) cell arrest in 
response to damaged DNA[260]. Rbm3 (down regulated) encodes an mRNA 
binding protein that enhances phosphorylation of translation initiation factors and 
active polysome formation, along with the degradation of over-expressed 
microRNAs[260]. Ppp2r3a (up regulated) encodes a protein phosphatase 
regulatory subunit that plays a role in the negative control of cell growth and 
division[260]. Prdx3 (down regulated) encodes a mitochondrial protein that 
regulates that activation of nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-kappa-B), proliferation, differentiation and cell protection against 
oxidative stress[260]. Apod (up regulated) encodes a glycoprotein which transports 
ligands and is involved in lipoprotein metabolism[260]. Gjc3 (up regulated) 
encodes a gap junction protein involved in cell-cell contacts[260]. Ank3 (up 
regulated) encodes an ankyrin actin-cytoskeletal protein found in axonal nodes of 
Ranvier and is implicated in cell motility, activation, proliferation and signaling[260]. 
Strn (up regulated) encodes a scaffolding calmodulin-binding protein involved in 
dendritic Ca2+ signaling[260]. Mal (up regulated) encodes an endoplasmic 
reticulum (ER) proteolipid involved in myelin biogenesis, function and vesicular 
trafficking[260]. Edil3 (up regulated) encodes an integrin ligand critical for 
embryonic angiogenesis[260]. Lastly, Anln (up regulated) encodes an actin-binding 
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protein with significant roles in cytokinesis, mitosis, and podocyte cell 
migration[260]. 
The list of significant DEGs in the HPC from the WT/KO and I172M/KO 
comparisons are given in Appendix E and F, respectively. The top 4 DEGs in both 
comparisons are identical and include Wdfy1, Slc6a4, Gabra2, and Nnt. In 
addition the analyses have 223 genes in common and 1439 genes that differ 
(Figure 3.9). The >4-fold increase in Slc6a4 expression is due to ectopic 
expression of the KO construct in the HPC (see below). Notably, in the HPC of 
KO’s there is an increased enrichment of DEGs involved in apoptosis and 
responses to cellular stress.  
 Remarkably, Wdfy1, Nnt and Gabra2 are in the top 9 most significant 
DEGs in the MB and the top 4 most significant DEGs in the HPC of WT/KO and 
I172M/KO indicating these genes are key targets affected by constitutive loss of 
SERT and therefore the following is a brief description of these genes. Wdfy1 
(down regulated) encodes a phosphatidylinositol 3-phosphate binding protein 
containing a FYVE zinc finger and multiple WD-40 repeat domains involved in 
positively regulating toll-like receptor (TLR) signaling[260]. Gabra2 (down 
regulated) encodes a ligand-gated Cl- channel gamma-aminobutyric acid 
receptor (GABAAR) component involved in the formation and function of the 
brains major inhibitory neurotransmitter synapses[260]. Nnt (down regulated) 
encodes a mitochondrial integral membrane protein responsible for producing 
high concentrations of nicotinamide adenine dinucleotide phosphate + hydrogen 
(NADPH) required for biosynthesis[260] and reduction of Nnt activity has been 
suggested to increase reactive oxygen species (ROS) production and could 
promote neurodegeneration in dopaminergic neurons[261].Analysis and 
Characterization of Slc6a4 
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Transcript Analysis 
 The engineered Slc6a4 locus in I172M and KO mice was verified by 
analysis of mRNA transcripts by identifying the single-point C to G mutation that 
changes isoleucine to methionine in exon 4 of I172M mice[158], or the complete 
loss of exon 2 transcription in KO mice[153]. Assessment of gene transcripts were 
performed on the MB and HPC. As expected the Slc6a4 transcripts from WT and 
I172M mice are abundant and full-length in the MB (Figure 3.5 A), and absent in 
the HPC (Figure 3.5 B). MB transcript evaluation of Slc6a4 exon 4 confirmed the 
absence of mutations in WT, and the presence of the C to G mutation (I172M) in 
I172M transcripts (Figure 3.5 A, inset). In contrast to WT mice, KO MB transcripts 
of Slc6a4 are down regulated and lack exon 2 which codes a critical 
transmembrane domain of the transporter that is required for function (Figure 3.6 
A). Slc6a4 expression in the HPC is very low as verified by our WT and I172M 
analysis. However, a >4-fold increase in a truncated Slc6a4 transcript is 
observed in the KO animal (Figure 3.6 B). This is likely an effect of how the SERT 
KO was engineered as the KO construct replaces exon 2 with a neomycin (Neo) 
expression cassette. The Neo promoter could be constitutively driving 
transcription of truncated Slc6a4 in all tissues. 
Fragment Counts 
To visualize the DE of Slc6a4 in the MB of WT, I172M and KO mice 
represented in Table 3.5, log transformed fragment counts were plotted (Figure 
3.7). WT mice have the highest expression of Slc6a4 transcripts, I172M mice 
display a slight decrease in the expression of Slc6a4 transcripts, whereas KO 
mice have the most significant decrease in expression of truncated Slc6a4 
transcripts. In comparison to WT, Slc6a4 is down-regulated 1.53 fold in the MB of 
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Figure 3.5. Validation of Slc6a4 Genotype and Tissue-Specific Expression in 
WT and I172M mRNA Transcript Analysis. Validation of transcripts were performed 
using Integrative Genomics Viewer. The above panels evaluate the presence or 
absence of the I172M mutation in exon 4 (A) in the midbrain, and (B) the 
hippocampus. Transcripts were not expected to be identified in the hippocampus 
because Sert mRNA is not transcribed in this brain region.
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Figure 3.6. Validation of Slc6a4 Genotype and Dysregulated Tissue-Specific 
Expression in KO mRNA Transcript Analysis. Validation of transcripts were 
performed using Integrative Genomics Viewer. The above panels evaluate the 
presence or absence of exon 2 (A) in the midbrain, and (B) the hippocampus. 
Transcripts were not expected to be identified in the hippocampus because Sert 
mRNA is not transcribed in this brain region.
As an added level of assessment, the relative expression of MB and HPC 
Slc6a4 in WT/KO was determined by normalizing Slc6a4 fragment counts to the 
reference genes beta-2-microglobulin (B2m) and glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) (Table 3.6). In comparison to WT, Slc6a4 is down-
regulated 1.87 fold in the MB of KO mice and up-regulated 136 fold in the HPC. 
These patterns are consistent with FC values reported from RNA-Seq LFC 
estimations discussed above. 
Differential Exon Expression  
Differential expression of Slc6a4 exons has been identified as a 
mechanism to regulate tissue-specific expression[262]. In light of the ectopic 
expression of Slc6a4 in the HPC of KO mice discussed above, an analysis 
comparing Slc6a4 exon expression in the MB of WT/KO was performed using 
DEXSeq[263]. DEXSeq revealed that in the MB of KO mice, exon 1 is down-
regulated by 1.65 fold, exon 2 is down-regulated by 10.93 fold, exon 3 is down-
regulated by 1.36 fold and exon 14 is up-regulated by 1.11 fold (Figure 3.8). The 
large down-regulation of exon 2 is consistent with this region being replaced with 
the Neo cassette.  
qPCR Validation of RNA-Sequencing Data 
 A subset of up- and down-regulated genes from the MB and HPC of WT/
172M and WT/KO comparisons were selected along with Slc6a4 for qPCR 
validation using the following criteria, (1) magnitude of FC, (2) level of 
significance, (3) base mean greater than 800 counts, and (4) ability to design 
intron-spanning primers that amplify all protein coding variants. qPCR validated 
genes are listed in Table 3.7, which compares RNA-Seq and qPCR fold changes. 
In the MB all qPCR fold changes, except for Slc6a4, consistently follow RNA-Seq 
FC patterns though only Rbm3 in the MB reaches statistical significance. In the 
80
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16-002 9-wk Midbrain Slc6a4
























































































Figure 3.7. Slc6a4 mRNA Transcript Fragment Counts for the Midbrain of WT, I172M and 
KO Mice. A visual representation of Sert fragment count variance on a log2 normalized scale.






















Figure 3.8. Differentially Expressed Exon Usage in the MB of KO Mice. DEX-Seq 
comparative analysis of transcribed exons for WT full-length Slc6a4 and KO truncated Slc6a4. 
FDR 0.05. 
HPC all qPCR fold changes, except for calreticulin (Calr) and Rbm3, consistently 
follow RNA-Seq FC patterns. Nrxn1 is the only gene from the WT/I172M HPC 
comparison to have qPCR fold changes that reach statistical significance, 
whereas Slc6a4, Rbm3 and Nrxn1 all reach statistical significance in the WT/KO 
HPC comparison. Overall, qPCR data support DE obtained from RNA-Seq 
analysis.  
Comparisons of Overlapping Differentially Expressed Genes in the Midbrain 
versus Hippocampus. 
 Comparison of KO to WT and I172M in the MB yields 1012 and 1442 
DEGs, respectively, whereas WT versus I172M results in only 28 DEGs (Figure 
3.9A). Of the 28 DEGs of WT/I172M, 19 were also identified in the WT/KO 
comparison and 6 in the I172M/KO comparison, with 2 of the 19 and 6 genes 
overlapping between comparisons. There are 673 DEGs that appear in both the 
KO versus WT and KO versus I172M analyses. Two genes are differentially 
expressed across all 3 MB pairwise comparisons, Ddx3y and Dbp.   
 Comparison of KO to WT and I172M in the HPC yields 324 and 1662 
DEGs, respectively, whereas WT versus I172M results in 17 (Figure 3.9B). Of the 
17 DEGs of WT/I172M, 11 were also identified in the WT/KO comparison and 4 
in the I172M/KO comparison, with 3 of the 11 and 4 genes overlapping between 
comparisons. The WT versus KO and I172M versus KO comparisons share 223 
DEGs. The genes Dbp, Rbm3 and Ccng1 are shared by all three analyses.  
 
Midbrain Versus Hippocampus: A Comparison of Genes Differentially Expressed 
Between WT/KO and I172M/KO.  
 The DEGs that are common to both brain regions between WT/KO and 
I172M/KO are of particular interest as they provide greater confidence that these 
genes are impacted by constitutive loss of functional SERT than DEGs that only 
82
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Expression data was obtained from RNA-Seq analysis and statistics were performed to 















Genotype N1 N2 N3 AVG SD SEM
MB
WT 1858 1856 1526 1747 ±191.10 ±110.30
I172M 1349 1547 1355 1417 ±112.60 ±65.02
KO 1217 1052 1072 1114 ±90.05 ±51.99
HPC
WT 2 1 2 2 ±0.58 ±0.33
I172M 2 1 3 2 ±1.00 ±0.58
KO 212 201 222 211 ±10.50 ±6.06
Table 3.11: Sert Frag Counts
Genotype N1 N2 N3 Mean SD SEM FC from WT P Adj
WT 1858 1856 1526 1747 ±191.11 ±110.33 ~ ~
I172M 1349 1547 1355 1417 ±112.60 ±65.02 ~ ~
KO 1217 1052 1072 1114 ±90.05 ±51.99 -1.44 1.52E-10
WT 2 1 2 2 ±0.58 ±0.33 ~ ~
I172M 2 1 3 2 ±1.00 ±0.58 ~ ~






~ Indicates no FC or P Adj values for this comparison
Mean, standard deviation (SD) and standard error of the mean (SEM) were determined by 
column statistics. Fold Change (FC) from WT and P Adj determined by RNA-Seq analysis.
Table 3.5. Fragment Counts for Slc6a4.
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Midbrain Hippocampus
Average Fold Change Average Fold Change
Target Gene RNA-Seq qPCR RNA-Seq qPCR
WT vs I172M
Pclo ~ ~ +1.28 +2.03
Mal ~ ~ +1.25 +1.44
Rbm3 ~ ~ -1.32 -0.81
Lrp1 +1.22 +1.81 ~ ~
Dbp -1.28 -0.61 -1.38 -0.74
Nrxn1 +1.40 +1.87 +1.47 +2.25 c
WT vs KO
Slc6a4 -1.44 -0.84 +4.65 +183.39 b
Pclo ~ ~ +1.28 +2.38
Mal +1.22 +1.75 +1.29 +1.86
Calr -1.36 -0.80 -1.36 +1.18 a
Rbm3 +1.69 +2.60 b -1.19 +2.23 a, c
Dbp +1.21 +1.31 +1.40 +1.03
Hsph1 -1.23 -0.95 -1.23 -0.97
Nrxn1 +1.51 +1.73 +1.33 +2.44 C
a RNA-Seq and qPCR results differ b qPCR p ≤ 0.01, c qPCR p ≤ 0.05
~ Indicates this gene was not differentially expressed in this comparison
Table 3.13. Comparison of RNA-Seq and qPCR validated average fold changes in a subset of DEGs. 
Table 3.7. qPCR Validation of RNA-Seq Differentially Expressed Genes. 
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WT vs I172M WT vs KO
Figure 3.9. Comparisons of Overlapping Differentially Expressed Genes in the Midbrain 
versus Hippocampus. Venn diagrams comparing the number of common DEGs. Genes listed 
to the right of each diagram are those that are differentially expressed in all three genetic 
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Figure 3.10. Comparison of Midbrain and Hippocampus 
Differentially Expressed Genes Common Between WT vs. KO and 
I172M vs. KO.
Figure 3.10. Midbrain Versus Hippocampus: A Comparison of Genes Differentially 
Expressed Between WT/KO and I172M/KO. Venn diagram comparing the number of common 
DEGs in the midbrain and hippocampus of SERT-KO compared to either WT or I172M.  
appear in the MB or HPC. Nevertheless, a comparison of MB and HPC DEGs 
was performed to parse out genes that are distinct from or common to the two 
brain regions. As expected a low percentage (14%) of MB DEGs are also 
differentially expressed in the HPC (Figure 3.10, See Appendix G). There are 582 
genes differentially expressed solely in MB (See Appendix H), and 130 in the 
HPC (See Appendix I), suggesting SERT functional loss causes greater 
transcriptomic perturbations in serotonergic somas than in neurons receiving 
input from serotonergic termini. However, genes differentially expressed between 
WT/KO and I172M/KO in both brain regions show enrichment for pathways 
involved in transcription, translation, phosphorylation, metabolism, apoptosis, cell 
maturation and axonal growth (See Appendices G, H, I). In the MB of KO mice, 
gene enrichment results show primary changes in pathways for synapse 
formation, synaptic plasticity, histone modifications, and vesicle trafficking (See 
Appendix H) whereas in the HPC, the major pathways impacted are protein and 
mRNA processing. 
Differential Expression of Epigenetic-Associated Genes in Serotonin    
Transporter Knock-Out Mice 
 Given the role of 5-HT signaling in development, one could expect the loss 
of SERT in the KO animals to impact epigenetic processes and might provide 
mechanisms for epigenetic modulation of genes involved in altering behavior in 
the KO animals[151, 264, 265]. Evaluation of epigenetic-associated genes (EAGs) 
differentially expressed in KO mice compared to WT and I172M animals 
identified 65 EAGs in the MB and HPC implicated in epigenetic regulation (See 
Appendix J). Forty-one EAGs are down-regulated, with 11 unique to the MB, 19 
to the HPC and 11 are found in both MB and HPC. Twenty-four EAGs are up-
regulated, with 14 unique to the MB, 5 to the HPC and 5 are found in both MB 
and HPC. Notably, the majority of all differentially expressed EAGs (46) are 
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involved in histone modification or regulation and 20 of these modify histone 3 
(H3). Of the non-histone related EAGs, 5 read, write, or erase N6-
methyladenosine (m6A) marks on mRNA[266, 267].  
Differential Expression of Brain-Derived Neurotrophic Factor Associated    
Genes in Serotonin Transporter Knock-Out Mice 
 Brain-derived neurotrophic factor (BDNF) is involved in regulating SERT 
function[268-270], 5-HT signaling and neuronal plasticity[271-275] and whereas BDNF 
is not differentially expressed in the MB or HPC of WT/KO or I172M/KO, there 
are 20 genes associated with BDNF maturation, trafficking, maintenance and 
signaling with altered expression (See Appendix K). Of these 20 DEGs, 7 are 
common in the MB and HPC, 8 are unique to the MB and 5 to the HPC and 
approximately half of these BDNF-associated genes are up-regulated. 
Differential Expression of Transporters, Receptors and Metabolic Enzymes  
of Neurotransmitter Systems and Amino Acids in Serotonin Transporter    
Knock-Out Mice 
 Neurotransmitter systems and glucocorticoids work in concert to either 
inhibit or propagate signal transduction and are involved in neuronal plasticity[274, 
276-279]. Additionally, amino acids are the building blocks of proteins and essential 
components for the synthesis of many neurotransmitters. We therefore evaluated 
DEGs for other signaling networks and amino acid associated genes affected by 
constitutive loss of functional SERT (See Appendix L). Forty-nine DEGs were 
identified from this analysis and the number of up- and down-regulated genes 
were relatively equivalent. Only 12 genes are common between the MB and 
HPC, whereas 22 genes were only found in the MB and 15 in the HPC. Genes 
involved in the dopaminergic, noradrenergic, glutamatergic, GABAergic, 
cholinergic, glycinergic and glucocorticoid signaling networks were identified 
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along with transcripts associated with amino acid synthesis, vesicular transport 
and neuropeptides. 
Differentially Expressed Genes Coding for Proteins That Interact with    
WT, KO and G56A SERT    
 A recent study elucidating the SERT interactome identified 459 proteins 
that co-immunoprecipitate (co-IP) with WT, KO, or the G56A autism-associated 
coding variant of SERT[280] and comparison of those SERT interacting proteins 
(SIPs) to DEGs identified in our study, showed that 136 of our DEGs in the MB or 
HPC of WT/KO and I172M/KO analysis encode SIPs (See Appendix M) lending 
support that the RNA-Seq DE analysis is capturing SERT and serotonergic 
relevant genes. Out of these 136 DEGs, 126 interact with the WT SERT protein. 
Of those 126 genes, 40 interact with the G56A mutant and 16 interact with the 
truncated KO. The remaining 10 SIPs which do not interact with WT or KO SERT 
are found to co-IP with SERT G56A. 
Gene Set Enrichment Analysis 
 To identify functional similarities of characteristics such as, biological 
processes (BP), cellular components (CC) and molecular functions (MF), that are 
over- or under-represented in DEG datasets, GO term enrichment analyses were 
performed[249, 250]. For WT/172M comparisons no functional characteristics were 
enriched in WT/172M MB or HPC. In contrast, there are 60 functional 
characteristics that are enriched in the MB of both WT/KO and I172M/KO mice,, 
with a range of approximately 5-70 genes differentially expressed for each GO 
term process (Figures 3.11-3.12). There are 28-36 functional characteristics 
enriched in the HPC of WT/KO and I172M/KO, respecetively, and the number of 
DEGs relating to each GO term ranges from 8-80 (Figures 3.13-3.14). GO term 
enrichment for the MB and HPC of WT/KO and I172M/KO consistently identify 
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BP, CC and MF terms that are linked to neuronal signaling and cellular 
responses to mis-folded proteins (Figures 3.11-3.14). Moreover, the MB had a 
great number of enriched terms involving neuronal signaling, whereas the HPC 
enriched terms involved cellular response to mis-folded proteins.  
Neuronal Signaling-Related Enriched Gene Ontology Terms  
 Genes exhibiting significant DGE were analyzed by gene ontology 
enrichment analysis and identified BP, CC, and MF involved in neuronal signaling 
in the MB of WT/KO including membrane potential regulation, neural synapse 
organization and specialization, neural projections and connections, 
axonogenesis, cell locomotion-related differentiation and organization, 
myelination, synaptic vesicle exocytosis and cycling, activity of ATPase, GTPase, 
and voltage-gated ion channels as well as neurotransmitter secretion, and 
neuroprotective development (Figure 3.11). BP, CC, and MF associated with 
neuronal signaling in the MB of I172M/KO include axo-dendritic and vesicle-
mediated transport, cycling and endocytosis, dendrite and cell projection 
development and organization, synaptic organization, neuronal differentiation, 
postsynaptic density and specialization, and ATPase, GTPase, transmembrane 
transporters, and voltage-gated ion channel activity (Figure 3.12). The BP, CC 
and MF altered in the HPC of WT/KO animals include postsynaptic organization, 
neural projections, excitatory synapse, membrane raft, dense core vesicles, glial 
cell genesis and differentiation, ensheathment and myelination of axons, and cell 
adhesion binding (Figure 3.13). Evaluation of the HPC of I172M/KO identifies 
energy metabolism, neural synapse, postsynaptic density and organization, 
myelination, and nicotinamide adenine dinucleotide + hydrogen (NADH) 
dehydrogenase activity (Figure 3.14). 
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Cellular Response to Mis-Folded Proteins Enriched Gene Ontology Terms 
 BP, CC and MF involved in the cellular response to mis-folded proteins in 
the MB of WT/KO includes mRNA and rRNA binding and splicing, 
ribonucleoprotein biogenesis, cytosolic ribosomal components , response to 
unfolded proteins and chaperone-mediated protein folding (Figure 3.11). 
Enriched GO terms related to the cellular response of mis-folded proteins in the 
MB of I172M/KO include cytoplasmic translation, ribonucleoprotein complex 
biogenesis and assembly, cytosolic ribosomal components, mRNA and rRNA 
binding and enzyme activity (Figure 3.12). Likewise, analysis of the HPC of WT/
KO yields the affected BP, CC and MF of protein folding, snRNP binding, RNA 
splicing, spliceosomal complex, responses to topologically incorrect proteins, 
unfolded proteins and ER stress, and components of the ER lumen and 
chaperone-complex (Figure 3.13). Evaluation of the HPC of I172M/KO identifies 
mRNA processing, RNA splicing, ribonucleoprotein complex biogenesis and 
assembly, protein folding, regulation of mRNA metabolic and proteasomal protein 
catabolic processes, ribosomes, mitochondrial respirasomes, and ubiquitin and 
ubiquitin-like protein ligase binding (Figure 3.14) 
Signaling Pathway Impact Analysis (SPIA) 
 The KEGG database[251-253] was used to investigate the predicted 
molecular impact of DE on biological pathways. For the WT/I172M MB 
comparison (Table 3.8), KEGG analysis identified enrichment of 24 pathways 
with only 1 DEG (NDE) in each pathway being differentially expressed. Half of 
these pathways have reported values for (1) predicted accumulation of 
perturbation (tA), (2) level of significance (pPERT) and (3) global probability (pG) 
of perturbation, however, these statistics have not been corrected and are not a 
combined evaluation of NDE, pathway size (pSize) and significance of FC. 
Importantly, when all types of evidence are combined and either the FDR is set at 
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0.05 (pGFdr) or the Family-Wise Error Rate (pGFWER) is calculated, none of the 
biological pathways enriched for the I172M MB reach significance[281]. 
 In the MB of WT/KO, 118 pathways are enriched, 95 have predicted 
perturbation, and only 14 have a significant pG. There are only 2 pathways 
considered to be significantly perturbed. The ER Protein Processing Pathway 
(ERPPP) which is predicted to be activated (pG=5.84E-04, pGFdr=0.03, 
pGFWER=0.07) and the Axon Guidance pathway which is predicted to be 
inhibited (pG=3.78E-04, pGFdr=0.03, pGFWER=0.04) (Table 3.9). Notable 
predicted activated pathways with significant pG are glutamatergic 
(pG=1.25E-02), serotonergic (pG=4.43E-02), and gamma-Aminobutyric acid 
(GABAergic) synapses (pG=8.43E-03), as well as Ca2+ (pG=9.73E-02) and 
mitogen-activated protein kinase (MAPK) signaling (pG=3.65E-02). One notable 
predicted inhibited pathway with significant pG is dopaminergic synapse 
(pG=1.94E-02). 
 In the MB of I172M/KO, 128 pathways are enriched, 96 have a reported tA 
and 30 have a significant pG. There are only 3 pathways considered to be 
significantly perturbed. The ERPPP is predicted to be activated (pG=1.75E-04, 
pGFdr=0.02, pGFWER=0.02), while the GABAergic synapse (pG=2.67E-04, 
pGFdr=0.02, pGFWER=0.02) and Fc gamma R-mediated phagocytosis 
(pG=8.06E-04, pGFdr=0.03, pGFWER=0.10) are predicted to be inhibited (Table 
3.10). Notable activated pathways with significant pG are focal adhesion 
(pG=1.57E-03), dopaminergic (pG=7.81E-03) and glutamatergic synapses 
(pG=2.52E-02), phosphatidylinositol signaling (pG=2.41E-02), SNARE interactions 
in vesicular transport (pG=8.09E-02) and RNA transport (pG=8.78E-02). Notable 
inhibited pathways with significant pG are axon guidance (pG=2.02E-03), 
regulation of actin cytoskeleton (pG=3.75E-03), oocyte meiosis (pG=1.21E-02), 
92
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Figur  .1 . Functional Gene Set Enrichment Analysis of the Midbrain in WT vs KO. 
Numbers located on the bottom of each figure indicated the number of DEGs associated with 
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Figure 3.12. Functional Gene Set Enrichment Analysis of the Midbrain in I172M vs KO. 
Numbers located on the bottom of each figure indicated the number of DEGs associated with 
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Figur  3.13. Functional Gene Set Enrichment Analysis of the Hippocampus in WT vs KO. 
Numbers located on the bottom of each figure indicated the number of DEGs associated with 
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Figu  3.14. Functional Gene Set Enrichment Analysis of the Hippocampus in I172M vs 
KO. Numbers located on the bottom of each figure indicated the number of DEGs associated 
with that particular functional characteristic. Significance level is provided on the right by a color 
scale.
cholinergic synapse (pG=9.58E-03), MAPK signaling (pG=2.66E-02), and circadian 
rhythm (pG=3.22E-02). 
 In the HPC of I172M/KO, only 7 pathways are enriched, and the only 
pathway with predicted perturbation is the dopaminergic synapse (pG=9.91E-02), 
which is predicted to be inhibited, however is not considered to be significant 
(Table 3.11).  
  In the HPC of WT/KO, 82 pathways are enriched, 28 have a 
reported tA and only 8 have a significant pG. Only the ERPPP is considered to 
be significantly perturbed (pG=1.75E-04, pGFdr=0.02, pGFWER=0.02) and is 
predicated to be inhibited (Table 3.12). Notable activated pathways with 
significant pG are axon guidance (pG=4.36E-02), phosphatidylinositol 
(pG=1.52E-02) and adipocytokine signaling (pG=1.54E-02). 
  In the HPC of I172M/KO, 124 pathways are enriched, 97 have a 
reported tA and 40 have a significant pG (Table 3.13). Notable activated 
pathways with significant pG are Alzheimer’s (pG=1.70E-10, pGFdr=0.00, 
pGFWER=0.00), Parkinson’s (pG=5.16E-10, pGFdr=0.00, pGFWER=0.00) and 
Huntington’s (pG=2.38E-09, pGFdr=0.00, pGFWER=0.00) diseases, 
phosphatidylinositol signaling (pG=4.00E-03, pGFdr=0.05, pGFWER=0.50) RNA 
transport (pG=6.9E-03), soluble N-ethylmaleimide-sensitive factor activating 
protein receptor (SNARE) interactions in vesicular transport (pG=1.14E-02), LTP 
(pG=2.13E-02), axon guidance (pG=2.14E-02) and dopaminergic synapse 
(pG=3.02E-02). Notable inhibited pathways with significant pG are circadian 
rhythm (pG=9.07E-05), ERPPP (pG=5.12E-04), regulation of actin cytoskeleton 
(pG=3.99E-03), RNA degradation (pG=3.95E-03), transforming growth factor beta 
(TGF-beta) (pG=3.20E-03), notch (pG=6.65E-03), and MAPK signaling 
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(pG=1.10E-02), cell cycle (pG=2.25E-02), focal adhesion (pG=3.37E-02), and 
GABAergic synapses (pG=3.27E-02). 
Midbrain Activation of the Serotonergic Synapse Pathway in Knock-Out 
Mice 
 The SERT is a key regulator of serotonergic signaling at the synapse, and 
its pathway is comprised of 136 genes[251-253]. A total of 12 DEGs involved in the 
serotonergic synapse were enriched in the MB of WT/KO, indicating significant 
pathway perturbation (tA=0.39, pPERT=0.54, pG=4.43E-02) resulting in synapse 
activation (Table 3.9, Table 3.14). Importantly, in the KO MB Slc6a4 expression is 
not just down regulated, it completely lacks functional SERTs. In addition to 
Slc6a4, another 7 DEGs in the SSP are down regulated and involved in 5-HT 
synthesis, internal Ca2+ regulation and synaptic transmission (Table 3.14, Figure 
3.15). Four of the 12 SSP DEGs are up regulated and involved in 5-HT signal 
transduction, adenylyl cyclase inhibition and metabolism of arachidonic acid to 
increase neuronal excitability (Table 3.14, Figure 3.15).  
Inhibition of Endoplasmic Reticulum Protein Processing in Knock-Out Mice 
 Protein translation and folding occur in the ER and are key molecular 
functions involved in the ERPPP, which consists of 161 genes[251-253] and serves 
to assist in protein folding as well as a quality control system for detection and 
elimination of misfolded proteins. In WT/KO there is an enrichment of 19 MB and 
17 HPC DEGs associated with the ERPPP (Tables 3.15-3.16), indicating 
significant pathway perturbation (MB: tA=0.05, pPERT=0.87, pG=5.84E-04; HPC: 
tA=-1.24, pPERT=0.16, pG=2.14E-08) and indicate inhibition in both the MB and 
HPC (Table 3.9, Figure 3.16). Fourteen of the 19 MB ERPPP DEGs are down-
regulated and involved in protein processing quality control, mediating and 
regulating protein folding, stabilizing newly folded proteins, reglycosylation of 
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misfolded proteins and protein trafficking (Table 3.15). The other 5 MB DEGs are 
up regulated, one of which is a protein chaperone, one is a mediator of cel death, 
one is a regulator of cell stress and the other two ubiquitinate misfolded proteins 
(Table 3.15). Seven of the down regulated MB DEGs are shared with the HPC. 
All 17 of the ERPPP DEGs in the HPC are down regulated and perform the same 
or similar functions as the DEGs in the MB, with the addition of DEGs involved in 
increasing transcription of ER stress proteins, catalyzing bond formation during 
protein folding, protein synthesis attenuation during ER stress, redirecting newly 
synthesized proteins for immediate degradation, and inhibiting the aggregation of 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.15. Predicted Serotonergic Synapse Activation in the Midbrain of WT vs KO. 
Serotonin (5-Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter that plays important 
roles in physiological functions such as learning and memory, emotion, sleep, pain, motor 
function and endocrine secretion, as well as in pathological states including abnormal mood and 
cognition. Once released from presynaptic axonal terminals, 5-HT binds to receptors, which 
have been divided into 7 subfamilies on the basis of conserved structures and signaling 
mechanisms. These families include the ionotropic 5-HT3 receptors and G-protein-coupled 5-
HT receptors, the 5-HT1 (Gi /Go -coupled), 5-HT2(Gq-coupled), 5-HT4/6/7 (Gs-coupled) and 5-
HT5 receptors. Presynaptically localized 5-HT1B receptors are thought to be the autoreceptors 
that suppress excess 5-HT release. 5-HT's actions are terminated by transporter- mediated 
reuptake into neurons, leading to catabolism by monoamine oxidase. Differentially expressed 
genes are highlighted in red text. Table 3.23 provides a brief description for each of the DEGs 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.16. Altered Endoplasmic Reticulum Protein Processing Pathway in the Midbrain 
and Hippocampus of WT vs KO. The endoplasmic reticulum (ER) is a subcellular organelle 
where proteins are folded with the help of lumenal chaperones. Newly synthesized peptides 
enter the ER via the sec61 pore and are glycosylated. Correctly folded proteins are packaged 
into transport vesicles that shuttle them to the Golgi complex. Misfolded proteins are retained 
within the ER lumen in complex with molecular chaperones. Proteins that are terminally 
misfolded bind to BiP and are directed toward degradation through the proteasome in a process 
called ER-associated degradation (ERAD). Accumulation of misfolded proteins in the ER 
causes ER stress and activates a signaling pathway called the unfolded protein response 
(UPR). In certain severe situations, however, the protective mechanisms activated by the UPR 
are not sufficient to restore normal ER function and cells die by apoptosis. Midbrain DEGs are 
highlighted in red text. Table 3.24 provides a brief description for each of the MB DEGs and their 
associated proteins function in the pathway. Hippocampus DEGs are highlighted indicated by 
blue boxes, and DEGs that were not identified by KEGG analysis, however are involved in the 
ERPPP are indicated by pink boxes. Table 3.25 provides a brief description for each of the HPC 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Evaluation of Gene Regulatory Properties of Slc6a4, Nrxn1 and Dbp to Identify 
Putative Regions of Expression Quantitative Trait Loci 
 In the MB and HPC, Nrxn1 is significantly up regulated in I172M/WT and 
KO/WT, while Dbp is down regulated in WT/I172M, and up regulated in WT/KO 
and I172M/KO (Tables 3.5-3.8, 3.10, 3.14). The common DE of Nrxn1 and Dbp 
across multiple comparisons was surprising because the I172M mutation 
maintains full 5-HT transport functionality and does not result in biochemical, 
physiological or neuroanatomical deviations from WT[157, 158, 176, 241-244]. These 
data suggest Nrxn1 and Dbp may share expression quantitative trait loci (eQTLs)
[282-284] with Slc6a4 in a region where I172M and KO differ from WT. There are 
two possibilities for this how this could occur, the first is disrupted DNA sequence 
from fragmented ends of the cloned DNA vector during homologous 
recombination and the second, more likely possibility is strain specific single 
nucleotide polymorphisms (SNPs) from the cloned region of Slc6a4 carried over 
into the transgenic lines. For example, while all mice in this study were 
maintained on the C57BL/6J (C57) background, fragments of Slc6a4 DNA from 
introns 1-5 in I172M and introns 1-7 in KO were cloned from embryonic stem 
cells obtained from a 129 mouse strain prior to injection into C57 embryos[153, 158], 
whereas WT Slc6a4 is derived purely from the C57 strain. Moreover, variance in 
gene sequences such as SNPs are common between 129 and C57 strains and 
often leads to differential expression of genetically linked genes[285-289], therefore 
we evaluated gene properties for Slc6a4, Nrxn1 and Dbp to determine if they 
share expression quantitative trait loci (eQTLs). 
 Complex gene regulation due to close 3-dimensional proximity of linked 
gene loci packed into nucleosomes allows for chromatin co-accessibility of 
transcriptional machinery[290] amongst genes on the same (cis) or different (trans) 
chromosomes[284, 291]. Such regions are referred to as eQTLs and display cell 
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type specificity[292, 293], transient and perpetual regulation[293, 294], as well as 
crosstalk with other eQTLs[291] and epigenetic marks[295]. eQTLs are typically 
located in regions of linkage disequilibrium (LD)[284, 295] where the intron 
sequence codes for gene regulatory elements (GREs) and is susceptible to the 
introduction of SNPs or repetitive sequences[284, 291, 292] that alter the binding 
affinity of nearby transcriptional machinery[295] resulting in a change in expression 
of eQTL-linked genes[284, 291, 292, 295]. Importantly, regions of LD have been 
associated with diseases and neuropsychiatric disorders in humans and rodent 
models[284, 294-298], in addition LD in both Slc6a4 and Nrxn1 has been linked to 
ASD[299, 300]. Therefore to determine if Nrxn1 and Dbp could potentially share 
eQTLs in a region of LD with Slc6a4, explorative evaluations of gene regulatory 
properties using mouse genome GRCm38/mm10 annotations from the University 
of California Santa Cruz (UCSC) Genome Browser[301] were performed and, 
unless otherwise indicated serve as the reference for the results described below 
which include GREs, candidate cis-regulatory elements (cCREs), 5’-cytosine-
phosphate-guanine-3’ (CpG) islands (CpGI), promoters, SNPs and repeating 
elements. Importantly, cCREs are potential trans CREs[291] and include members: 
(1) with high histone H3 lysine 4 trimethylation (H3K4me3), such as promoter-like 
signatures (P-L, also designated prom in the UCSC figures) and H3K4me3 
signatures (K4m3), (2) with high histone H3 lysine 27 acetylation (H3K27ac), 
such as distal enhancer-like signatures (enhD), (3) with high histone H3K4me3 
and H3K27ac are identified as proximal enhancer-like signatures (enhP), and (4) 
with high CCCTC-binding transcription factor activity (CTCF). Moreover, although 
these histone marks are typically associated with active transcription for the 
genes they regulate, sequence disruption within or flanking eQTLs can create an 
environment wherein active transcription-associated histone signatures become 
either transcriptionally hyperactive or repressive through crosstalk with 
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neighboring histone modifications from cis- and trans-chromosomes and 
-nucleosomes[302, 303]. 
Slc6a4 
 Slc6a4 is located on the positive strand of mouse chromosome 11 (chr11) 
at position 76,998,603-77,032,339 and is 33.74 kb in length (Figure 3.17 A). 
Currently, there are 5 GREs between 38.6 kb and 127 bp upstream of Slc6a4 
and 15 GREs within the gene body. Additionally, there are several hundred 
identified regions throughout the gene body that have been associated with 
mouse SNPs and 65 regions associated with repeating elements ranging from 
23-395 bp in length. Of particular interest are regions flanking restriction enzyme 
loci (REL), as homologous recombination (HR) of cloned DNA fragments in the 
I172M and KO constructs could have introduced SNPs if the REL are located 
near polymorphic sequences. The KO cloned DNA fragment was inserted at the 
NcoI[153] REL (chr11:77,005,650-77,005,655) in intron 1 (NcoII1) and the I172M 
cloned DNA fragment appears to have been inserted within the same region[158], 
we therefore evaluated regulatory properties flanking NcoII1 to determine if it has 
properties characteristic of LD (Figure 3.17 A-B). NcoII1 is located between exons 
1B and 1C and is surrounded by four enhD signatures, two ending at 2.37 kb and 
1.58 kb upstream and two beginning at 275 bp and 968 bp downstream. There 
are 4 potential SNPs ranging from 35-100 bp upstream and 5 SNPs ranging from 
8-118 bp downstream of NcoII1 (Figure 3.17 B). These data indicate the intronic 
biochemical signatures surrounding NcoII1 have characteristics that resemble 
regions of LD. 
 In addition to the above hypothetical intron 1 disruption, the KO construct 
also has an intron 1 and intron 2 regions potentially perturbed by Neo cassette 
replacement of the last 784 bp of intron 1, all 451 bp of exon 2 and the first 130 
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bp of intron 2[153] (Figure 3.17 A, C, D). The intron 1 BamHI (BamHII1) REL 
(chr11:77,009,542-77,009,547) resides downstream of exon 1C (413 bp) and 
promoter 2 (258 bp) and upstream from the start of exon 2 (784 bp) (Figure 3.17 
B). Multiple potential mouse SNPs flank BamHII1, however no known cCREs are 
found within 1 kb up or downstream of BamHII1. The intron 2 HindIII (HindIIII2) 
REL (chr11:77,010,912-77,010,917) resides 130 bp downstream from exon 2 and 
4 bp into the starting sequence of E01510691/enhP. Between exon 2 and 
HindIIII2 are 5 potential SNPs ranging from 21-119 bp upstream of HindIIII2 and 
one potential site 44 bp downstream. These data indicate the intronic 
biochemical signatures surrounding Neo cassette insertions sites are 
polymorphic and that SNPs are capable of being introduced near the BamHII1 
REL. In addition, E01510691/enhP is likely disrupted due to the HindIIII2 REL, 
hypothetically affecting promoter 2 and E01510691/enhP binding partners 
respectively. 
 Currently, there are 17 identified TF binding sites located within the Slc6a4 
gene body, of which 3 are within the cloned DNA fragment. Located 365 bp 
downstream of NcoII1 and contained within E0510687/enhD (Figure 3.17 A) is the 
signal transducer and activator of transcription (STAT) STAT5A::STAT5B binding 
site. Located in intron 2 downstream from E0510691/enhP by 788 bp and 1342 
bp are the TF binding sites for STAT6 and basic helix-loop-helix family member 
E40 (BHLHE40), respectively. If binding sites for these TFs are also found 
proximal to TSSs or within the gene body of Nrxn1 or Dbp and strain-specific 
SNPs have been introduced, this could link their expression to Slc6a4. 
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Nrxn1 
 Nrxn1 located on the negative strand of mouse chr17 at position 
90,033,644-91,093,071 is one of the largest known mammalian genes[304] at 
1.06 Mb in length, having one long 𝛼-Nrxn1 and two short β-Nrxn1 mRNA 
transcript variants (Figure 3.18 A). The 𝛼-Nrxn1 and β-Nrxn1 contain 5 and 2 
alternative splice sites, respectively, that are predicted to result in greater than a 
a thousand NRXN1 isoforms[305-307]. Multiple Nrxn1 mRNA variants are possible 
because there are four promoter regions and four transcription start sites (TSSs). 
𝛼-Nrxn1 utilizes promoters 1 & 3 which reside in exon 1 and their respective 
TSSs are located within exon 2, whereas, the TSSs for β-Nrxn1 are proximal to 
the promoters located in introns 17 and 21[305, 306, 308]. Due to inhibitory synaptic 
interactions between 𝛼-Nrxn1 variants and MB KO DEGs encoding NLGN2[308], 
NXPH1[309] and GABAA-R subunits, along with 𝛼-Nrxn1 roles in synaptic vesicle-
mediated neurotransmitter release, synaptic plasticity, GABAergic synapse 
differentiation[307-310], and the regulatory interplay that occurs between the 
serotonergic and GABAergic systems[311, 312], the evaluation was focused 
primarily at 𝛼-Nrxn1 promoter regions and TSSs, because sequences within 
these regions are plausible candidate eQTLs for Slc6a4 GRE interaction and 
could potentially alter the expression of Nrxn1. Within the Nrxn1 gene body are 
79 GREs including 2 CpGI, 3 gene promoters, 4 P-L, 5 K4m3, 46 enhD, 15 enhP 
and 4 CTCF biochemical signatures (Figure 3.18 A), along with 1 enhP and 1 P-L 
signature, 556 bp and 15 bp upstream from exon 1, respectively (Figure 3.18 B). 
Eleven of the 79 GREs are proximal to the exon 2 TSSs which are within the first 
7.57 kb of the Nrxn1 gene. In addition to the promoters sequences found within 
exon 1, the region contains a P-L signature as well as 4enhP and 1 K4m3 
signatures all located within the 2.99 kb that comprise intron 1[308]. The highly 
methylated CpGI 105 overlaps with the 3’ end of exon 2 and extends an 
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additional 30 bp[308]. Finally, two K4m3 signatures are located within the first 2.12 
kb of the 92.48 kb comprising intron 2. There are currently 96 TF binding sites 
throughout the Nrxn1 gene body, which include STAT5A::STAT5B and BHLHE40. 
Overall, these data indicate that the Nrxn1 gene contains GREs that could 
potentially interact with Slc6a4 GREs. 
Dbp 
 Dbp is located on the posit ive strand of chr7 at posit ion 
45,705,088-45,710,203. Within the Dbp gene body are 15 GREs including 3 
CpGIs, 1 gene promoter, 2 P-L, 4 enhP and 5 enhD biochemical signatures 
(Figure 3.19). Contained within exon 1 are the gene promoter, TSS, one CpGI, 
and a P-L and enhP signature. In addition to the 9 currently annotated TF binding 
sites within the Dbp gene body, BHLHE40 has been identified to transcriptionally 
regulate Dbp[313]. Overall, these data indicate that the Dbp gene has GREs that 
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 Mood disorders including anxiety and depression are complex disorders 
that involve numerous systems and structures in the brain. Uncovering the 
associated molecular mechanisms of the disorders and how antidepressants and 
anxiolytics act to moderate these processes remains poorly understood. Animal 
models serve a critical role in identifying the molecular and structural players 
associated with mood disorder behavioral perturbations and pathophysiology[117, 
122, 232-235] as well as mechanisms underlying antidepressant efficacy[117, 119, 122, 
236]. The generation of serotonin transporter knockout mice marked an important 
breakthrough for tools to provide greater insight into the serotonergic system and 
its impact on physiology and behavior[117, 122, 153, 232, 234, 236-239]. However, the 
trophic action of serotonin and its role in development[105, 123, 129, 133, 159, 162, 205, 224] 
suggested that disruption of serotonin homeostasis by eliminating SERT function 
may have impacts well beyond the serotonergic system. Therefore we generated 
a SERT I172M SSRI-insensitive mouse line[157, 158] that is physiologically and 
behaviorally indistinguishable from WT and appears to maintain an intact 
serotonergic system[158, 176, 241-244]. Importantly, SSRI effects in the I127M and 
comparisons to the WT and KO animals should allow for direct assessment of 
SSRI-mediated transcriptomic changes, in molecular determinants and pathways 
associated with increased susceptibility to mood disorder manifestations which 
appears to result from developmental programming in response to early life SSRI 
exposure. 
 In this study, we use RNA-Seq to compare the transcriptomes from the MB 
and HPC of adult WT, I172M, and KO mice where the MB contains serotonergic 
soma and the HPC contains serotonergic termini. Our findings show minimal 
DGE changes between the WT and I172M animals whereas KO mice exhibit 
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numerous DEGs compared to WT and I172M. These findings are in complete 
agreement with biochemical, pharmacological, and behavioral analysis which 
showed no significant differences between the WT and I172M animals[158, 176, 
241-244] in contrast to the behavioral and physiological disturbances observed in 
SERT KO animals[117, 122, 153, 232, 234, 236-239]. Furthermore, pathway analysis of 
significant DEGs did not identify any changes in the I172M mouse MB and HPC 
further supporting its similarity to the WT animal which is in direct contrast to the 
constitutive loss of SERT which impacts multiple pathways critical for proper 
neuronal development, maintenance, signaling and processing of external stimuli 
associated with behavior, mood disorder pathophysiology and antidepressant 
efficacy.  
 Pathway analysis of the MB identified significant inhibition of axon 
guidance (AG) and a propensity for attenuated actin cytoskeletal regulation 
(ACR). Importantly, these pathways are vital components for healthy 
conductance of signal propagation through the outgrowth and arborization of 
axons and the formation and pruning of synapses. The hindrance of AG and ACR 
pathways is in line with the reduction of serotonergic cells and their firing rates 
observed in the DRN of KO mice[199], as well as mechanisms associated with 
mood disorder neurovegetative states. Likewise Ansorge and colleagues have 
proposed that the increased propensity of adult mice to develop depression-like 
behavior following SSRIs challenge during an early developmental window is due 
to altered serotonergic neuronal pruning in the cortex[117, 119]. These findings 
strengthen the argument for the role of structural changes in neural connections 
and the depressive state. The SPIA prediction for MB activation of serotonergic, 
GABAergic, glutamatergic, MAPK and Ca2+ signaling is characteristic of the 
neural response to chronic stress implicated in the death of limbic system 
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neurons, which is a contributing factor to impaired memory and the aberrant 
behaviors linked to MDD. The change in GABAergic and glutamatergic signaling 
pathways in the SERT KO animals is noteworthy and compelling given they have 
been identified as key mechanisms for the fast-acting amelioration of depressive 
and anxiety symptoms by the anesthetic ketamine and neurosteroid 
allopregnanolone. Future study of the relationship between these rapid acting 
agents and the relatively slow acting AD at SERT could provide further insight 
into the molecular determinants underlying mood disorder pathophysiology. 
 Interestingly, the behavioral and physiological changes identified in SERT 
KO mice may not be solely due to loss of SERT function. Ravary et al (2001) 
examined the MB raphe for possible transcripts resulting from the disruption 
cassette used to create the SERT KO animals and found truncated Sert mRNA 
transcripts lacking the first 450 bp, a region which includes exon 2 of the Sert 
gene. The truncated Sert transcript resulted in translation of a non-functional 
truncated SERT protein that could be detected by two different antibodies with 
reactivity to the C-terminus of SERT. The truncated SERT protein was not 
trafficked to the plasma membrane or axon but rather localized to ER cisternae in 
raphe somatodendritic compartments where it appeared to distort the structure. 
In addition, Ravary et al (2001) evaluated if ventrobasal thalamic nuclei or retinal 
ganglion cells, both of which transiently express SERT during development also 
expressed truncated Sert mRNA and protein. However, they were unable to 
detect truncated SERT protein in these tissues suggesting there may be transient 
or tissue-specific translation inhibition of the truncated SERT mRNA.  
 The truncated SERT protein may be causing dysfunction in protein 
processing and inducing cell death as our pathway analysis of the SERT KO 
animal found significant expression changes in the ER Protein Processing 
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Pathway (ERPPP) which are predicted to activate the Unfolded Protein 
Response (UPR) and induce apoptosis in the HPC of KO mice. This becomes 
particularly compelling when considering Ravary et al. observed ER blebbing in 
the serotonergic neurons of KO animals leading them to assess activation of the 
UPR pathway by looking at ER chaperone binding immunoglobulin protein (BiP) 
or ubiquitin C levels. However, as the level of these two markers were 
unchanged it was concluded that the UPR pathway was not induced. Our 
transcriptomic data agreed with their findings in regards to unchanged BiP and 
UBC expression, however, as our method is able to look at all the genes in a 
pathway, we were able to detect the changes that would indicate activation of the 
UPR and suggest that the truncated SERT may alter global protein processing as 
well as push cells to apoptosis and perhaps could explain decreases in cell 
density. Furthermore, the truncated mRNA could also alter protein expression 
through induction of ribosomal stalling and it is reasonable to conceive that all of 
these effects could expand to multiple tissues based on our finding of ectopic 
expression of the truncated SERT mRNA in the HPC. Overall, these data indicate 
that in addition to loss of functional SERT and dysregulated serotonergic 
innervation, ectopic expression of Sert transcripts in the HPC are all contributing 
to altered hippocampal function, reduced hippocampal volume and the aberrant 
behaviors observed in KO mice. 
 The outcomes in this work are further supported by a recent proteomic 
study looking at proteins that interact with SERT in that a large number of DEG 
identified in our study were also shown to be part of the SERT interactome[280]. 
 Unexpectedly, a small number of DEGs were shared by the I172M and KO 
animal in comparison to the WT. Some of the genes have been implicated in 
autism and depression and suggest that there may be gene regulatory elements 
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(GREs) contained within the Sert locus that regulate expression of these genes 
and that introduction of the transgene cassettes to engineer the I172M and KO 
animals may have disrupted these GREs and explain why these genes are only 
altered in the I172M and KO animals. If true, this could open a new path for 
understanding serotonergic regulation as well as potential to uncover novel 
pathophysiologic mechanisms into autism and depression. 
 Overall, the transcriptomic findings from this study reveal the close 
similarity of the WT and I172M mouse in the HPC and MB and further validate 
the use of the I172M antidepressant insensitive mouse as a better model system 
to study the effects of SERT-targeting antidepressants compared to SERT null 
animals. In addition, analysis of the KO animal identified neural signaling 
pathway perturbations that are connected to the recently discovered fast-acting 
antidepressants ketamine and allopregnanolone, and provide a basis that the 
fast and delayed-acting antidepressant pathways are connected and worthy of 
further study. Notably, our results provide gene and protein targets that could be 
leveraged to uncover the mechanistic connection between these temporally 
disparate treatment paradigms. In addition, the predictive induction of the UPR 
and apoptotic pathways refine and advance a previous study investigating 
putative transcripts resulting from the construction of the SERT null mouse, and 
implicate the truncated SERT protein and/or mRNA in dysfunction of protein 
processing that could result in relevant pathophysiologies. Unexpectedly, our 
findings suggest that the Sert locus may merit closer examination, as it may 
contain important GREs that impact genes linked to autism. Collectively, these 
findings provide confidence for moving forward with this model as a novel means 
to detect SERT-SSRI mediated versus non-SSRI SERT mediated changes, and 
will be an invaluable investigative tool in the forthcoming future, especially when 
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combined with neonate SSRI exposure during critical windows of development 
and biochemical assays to assess the impact of transcriptomic changes on 




DISCUSSION AND CONCLUSIONS 
Depression, perinatal depression (PD) and anxiety are characterized by multiple 
undesirable and obtrusive physical and psychological manifestations, the most 
severe being suicidal ideation[1, 28, 29, 314]. These mood disorders have one of the 
largest socioeconomic impacts in the developed world[2, 3, 5, 6] and depressive 
disorders threaten to become the largest contributing factor to the global burden 
of disease[25], not only due to population increases, but also because current 
SSRI treatment of PD leads to higher incidence of depression in society[115, 126]. 
Importantly, while genetic predisposition to depressive disorders may contribute 
to increased susceptibility[115, 126, 141, 195, 196], Malm et al (2016) and Liu et al (2017) 
identified that it is PD treatment with SSRIs and the associated dysregulation of 
trophic 5-HT[70, 123, 127-129, 133, 224, 227, 229, 230, 315] during 3rd trimester brain 
development which results in a 9% increased risk in depression diagnoses by the 
age of 15[115, 126]. These data support decades of rodent studies elucidating acute 
SSRI exposure during a critical window of brain development resulting in altered 
serotonergic tone, fiber density, neuronal activity, arborization, cytoarchitechture, 
and 5-HT receptor activation which ultimately leads to persistent anxiety- and 
depressive-like behaviors throughout the life of the organism[105, 117, 119, 122, 123, 162, 
199, 205]. This SSRI-sensitive window (SSW) of brain development has been 
identified as postnatal (PN) days 2-21 in rodents and corresponds to the end of 
2nd and the duration of 3rd trimesters for in utero human brain development[105, 117, 
119, 205]. It was these findings of transient early-life disruption to serotonergic 
signaling and the resulting enduring behavioral alterations which peaked our 
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interest of gaining a better understanding of SSRI-mediated disordered 
physiological processes associated with depression. 
 The pathophysiology underlying depressive mood disorders is proposed to 
occur from the culmination of aberrant neuronal signaling between the prefrontal 
cortex (PFC) and structures of the limbic system[43, 106, 198, 258], such as the control 
center for serotonergic innervation, the midbrain (MB), and a region which 
receives a high levels of serotonergic input, the hippocampus (HPC)[43, 258, 259]. 
The PFC is responsible for consciously executing highly complex cognitive 
behaviors, whereas the MB and HPC are involved in processes of the 
subconscious mind which participate in the formation of memories, learning and 
emotions[42, 43, 258, 259]. Importantly, the serotonergic system provides a 
mechanistic connection between the subconscious and conscious, allowing 
emotions to influence behavior[32, 38, 41-43, 45]. Moreover, while dysregulation of 5-
HT is the primary neurotransmitter implicated in depression pathophysiology[96, 
100], it is the complex, interconnected modulation and reciprocal regulation of 
serotonergic, glutamatergic and GABAergic systems in combination with Brain-
Derived Neurotrophic Factor (BDNF) and the inflammatory response which 
creates a neurotoxic environment and likely results in the neurovegetative effects 
present in mood disorders[48, 97, 98, 106, 108-111, 271]. This integrated hypothesis of 
depression has been beneficial not only to the understanding of how the 
symptoms of depression begin to manifest, and how slow- versus fast-acting 
antidepressants may provide symptom amelioration; but also by providing a 
means through which we can be confident in our data if genes associated with 
these pathways are differentially expressed in our mouse model in response to 
AD challenge. What the integrated hypothesis of depression lacks in providing an 
explanation for, is how acute SSRI exposure during the SSW of development 
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results in persistent aberrant behavioral alterations. Long-lasting changes to 
expression and therefore function can be accomplished through epigenetic 
modifications and it is that process that we hypothesize is responsible for the 
long-term effects 
 Adaptations to the epigenome can be transient or persistent and have 
been shown to shape behavior through modifications on DNA, histones and 
RNA[105, 151, 264-267, 316, 317]. DNA modifications such as 5-methylcytosine (5mC) 
and 5-hydroxymethylcytosine (5hmC) marks are typically associated with gene 
silencing and enhancement of expression, respectively[105, 151, 264-267, 316, 317]. 
However, the regulation of gene expression through 5mC can also turn on gene 
expression if methylation marks are located in regions near gene repressors[43, 
316]. Methylation and acetylation on histone tails differentially alters chromatin 
accessibility for transcriptional machinery required for gene transcription, and 
therefore can lead to either silencing or enhancement[43, 265, 316, 317]. The 
epigenetic modification of RNA termed N6-methyladenosine (m6A) occurs on 
messenger RNA (mRNA)[266, 267]. m6A differentially regulates mRNA splicing, 
transport, stability and translation, depending on the location and number of m6A 
marks[266, 267]. Importantly, any one of these epigenetic modifications, or 
combination thereof can result from developmental exposure to drugs or stress, 
becoming a permanent change to the epigenome resulting in aberrant gene 
expression or mRNA regulation, and thereby altering lifelong behavior[105, 151, 
264-267, 316, 317].  
 To investigate epigenetic mechanisms contribution to behavioral 
perturbations induced by early life SSRI exposure, we look to mouse models. 
Since 1998, when Bengal et al, created the serotonin transporter knock-out 
(SERT-KO) mouse, it has been instrumental in elucidating the serotonergic 
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systems role in anxiety- and depressive-like behaviors, as well as the 
neurovegatative effects, many of which mimic those descried above for SSW 
exposure[117, 122, 153, 177, 232-240, 245, 318]. However, due to the trophic role of 5-HT 
during development [70, 123, 127-129, 133, 224, 227, 229, 230, 315] and the method by which 
the KO was created[153] (discussed below), constitutive loss of SERT results in 
compensatory mechanisms[236-238, 319-322] and the aggregation of misfolded 
truncated SERT protein in the somatodendritic compartments[262], respectively. 
These abnormal processes within the KO mouse make it difficult to infer SERT 
specific outcomes. In addition, because SSRIs block SERT to prevent the uptake 
of 5-HT from the synapse[139, 165, 166], SSRI-mediated behavioral changes cannot 
be determined from KO mice, as they lack a functioning transporter. Moreover, 
because SERT-KO animals begin development lacking SERTs, they have 
substantial neurological deficits that occur prior to the SSW[122, 154-156], indicating 
their emotional and behavioral abnormalities may not be consistent with SSW 
exposure[122]. It was for these reasons that Henry et al, 2006 began to seek a 
better model system for evaluating SSRI-mediated effects which result from SSW 
exposure.  
 It has been shown that drosophila exhibits reduced potency for many 
SSRIs and cocaine , yet maintained normal potency for 5-HT in cell culture 
studies[157]. Henry et al (2006) therefore performed species scanning analysis 
and identified that while the amino acid sequences for SERT were largely 
conserved across species, insects consistently differed by one amino acid in 
comparison to mammals[157]. This amino acid is an isoleucine (I) at position 172 
in mammals and a methionine (M) in insects and is located in transmembrane 
domain 3, a region important for substrate and inhibitor recognition[157]. These 
data led to the subsequent creation of the transgenic I172M mouse by Thompson 
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et al, 2011. Importantly, cell culture studies showed normal 5-HT transport 
function and SERT expression for the I172M mutant in hSERT and mSERT[158]. 
Moreover, competition uptake analysis of WT and I172M forebrain-derived 
synaptosomes revealed the potency for all substrates to inhibit uptake remained 
unchanged in the I172M mutant[158]. Similar to cell culture studies with dSERT, 
I172M SERT had significantly reduced potency for FLX and S-CIT while 
maintaining normal potency for PXT[158]. In addition, I172M mice do not differ 
from WT in the number of MB raphe serotonergic cells, their associated firing 
rates, levels of neurogenesis, circadian rhythm patterns or anxiety- and 
depressive-like behaviors[158, 176, 241-244]. These data suggested I172M mice are 
physiologically and behaviorally indistinguishable from WT and they appear to 
maintain an intact serotonergic system, while being pharmacologically insensitive 
to FLX and S-CIT[158, 176, 241-244]. While these data were promising that we had 
created a more appropriate mouse model for investigating the epigenetic effects 
associated with the persistent behavioral changes which occur as a result of PN 
SSRI challenge, before such experiments can be successfully carried out, 
transcriptomic characterization of the I172M mouse model is required.  
 We performed RNA-Sequencing on the MB and HPC of 9-week old 
untreated SERT WT, I172M and KO mice to compare transcriptomes. The MB 
was chosen because as the control center for serotonergic innervation it houses 
serotonergic cell bodies which is the primary location for Sert gene transcription 
and subsequent translation into mRNA, in addition to its role in processing 
external stimuli and mediating unconscious physiological responses [32, 35, 43, 45, 47, 
258, 259]. In contrast, the HPC was chosen because it receives a high levels of 
input from serotonergic termini, is the primary site of adult neurogenesis in the 
brain and has been implicated in the neurovegetative effects associated with 
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mood disorders in humans and rodents[36, 39, 40, 43, 45-48, 51, 52, 258, 259]. RNA-Seq 
data was analyzed for differential gene expression (DGE) by comparing each of 
the mouse genetic backgrounds, and analyzed by comprehensive unbiased 
analyses using Gene Set Enrichment Analysis (GSEA) and Signaling Pathway 
Impact Analysis (SPIA) with the goal of identifying putative mechanistic targets 
associated with serotonergic dysregulation. 
 DGE between the WT and I172M identified a small number of genes in the 
MB and HPC. In direct contrast, comparison of KO to either WT or I172M 
revealed more than a thousand genes differentially expressed in the MB and a 
similar pattern is observed in the HPC. Notably, in the HPC only 324 genes were 
differentially expressed between WT/KO, whereas over 1600 genes in the I172M/
KO comparison which is due different levels of variance within the sample groups 
such that variance was relatively low in our 3 KO and I172M replicates compared 
to the greater variance observed amongst the 3 WT replicates. Importantly, the 
amount of variance in our WT replicates was not significant enough to exclude 
any WT samples from the analysis. Overall, the outcomes from the DGE 
analyses were expected and support the biochemical, physiological and 
behavioral analyses which strongly indicate I172M mice are virtually the same as 
WT[158, 176, 241-244] and that the KO animals are dramatically different[117, 122, 153, 177, 
232-240, 245, 318]. 
 Our unbiased approach for GSEA evaluated enrichment of functional 
characteristics, such as biological processes (BP), cellular components (CC) and 
molecular functions (MF) and as anticipated found no functional characteristics 
enriched in the MB or HPC for WT/I172M comparisons. In contrast, KO 
comparisons to either WT or I172M revealed multiple BP, CC and MF enriched in 
the MB and HPC with many of the functional characteristics being consistently 
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identified in each of the WT/KO and I172M/KO analyses related to either 
neuronal signaling, signaling system metabolism, or cellular response to 
misfolded proteins. 
 To determine if the enriched functional characteristics resulted in 
perturbation of pathways, we performed an unbiased evaluation of DGE data 
using SPIA. Again as expected, no predicted perturbation of signaling pathways 
in the MB or HPC of WT/I172M were identified. Contrastingly, a large number of 
signaling pathways in WT/KO and I172M/KO comparisons were predicted to 
have perturbation, although perturbation was significant in only 3 of the MB and 9 
of the HPC pathways. It is important to note here that the SPIA database only 
includes incomplete data, which is why multiple pathways may not be considered 
significantly perturbed and why we can still use predicted pathway perturbation to 
draw conclusions from. Moreover, our model provides us with greater confidence 
in the findings of our data analyses because many of the same pathways have 
predicted perturbation in both the WT/KO and I172M/KO comparisons. 
 Functional characteristics associated with neuronal signaling were 
expected as KO mice display a significant reduction in MB raphe serotonergic 
cells and their associated firing rates[233], reduced HPC volume[318] as well as 
reduced 5-HT receptor 1A (5-HT1AR) binding and function[232]. Importantly, the 
identification of functional characteristics involved in membrane potentials, Ca2+ 
regulation, synapse organization, specialization, and synaptic vesicle cycling, 
infers that neuronal signaling beyond the serotonergic system is perturbed in the 
MB and HPC of KO mice. Additionally, the enrichment of functional 
characteristics such as glio- and axonogenesis, axo-dendritic transport, and 
myelination are related to the inhibited pathways of axon guidance in the MB and 
regulation of actin cytoskeleton in the HPC. These components and pathways 
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are critical for the proper arborization of neuron and glial cell projections, which is 
required for proper development of neurotransmitter systems, and their ability to 
connect with other neurons and carry out signal propagation[32, 33, 36]. 
 Functional characteristics associated with metabolism of the serotonergic 
system was also expected because KO mice have a significant increase in 5-HT 
metabolism[237]. The identification of functional characteristics associated with the 
metabolism of glutamatergic, GABAergic, cholinergic, and glycinergic synapses, 
as well as amino acid synthesis were compelling because previous studies in KO 
mice have not evaluated these specific components. In addition to functional 
enrichment of metabolic enzymes, genes for transporters and receptors 
associated with the perturbed synaptic pathways for serotonergic, dopaminergic, 
glutamatergic, GABAergic, and cholinergic systems were differentially expressed. 
These data are consistent with the serotonergic systems complex, 
interconnected modulation and reciprocal regulation with other neurotransmitter 
systems, as well as these systems role in depression pathophysiology and 
provide a mechanistic connection between slow- and fast-acting antidepressant 
therapy[43, 48, 98, 106, 108, 109, 111]. Furthermore, these data support and expound upon 
our hypothesis that the substantial neurological deficits and aberrant behaviors 
resulting from constitutive loss of SERT disrupts multiple neurotransmitter 
systems and therefore the SERT-KO mouse is not comparable to acute SSW 
exposure in WT mice. 
 Functional characteristics associated with the cellular response to 
misfolded proteins and induction of the Endoplasmic Reticulum Protein 
Processing Pathway (ERPPP) in the MB and HPC of KO mice was an 
unexpected discovery. Because even though Ravary et al (2001) observed an 
aggregation of misfolded truncated SERT protein in the somatodendritic 
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compartments of KO MB raphe, their investigation of the levels of two Unfolded 
Protein Response (UPR) markers remained unchanged leading them to the 
conclusion that the UPR pathway was not induced. Moreover, it was not 
anticipated to observe ectopic expression of truncated Sert mRNA in the HPC, a 
region where it is not typically expressed because the HPC lacks serotonergic 
soma. The ectopic expression of HPC Sert may result from the transgenic 
generation of KO mice either by (1) disrupting exon 1C, which is known for 
directing tissue-specific expression[323-326], or (2) the presence of the ubiquitously 
expressed phosphoglycerate kinase-1 (PGK) promoter maintained in the KO 
targeting vector, which is known to drive high levels of reporter gene 
expression[327-329]. In addition to ectopic HPC Sert expression, novel to our study 
is the functional enrichment of multiple processes of the UPR and ERPP 
pathways involved in mRNA binding, processing and splicing, as well as, protein 
folding, trafficking, aggregation and degradation in both the MB and HPC of KO 
mice. Importantly, induction of the ERPPP is likely an attempt to overcome the 
cytotoxic effects of misfolded protein accumulation in the MB and ribosomal 
stalling in the HPC. Overall, these data infer that reduced HPC volume and 
function in KO mice is a result of ectopic Sert mRNA expression and that 
induction of the ERPPP may contribute to aberrant behaviors observed in KO 
mice.  
 In addition to the above findings, we performed a manual search of the 
differentially expressed genes in WT/KO and I172M/KO for those associated with 
BDNF because (1) the Bdnf gene itself was not differentially expressed in our 
analysis, and (2) Bdnf mRNA is known to exist as multiple alternatively spliced 
transcripts, all of which are differentially regulated but encode for BDNF 
protein[330]. Interestingly, twenty genes associated with BDNF mRNA binding and 
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splicing, protein expression and trafficking, as well as, maintenance of BDNF 
protein levels and BDNF-dependent signaling were found to be differentially 
expressed between the MB and HPC of KO mice. Collectively these data imply 
that constitutive loss of SERT alters the regulation of BDNF mRNA splicing and 
protein function, without effect on gene expression levels. These data support (1) 
a role for dysregulated BDNF neurotrophin levels lending to the loss of neurons 
in the MB and HPC of SERT-KO mice[233, 318], (2) the reciprocal regulation of 
SERT and BDNF for proper neuronal growth and the formation and maintenance 
of synaptic connections[105, 106, 268, 330], and (3) the monoamine, BDNF, 
neuroplastic and inflammatory response integrated hypothesis of depression[106, 
162, 183]. 
 Due to the role that epigenetic modifications can play in depressive 
disorders and in shaping behavior, we performed a manual search for epigenetic-
associated genes amongst the DEGs identified in WT/KO and I172M/KO 
comparisons. We identified several genes involved in histone and m6A 
modifications. These data provide a plausible mechanistic connection between 
developmental serotonergic disruption and lifelong altered behaviors.  
 Moreover, several of the BDNF-associated and epigenetic-associated 
DEGs have been linked to mood, stress, sleep and autism spectrum disorders, 
schizophrenia and neurological diseases such as Alzheimer’s, Parkinson’s and 
Huntington’s[249, 250]. These disease-linked genes provide putative targets to 
evaluate for their role in PN SSRI exposure-induced anxiety- and depressive-like 
behaviors. 
 One of the most interesting and unanticipated findings of our study was 
the significant differential expression of Nrxn1 and Dbp in the MB and HPC of 
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SERT I172M and KO in comparison to WT. The consistent differential expression 
of these two genes in both our transgenic lines regardless of whether or not Sert 
was differentially expressed, or even expressed at all, led us to believe that the 
Sert locus may share expression quantitative trait loci (eQTL) with Nrxn1 and 
Dbp. In order to understand how this could occur, I began an extensive 
investigation into (1) how the transgenic mice were created, (2) what gene 
elements can regulate the expression of another gene, and (3) what gene 
regulatory elements (GREs) are located within Sert, Nrxn1, and Dbp gene 
sequences.  
 Both SERT I172M and KO mouse lines were generated from cultured 
B129 strain embryonic stem cells (ESC), which were then transfected with the 
appropriate targeting vector for either the I172M or KO constructs[153, 158]. The 
SERT I172M targeting vector contained exons 2-5 and portions of the flanking 
intronic regions[158]. Similarly, the SERT KO targeting vector contained exons 2-7 
and portions of the flanking intronic regions[153]. Next, ESC clones selected for by 
homologous recombination were injected into C57BL/6J strain blastocysts and 
then implanted in the uteri of C57BL/6J mice[153, 158]. After confirmation of the 
integrated desired mutation, mice were backcrossed with C57BL/6J mice for 
more than 14 generations[153, 158]. Interestingly, while this method of transgenic or 
KO mouse creation is the most commonly used, it undesirably results in the 
persistence of B129 strain genetic information[285] which can be problematic 
when WT mice used for comparisons contain strictly C57BL/6J genetics. While 
these data confirm a difference may exist in the Sert locus between I172M and 
KO mice in comparison to WT, they do not provide enough information to infer 
whether or not Nrxn1 and Dbp share an eQTL with Sert. 
140
 The presence of single nucleotide polymorphisms (SNPs) near GREs or 
transcription factor (TF) binding sites can alter the accessibility of transcriptional 
machinery and change the expression of genes associated with the nearby 
GREs or TF binding sites[282, 288, 295]. Importantly, B129 strains often contain SNPs 
which are not present in C57 strains, and vice versa[285, 287]. It is therefore 
conceivable that the B129 Sert locus contains SNPs which interfere with Nrxn1 
and Dbp transcriptional machinery, and are not present in the C57 background. 
We therefore evaluated GREs and TF binding sites in the Sert, Nrxn1 and Dbp 
gene maps available on the UCSC genome browser website to determine if Sert 
shares any of these specific elements with Nrxn1 or Dbp. Indeed multiple GREs 
and TF binding sites were common between Sert and Nrxn1, as well as Sert and 
Dbp[301]. Evaluation for SNPs present in Sert gene transcripts will be carried out 
in the future. These data indicate the presence of putative gene elements in Sert 
which could be responsible for the consistent differential expression of Nrxn1 and 
Dbp observed in SERT I172M and KO mice in comparison to WT. Importantly, 
while Nrxn1 and Dbp were significantly differentially expressed in WT/I172M 
comparisons, the previous biochemical, physiological and behavioral 
characterizations of the I172M mouse line[158, 176, 241-244], combined with our 
current transcriptomic profiles, provides us with great confidence that the I172M 
model is more appropriate than SERT KO mice for investigating the effects, 
epigenetic or otherwise of PN SSRI exposure.  
 Collectively, the results of our study provide further validation that I172M 
mice are practically indistinguishable from WT and reassure us that our model 
will be able to detect SERT-SSRI mediated and non-SSRI SERT mediated 
changes in response to early life SSRI challenge. Additionally, by leveraging 
SERT KO against both WT and I172M backgrounds we have confidently 
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identified putative mechanistic targets for future investigation of their roles in 
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Gene NameWT vs. KO I172M vs. KO
FC in KO P Adj FC in KO P Adj
1 Srsf3 1.22 6.64E-06 1.36 4.63E-15 serine/arginine-rich splicing factor 3 [Source:MGI Symbol;Acc:MGI:98285]
2 Kcnab3 -1.32 8.29E-11 -1.37 2.12E-14
potassium voltage-gated channel, shaker-related 
subfamily, beta member 3 [Source:MGI 
Symbol;Acc:MGI:1336208]
3 Ogdhl -1.20 2.62E-07 -1.25 5.93E-12 oxoglutarate dehydrogenase-like [Source:MGI Symbol;Acc:MGI:3616088]
4 Snrpd1 1.36 4.63E-08 1.43 2.83E-11 small nuclear ribonucleoprotein D1 [Source:MGI Symbol;Acc:MGI:98344]
5 Ulk1 -1.21 1.70E-06 -1.26 2.04E-10 unc-51 like kinase 1 [Source:MGI Symbol;Acc:MGI:1270126]
6 Arsg 1.29 2.30E-07 1.35 2.57E-10 arylsulfatase G [Source:MGI Symbol;Acc:MGI:1921258]
7 Elmo1 -1.20 7.54E-07 -1.24 9.00E-10 engulfment and cell motility 1 [Source:MGI Symbol;Acc:MGI:2153044]
8 Tmem151b -1.29 4.01E-10 -1.28 1.21E-09 transmembrane protein 151B [Source:MGI Symbol;Acc:MGI:2685169]
9 Hnrnpdl 1.25 2.04E-04 1.39 1.77E-09 heterogeneous nuclear ribonucleoprotein D-like [Source:MGI Symbol;Acc:MGI:1355299]
10 Sgpp2 -1.29 4.11E-07 -1.34 2.02E-09 sphingosine-1-phosphate phosphotase 2 [Source:MGI Symbol;Acc:MGI:3589109]
11 Gpx3 -1.25 2.71E-04 -1.38 2.65E-09 glutathione peroxidase 3 [Source:MGI Symbol;Acc:MGI:105102]
12 Nap1l2 1.22 2.06E-07 1.24 7.56E-09 nucleosome assembly protein 1-like 2 [Source:MGI Symbol;Acc:MGI:106654]
13 Kcnj10 -1.24 9.36E-09 -1.23 1.06E-08 potassium inwardly-rectifying channel, subfamily J, member 10 [Source:MGI Symbol;Acc:MGI:1194504]
14 Cplx1 -1.18 7.34E-07 -1.20 1.28E-08 complexin 1 [Source:MGI Symbol;Acc:MGI:104727]
15 Khdrbs1 1.20 1.88E-06 1.22 2.20E-08 KH domain containing, RNA binding, signal transduction associated 1 [Source:MGI Symbol;Acc:MGI:893579]
16 Madd -1.16 3.73E-05 -1.20 2.39E-08 MAP-kinase activating death domain [Source:MGI Symbol;Acc:MGI:2444672]
17 Abcc5 -1.22 1.02E-04 -1.29 3.08E-08 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 [Source:MGI Symbol;Acc:MGI:1351644]
18 4930506M07Rik 1.35 6.16E-08 1.35 3.34E-08 NA
19 Slc2a4 -1.44 3.65E-06 -1.51 3.69E-08 solute carrier family 2 (facilitated glucose transporter), member 4 [Source:MGI Symbol;Acc:MGI:95758]
20 Hnrnpd 1.28 2.58E-08 1.27 4.01E-08 heterogeneous nuclear ribonucleoprotein D [Source:MGI Symbol;Acc:MGI:101947]
21 Sez6l2 -1.13 1.74E-03 -1.20 4.44E-08 seizure related 6 homolog like 2 [Source:MGI Symbol;Acc:MGI:2385295]
22 Ssb 1.19 3.73E-04 1.28 4.54E-08 Sjogren syndrome antigen B [Source:MGI Symbol;Acc:MGI:98423]
23 Scrt1 -1.17 3.65E-06 -1.19 5.46E-08 scratch family zinc finger 1 [Source:MGI Symbol;Acc:MGI:2176606]
24 H3f3b 1.15 1.96E-03 1.25 5.47E-08 H3 histone, family 3B [Source:MGI Symbol;Acc:MGI:1101768]
25 Ncl 1.20 4.79E-06 1.23 5.67E-08 nucleolin [Source:MGI Symbol;Acc:MGI:97286]
26 Hmgcs1 1.23 1.97E-05 1.28 1.60E-07 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 [Source:MGI Symbol;Acc:MGI:107592]
27 Ptn 1.16 3.85E-04 1.22 1.83E-07 pleiotrophin [Source:MGI Symbol;Acc:MGI:97804]
28 Eid1 1.18 4.33E-04 1.24 2.69E-07 EP300 interacting inhibitor of differentiation 1 [Source:MGI Symbol;Acc:MGI:1889651]
29 Rab4a -1.23 1.16E-04 -1.29 3.09E-07 RAB4A, member RAS oncogene family [Source:MGI Symbol;Acc:MGI:105069]
30 Fabp5 1.28 1.43E-06 1.29 3.23E-07 fatty acid binding protein 5, epidermal [Source:MGI Symbol;Acc:MGI:101790]
31 Apba1 -1.09 2.52E-02 -1.17 3.79E-07 amyloid beta (A4) precursor protein binding, family A, member 1 [Source:MGI Symbol;Acc:MGI:1860297]
32 Ppip5k1 -1.15 1.60E-04 -1.19 4.33E-07 diphosphoinositol pentakisphosphate kinase 1 [Source:MGI Symbol;Acc:MGI:2443281]
APPENDIX H. Midbrain Specific DEGs in WT vs KO and I172M vs KO.
291
33 Slc13a5 1.23 2.44E-02 1.46 4.59E-07
solute carrier family 13 (sodium-dependent citrate 
transporter), member 5 [Source:MGI 
Symbol;Acc:MGI:3037150]
34 Gamt 1.22 7.12E-03 1.37 5.38E-07 guanidinoacetate methyltransferase [Source:MGI Symbol;Acc:MGI:1098221]
35 Tspyl2 1.22 1.34E-06 1.22 5.38E-07 TSPY-like 2 [Source:MGI Symbol;Acc:MGI:106244]
36 Npm1 1.21 5.35E-06 1.23 5.57E-07 nucleophosmin 1 [Source:MGI Symbol;Acc:MGI:106184]
37 Slc36a1 -1.15 2.31E-03 -1.22 6.34E-07 solute carrier family 36 (proton/amino acid symporter), member 1 [Source:MGI Symbol;Acc:MGI:2445299]
38 Lynx1 -1.12 6.54E-04 -1.16 7.17E-07 Ly6/neurotoxin 1 [Source:MGI Symbol;Acc:MGI:1345180]
39 Hdac5 -1.15 4.80E-04 -1.20 7.22E-07 histone deacetylase 5 [Source:MGI Symbol;Acc:MGI:1333784]
40 Bhlhe40 1.25 6.12E-06 1.27 7.81E-07 basic helix-loop-helix family, member e40 [Source:MGI Symbol;Acc:MGI:1097714]
41 Hnrnpr 1.25 7.09E-06 1.26 8.50E-07 heterogeneous nuclear ribonucleoprotein R [Source:MGI Symbol;Acc:MGI:1891692]
42 Mlec -1.18 5.46E-04 -1.23 9.59E-07 malectin [Source:MGI Symbol;Acc:MGI:1924015]
43 Atxn7l3 -1.13 7.07E-04 -1.17 1.22E-06 ataxin 7-like 3 [Source:MGI Symbol;Acc:MGI:3036270]
44 Erbb3 -1.26 1.17E-03 -1.37 1.24E-06 erb-b2 receptor tyrosine kinase 3 [Source:MGI Symbol;Acc:MGI:95411]
45 Tra2b 1.14 2.53E-02 1.27 1.24E-06 transformer 2 beta [Source:MGI Symbol;Acc:MGI:106016]
46 Pspc1 1.23 1.74E-04 1.29 1.32E-06 paraspeckle protein 1 [Source:MGI Symbol;Acc:MGI:1913895]
47 Syndig1l -1.26 8.33E-04 -1.36 1.33E-06 synapse differentiation inducing 1 like [Source:MGI Symbol;Acc:MGI:2685107]
48 Cdc42bpa -1.13 3.14E-03 -1.19 1.73E-06 CDC42 binding protein kinase alpha [Source:MGI Symbol;Acc:MGI:2441841]
49 Srrm3 -1.25 1.13E-05 -1.26 1.86E-06 serine/arginine repetitive matrix 3 [Source:MGI Symbol;Acc:MGI:1920309]
50 Rbmx 1.28 2.37E-04 1.35 1.87E-06 RNA binding motif protein, X chromosome [Source:MGI Symbol;Acc:MGI:1343044]
51 Slc38a2 -1.21 1.58E-03 -1.30 1.90E-06 solute carrier family 38, member 2 [Source:MGI Symbol;Acc:MGI:1915010]
52 Cd9 1.27 6.31E-06 1.28 1.90E-06 CD9 antigen [Source:MGI Symbol;Acc:MGI:88348]
53 Eng -1.32 6.31E-07 -1.30 1.96E-06 endoglin [Source:MGI Symbol;Acc:MGI:95392]
54 Ank1 -1.22 4.74E-05 -1.25 2.03E-06 ankyrin 1, erythroid [Source:MGI Symbol;Acc:MGI:88024]
55 Vgf -1.25 8.23E-05 -1.29 2.12E-06 VGF nerve growth factor inducible [Source:MGI Symbol;Acc:MGI:1343180]
56 Efnb3 1.23 6.76E-09 1.19 2.56E-06 ephrin B3 [Source:MGI Symbol;Acc:MGI:109196]
57 Atp1b2 -1.15 7.16E-05 -1.17 2.66E-06 ATPase, Na+/K+ transporting, beta 2 polypeptide [Source:MGI Symbol;Acc:MGI:88109]
58 Plekha6 -1.13 3.22E-03 -1.19 3.38E-06 pleckstrin homology domain containing, family A member 6 [Source:MGI Symbol;Acc:MGI:2388662]
59 Dcaf12l1 1.23 1.82E-06 1.22 3.38E-06 DDB1 and CUL4 associated factor 12-like 1 [Source:MGI Symbol;Acc:MGI:2444462]
60 Iqsec3 -1.14 4.59E-03 -1.21 3.41E-06 IQ motif and Sec7 domain 3 [Source:MGI Symbol;Acc:MGI:2677208]
61 Adarb1 -1.09 2.18E-02 -1.15 3.42E-06 adenosine deaminase, RNA-specific, B1 [Source:MGI Symbol;Acc:MGI:891999]
62 B230217O12Rik 1.24 2.15E-02 1.43 3.42E-06 RIKEN cDNA B230217O12 gene [Source:MGI Symbol;Acc:MGI:2444948]
63 Cacna1a -1.31 2.30E-06 -1.29 4.55E-06 calcium channel, voltage-dependent, P/Q type, alpha 1A subunit [Source:MGI Symbol;Acc:MGI:109482]
64 Gatsl2 -1.14 1.70E-02 -1.23 5.18E-06 NA
65 Arhgap35 -1.12 1.95E-02 -1.21 5.69E-06 Rho GTPase activating protein 35 [Source:MGI Symbol;Acc:MGI:1929494]
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66 Hmg20a 1.22 1.78E-04 1.26 5.78E-06 high mobility group 20A [Source:MGI Symbol;Acc:MGI:1914117]
67 Jun -1.17 8.72E-03 -1.27 6.13E-06 jun proto-oncogene [Source:MGI Symbol;Acc:MGI:96646]
68 Atg9a -1.13 2.10E-03 -1.18 6.54E-06 autophagy related 9A [Source:MGI Symbol;Acc:MGI:2138446]
69 Pnck 1.22 1.53E-05 1.22 6.98E-06 pregnancy upregulated non-ubiquitously expressed CaM kinase [Source:MGI Symbol;Acc:MGI:1347357]
70 Sspn 1.23 2.26E-03 1.32 7.24E-06 sarcospan [Source:MGI Symbol;Acc:MGI:1353511]
71 Cntnap1 -1.12 1.59E-03 -1.16 7.88E-06 contactin associated protein-like 1 [Source:MGI Symbol;Acc:MGI:1858201]
72 Rps15a 1.16 1.75E-04 1.18 8.89E-06 ribosomal protein S15A [Source:MGI Symbol;Acc:MGI:2389091]
73 Srxn1 -1.17 4.57E-05 -1.18 8.95E-06 sulfiredoxin 1 homolog (S. cerevisiae) [Source:MGI Symbol;Acc:MGI:104971]
74 Rnf157 -1.08 3.63E-02 -1.15 8.99E-06 ring finger protein 157 [Source:MGI Symbol;Acc:MGI:2442484]
75 Sptbn4 -1.18 4.00E-04 -1.21 8.99E-06 spectrin beta, non-erythrocytic 4 [Source:MGI Symbol;Acc:MGI:1890574]
76 Unc13c 1.17 7.62E-04 1.21 8.99E-06 unc-13 homolog C [Source:MGI Symbol;Acc:MGI:2149021]
77 Ube2d3 1.13 2.03E-03 1.17 9.37E-06 ubiquitin-conjugating enzyme E2D 3 [Source:MGI Symbol;Acc:MGI:1913355]
78 Tgfb3 -1.20 2.23E-02 -1.35 9.70E-06 transforming growth factor, beta 3 [Source:MGI Symbol;Acc:MGI:98727]
79 Clip3 -1.16 1.19E-05 -1.16 9.70E-06 CAP-GLY domain containing linker protein 3 [Source:MGI Symbol;Acc:MGI:1923936]
80 Sec11c 1.19 1.35E-03 1.25 1.05E-05 SEC11 homolog C, signal peptidase complex subunit [Source:MGI Symbol;Acc:MGI:1913536]
81 Actb 1.11 3.74E-03 1.15 1.08E-05 actin, beta [Source:MGI Symbol;Acc:MGI:87904]
82 Fkbp1a 1.14 9.86E-04 1.17 1.08E-05 FK506 binding protein 1a [Source:MGI Symbol;Acc:MGI:95541]
83 Mtss1l -1.11 2.01E-02 -1.18 1.24E-05 metastasis suppressor 1-like [Source:MGI Symbol;Acc:MGI:3039591]
84 Nat8l -1.08 2.53E-02 -1.13 1.28E-05 N-acetyltransferase 8-like [Source:MGI Symbol;Acc:MGI:2447776]
85 Tspan2 1.23 1.73E-07 1.19 1.29E-05 tetraspanin 2 [Source:MGI Symbol;Acc:MGI:1917997]
86 1110004F10Rik 1.17 1.73E-03 1.22 1.29E-05 RIKEN cDNA 1110004F10 gene [Source:MGI Symbol;Acc:MGI:1929274]
87 Smarca1 1.33 6.64E-06 1.32 1.31E-05
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 1 
[Source:MGI Symbol;Acc:MGI:1935127]
88 Mgat4c 1.35 1.97E-05 1.35 1.33E-05 MGAT4 family, member C [Source:MGI Symbol;Acc:MGI:1914819]
89 Tceal8 1.19 1.84E-02 1.31 1.38E-05 transcription elongation factor A (SII)-like 8 [Source:MGI Symbol;Acc:MGI:1913934]
90 Rpl6 1.17 1.27E-04 1.19 1.46E-05 ribosomal protein L6 [Source:MGI Symbol;Acc:MGI:108057]
91 Atn1 -1.14 4.32E-03 -1.20 1.56E-05 atrophin 1 [Source:MGI Symbol;Acc:MGI:104725]
92 Apba3 -1.32 6.44E-05 -1.33 1.65E-05 amyloid beta (A4) precursor protein-binding, family A, member 3 [Source:MGI Symbol;Acc:MGI:1888527]
93 Setd7 -1.21 7.21E-05 -1.22 1.65E-05 SET domain containing (lysine methyltransferase) 7 [Source:MGI Symbol;Acc:MGI:1920501]
94 AI854517 1.27 4.20E-03 1.38 1.65E-05 NA
95 Jup -1.26 1.67E-05 -1.26 1.66E-05 junction plakoglobin [Source:MGI Symbol;Acc:MGI:96650]
96 Faim2 -1.10 2.06E-02 -1.16 1.66E-05 Fas apoptotic inhibitory molecule 2 [Source:MGI Symbol;Acc:MGI:1919643]
97 Cnbp 1.13 7.02E-03 1.19 1.66E-05 cellular nucleic acid binding protein [Source:MGI Symbol;Acc:MGI:88431]
98 Eef1a1 1.19 9.72E-07 1.17 1.68E-05 eukaryotic translation elongation factor 1 alpha 1 [Source:MGI Symbol;Acc:MGI:1096881]
293
99 Bclaf1 1.18 9.45E-04 1.22 1.81E-05 BCL2-associated transcription factor 1 [Source:MGI Symbol;Acc:MGI:1917580]
100 Phtf1 -1.22 2.34E-04 -1.24 1.94E-05 putative homeodomain transcription factor 1 [Source:MGI Symbol;Acc:MGI:1332671]
101 Wbp5 1.16 9.64E-03 1.24 2.08E-05 NA
102 Acot11 -1.19 2.31E-03 -1.24 2.44E-05 acyl-CoA thioesterase 11 [Source:MGI Symbol;Acc:MGI:1913736]
103 Chtop 1.16 3.34E-04 1.17 2.59E-05 chromatin target of PRMT1 [Source:MGI Symbol;Acc:MGI:1913761]
104 Slc45a4 -1.14 2.06E-02 -1.22 2.70E-05 solute carrier family 45, member 4 [Source:MGI Symbol;Acc:MGI:2146236]
105 Fcrls 1.30 5.77E-04 1.35 2.70E-05 Fc receptor-like S, scavenger receptor [Source:MGI Symbol;Acc:MGI:1933397]
106 Heatr5b -1.23 6.64E-06 -1.21 3.10E-05 HEAT repeat containing 5B [Source:MGI Symbol;Acc:MGI:2444098]
107 Lime1 -1.40 5.14E-07 -1.32 3.12E-05 Lck interacting transmembrane adaptor 1 [Source:MGI Symbol;Acc:MGI:1919949]
108 Mast2 -1.16 9.38E-03 -1.23 3.13E-05 microtubule associated serine/threonine kinase 2 [Source:MGI Symbol;Acc:MGI:894676]
109 Kcnh2 -1.18 3.18E-04 -1.19 3.23E-05
potassium voltage-gated channel, subfamily H (eag-
related), member 2 [Source:MGI 
Symbol;Acc:MGI:1341722]
110 Calm2 1.11 3.45E-03 1.15 3.31E-05 calmodulin 2 [Source:MGI Symbol;Acc:MGI:103250]
111 Klhl32 -1.34 4.57E-05 -1.33 3.61E-05 kelch-like 32 [Source:MGI Symbol;Acc:MGI:3612790]
112 Snca 1.24 5.77E-04 1.27 3.86E-05 synuclein, alpha [Source:MGI Symbol;Acc:MGI:1277151]
113 Rusc1 -1.11 1.24E-02 -1.15 4.24E-05 RUN and SH3 domain containing 1 [Source:MGI Symbol;Acc:MGI:1919546]
114 Hsp90aa1 -1.14 6.49E-04 -1.16 4.35E-05 heat shock protein 90, alpha (cytosolic), class A member 1 [Source:MGI Symbol;Acc:MGI:96250]
115 6030419C18Rik -1.16 6.31E-04 -1.19 4.35E-05 NA
116 Mroh1 -1.17 2.00E-04 -1.18 4.85E-05 maestro heat-like repeat family member 1 [Source:MGI Symbol;Acc:MGI:2442558]
117 Scn1b -1.18 3.65E-06 -1.16 4.88E-05 sodium channel, voltage-gated, type I, beta [Source:MGI Symbol;Acc:MGI:98247]
118 Hspa4l -1.13 1.36E-02 -1.19 5.02E-05 heat shock protein 4 like [Source:MGI Symbol;Acc:MGI:107422]
119 Tnip1 -1.20 1.76E-03 -1.25 5.39E-05 TNFAIP3 interacting protein 1 [Source:MGI Symbol;Acc:MGI:1926194]
120 Unc45a -1.21 1.25E-03 -1.25 5.63E-05 unc-45 myosin chaperone A [Source:MGI Symbol;Acc:MGI:2142246]
121 Scrt2 -1.25 2.36E-04 -1.26 5.78E-05 scratch family zinc finger 2 [Source:MGI Symbol;Acc:MGI:2139287]
122 Cdc42 1.10 2.09E-02 1.15 6.33E-05 cell division cycle 42 [Source:MGI Symbol;Acc:MGI:106211]
123 Uri1 1.21 1.77E-03 1.25 7.15E-05 URI1, prefoldin-like chaperone [Source:MGI Symbol;Acc:MGI:1342294]
124 Sh3bp5l -1.16 9.78E-04 -1.19 7.17E-05 SH3 binding domain protein 5 like [Source:MGI Symbol;Acc:MGI:1933124]
125 Klc2 -1.12 1.37E-03 -1.14 7.64E-05 kinesin light chain 2 [Source:MGI Symbol;Acc:MGI:107953]
126 Sh3bgrl 1.12 3.91E-02 1.20 8.89E-05 SH3-binding domain glutamic acid-rich protein like [Source:MGI Symbol;Acc:MGI:1930849]
127 Rpl12 1.18 1.10E-03 1.21 8.91E-05 ribosomal protein L12 [Source:MGI Symbol;Acc:MGI:98002]
128 Arhgef12 -1.11 3.73E-02 -1.19 8.91E-05 Rho guanine nucleotide exchange factor (GEF) 12 [Source:MGI Symbol;Acc:MGI:1916882]
129 Tceal1 1.24 2.99E-04 1.25 8.91E-05 transcription elongation factor A (SII)-like 1 [Source:MGI Symbol;Acc:MGI:2385317]
130 Rnf13 1.15 8.98E-04 1.16 9.13E-05 ring finger protein 13 [Source:MGI Symbol;Acc:MGI:1346341]
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131 Cdh24 -1.22 1.05E-02 -1.30 9.23E-05 cadherin-like 24 [Source:MGI Symbol;Acc:MGI:1928330]
132 Serbp1 1.12 1.00E-02 1.16 9.54E-05 serpine1 mRNA binding protein 1 [Source:MGI Symbol;Acc:MGI:1914120]
133 Rps4x 1.16 2.40E-03 1.20 1.01E-04 ribosomal protein S4, X-linked [Source:MGI Symbol;Acc:MGI:98158]
134 Mybbp1a -1.20 1.76E-04 -1.20 1.09E-04 MYB binding protein (P160) 1a [Source:MGI Symbol;Acc:MGI:106181]
135 Tnfrsf12a -1.41 3.89E-06 -1.34 1.12E-04 tumor necrosis factor receptor superfamily, member 12a [Source:MGI Symbol;Acc:MGI:1351484]
136 A730017C20Rik 1.26 3.65E-06 1.21 1.12E-04 NA
137 Tmcc2 -1.15 7.54E-04 -1.16 1.13E-04 transmembrane and coiled-coil domains 2 [Source:MGI Symbol;Acc:MGI:1916125]
138 Mrpl50 1.23 5.39E-04 1.24 1.13E-04 mitochondrial ribosomal protein L50 [Source:MGI Symbol;Acc:MGI:107329]
139 Arl8a -1.15 8.49E-04 -1.16 1.14E-04 ADP-ribosylation factor-like 8A [Source:MGI Symbol;Acc:MGI:1915974]
140 Ndrg4 -1.11 1.36E-03 -1.12 1.14E-04 N-myc downstream regulated gene 4 [Source:MGI Symbol;Acc:MGI:2384590]
141 Cspg5 1.16 3.08E-03 1.20 1.20E-04 chondroitin sulfate proteoglycan 5 [Source:MGI Symbol;Acc:MGI:1352747]
142 Iqcb1 1.21 1.31E-03 1.24 1.24E-04 IQ calmodulin-binding motif containing 1 [Source:MGI Symbol;Acc:MGI:2443764]
143 Pgrmc1 1.17 1.35E-04 1.17 1.24E-04 progesterone receptor membrane component 1 [Source:MGI Symbol;Acc:MGI:1858305]
144 Meis2 -1.22 8.20E-05 -1.21 1.35E-04 Meis homeobox 2 [Source:MGI Symbol;Acc:MGI:108564]
145 Rnpep -1.16 2.04E-02 -1.23 1.45E-04 arginyl aminopeptidase (aminopeptidase B) [Source:MGI Symbol;Acc:MGI:2384902]
146 Iglon5 -1.16 2.50E-03 -1.19 1.56E-04 IgLON family member 5 [Source:MGI Symbol;Acc:MGI:2686277]
147 Ilf2 1.17 1.10E-03 1.19 1.58E-04 interleukin enhancer binding factor 2 [Source:MGI Symbol;Acc:MGI:1915031]
148 Trnp1 -1.12 2.09E-02 -1.17 1.58E-04 TMF1-regulated nuclear protein 1 [Source:MGI Symbol;Acc:MGI:1916789]
149 Ttbk1 -1.15 1.94E-02 -1.22 1.65E-04 tau tubulin kinase 1 [Source:MGI Symbol;Acc:MGI:2147036]
150 Tpbg -1.23 6.22E-03 -1.30 1.67E-04 trophoblast glycoprotein [Source:MGI Symbol;Acc:MGI:1341264]
151 Gtdc1 1.15 4.09E-02 1.25 1.73E-04 glycosyltransferase-like domain containing 1 [Source:MGI Symbol;Acc:MGI:2444269]
152 Ciart 1.24 1.40E-02 1.33 1.90E-04 circadian associated repressor of transcription [Source:MGI Symbol;Acc:MGI:2684975]
153 Rab11fip5 -1.11 8.31E-03 -1.14 1.96E-04 RAB11 family interacting protein 5 (class I) [Source:MGI Symbol;Acc:MGI:1098586]
154 Ube2e1 1.14 8.79E-03 1.18 1.98E-04 ubiquitin-conjugating enzyme E2E 1 [Source:MGI Symbol;Acc:MGI:107411]
155 Bag3 -1.29 9.91E-04 -1.32 2.01E-04 BCL2-associated athanogene 3 [Source:MGI Symbol;Acc:MGI:1352493]
156 Zfp771 -1.22 4.56E-03 -1.27 2.03E-04 zinc finger protein 771 [Source:MGI Symbol;Acc:MGI:2442050]
157 Inpp5j -1.23 7.16E-05 -1.21 2.15E-04 inositol polyphosphate 5-phosphatase J [Source:MGI Symbol;Acc:MGI:2158663]
158 Papss1 1.16 7.54E-04 1.17 2.15E-04 3'-phosphoadenosine 5'-phosphosulfate synthase 1 [Source:MGI Symbol;Acc:MGI:1330587]
159 Gltscr2 1.23 2.62E-05 1.20 2.16E-04 NA
160 Celsr3 -1.23 1.62E-03 -1.25 2.18E-04 cadherin, EGF LAG seven-pass G-type receptor 3 [Source:MGI Symbol;Acc:MGI:1858236]
161 Ccdc85c -1.19 2.21E-02 -1.27 2.18E-04 coiled-coil domain containing 85C [Source:MGI Symbol;Acc:MGI:3644008]
162 Brsk1 -1.09 2.44E-02 -1.13 2.32E-04 BR serine/threonine kinase 1 [Source:MGI Symbol;Acc:MGI:2685946]
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163 Grip2 -1.13 4.11E-02 -1.20 2.43E-04 glutamate receptor interacting protein 2 [Source:MGI Symbol;Acc:MGI:2681173]
164 Atp13a2 -1.11 1.43E-02 -1.15 2.49E-04 ATPase type 13A2 [Source:MGI Symbol;Acc:MGI:1922022]
165 Hnrnpk 1.12 1.79E-03 1.14 2.49E-04 heterogeneous nuclear ribonucleoprotein K [Source:MGI Symbol;Acc:MGI:99894]
166 Spock2 -1.11 9.50E-03 -1.14 2.53E-04 sparc/osteonectin, cwcv and kazal-like domains proteoglycan 2 [Source:MGI Symbol;Acc:MGI:1891351]
167 Kcnc3 -1.31 5.35E-06 -1.24 2.67E-04
potassium voltage gated channel, Shaw-related 
subfamily, member 3 [Source:MGI 
Symbol;Acc:MGI:96669]
168 Map3k9 -1.19 3.74E-03 -1.22 2.67E-04 mitogen-activated protein kinase kinase kinase 9 [Source:MGI Symbol;Acc:MGI:2449952]
169 Gtf2i -1.12 2.08E-03 -1.13 2.67E-04 general transcription factor II I [Source:MGI Symbol;Acc:MGI:1202722]
170 Slc24a4 -1.24 1.63E-02 -1.33 2.67E-04
solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 4 [Source:MGI 
Symbol;Acc:MGI:2447362]
171 Peg10 -1.21 1.02E-02 -1.27 2.73E-04 paternally expressed 10 [Source:MGI Symbol;Acc:MGI:2157785]
172 Kansl1 -1.14 1.45E-02 -1.19 2.97E-04 KAT8 regulatory NSL complex subunit 1 [Source:MGI Symbol;Acc:MGI:1923969]
173 Ncs1 -1.09 2.06E-02 -1.12 3.07E-04 neuronal calcium sensor 1 [Source:MGI Symbol;Acc:MGI:109166]
174 Gpld1 -1.13 1.44E-02 -1.17 3.26E-04 glycosylphosphatidylinositol specific phospholipase D1 [Source:MGI Symbol;Acc:MGI:106604]
175 Plekha1 1.16 1.16E-03 1.17 3.29E-04
pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 1 
[Source:MGI Symbol;Acc:MGI:2442213]
176 Tbc1d9b -1.12 4.89E-03 -1.14 3.38E-04 TBC1 domain family, member 9B [Source:MGI Symbol;Acc:MGI:1924045]
177 Serinc5 1.25 4.94E-06 1.20 3.38E-04 serine incorporator 5 [Source:MGI Symbol;Acc:MGI:2444223]
178 Fam57b -1.21 5.32E-06 -1.17 3.40E-04 family with sequence similarity 57, member B [Source:MGI Symbol;Acc:MGI:1916202]
179 Rimkla -1.17 1.65E-02 -1.22 3.62E-04 ribosomal modification protein rimK-like family member A [Source:MGI Symbol;Acc:MGI:3040686]
180 Rps27a 1.16 2.45E-02 1.22 3.63E-04 ribosomal protein S27A [Source:MGI Symbol;Acc:MGI:1925544]
181 Cobl -1.16 1.36E-02 -1.21 3.68E-04 cordon-bleu WH2 repeat [Source:MGI Symbol;Acc:MGI:105056]
182 Rpl23 1.19 1.10E-03 1.20 3.68E-04 ribosomal protein L23 [Source:MGI Symbol;Acc:MGI:1929455]
183 Ppp3r1 1.16 3.62E-04 1.16 3.73E-04
protein phosphatase 3, regulatory subunit B, alpha 
isoform (calcineurin B, type I) [Source:MGI 
Symbol;Acc:MGI:107172]
184 Cyb5r3 1.12 3.54E-02 1.18 3.88E-04 cytochrome b5 reductase 3 [Source:MGI Symbol;Acc:MGI:94893]
185 Zmynd8 -1.14 9.24E-03 -1.17 3.98E-04 zinc finger, MYND-type containing 8 [Source:MGI Symbol;Acc:MGI:1918025]
186 Clstn3 -1.11 5.00E-03 -1.13 3.99E-04 calsyntenin 3 [Source:MGI Symbol;Acc:MGI:2178323]
187 Trim37 -1.10 7.02E-03 -1.12 4.15E-04 tripartite motif-containing 37 [Source:MGI Symbol;Acc:MGI:2153072]
188 Rpl7 1.16 1.03E-03 1.17 4.15E-04 ribosomal protein L7 [Source:MGI Symbol;Acc:MGI:98073]
189 Bzw1 1.13 2.49E-03 1.15 4.55E-04 basic leucine zipper and W2 domains 1 [Source:MGI Symbol;Acc:MGI:1914132]
190 Usp31 -1.15 3.16E-02 -1.22 4.77E-04 ubiquitin specific peptidase 31 [Source:MGI Symbol;Acc:MGI:1923429]
191 Nwd1 -1.17 2.70E-02 -1.23 4.98E-04 NACHT and WD repeat domain containing 1 [Source:MGI Symbol;Acc:MGI:2442268]
192 Wnk2 -1.13 2.44E-02 -1.17 5.08E-04 WNK lysine deficient protein kinase 2 [Source:MGI Symbol;Acc:MGI:1922857]
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193 Bcap29 1.21 1.59E-03 1.22 5.11E-04 B cell receptor associated protein 29 [Source:MGI Symbol;Acc:MGI:101917]
194 Rrm2b 1.15 1.99E-02 1.20 5.28E-04 ribonucleotide reductase M2 B (TP53 inducible) [Source:MGI Symbol;Acc:MGI:2155865]
195 6430548M08Rik -1.14 1.28E-03 -1.14 5.59E-04 RIKEN cDNA 6430548M08 gene [Source:MGI Symbol;Acc:MGI:2443793]
196 Anks1b 1.13 1.94E-02 1.18 5.74E-04 ankyrin repeat and sterile alpha motif domain containing 1B [Source:MGI Symbol;Acc:MGI:1924781]
197 Tunar -1.16 4.32E-03 -1.19 5.75E-04 Tcl1 upstream neural differentiation associated RNA [Source:MGI Symbol;Acc:MGI:1917202]
198 Pnpla6 -1.11 4.17E-02 -1.16 5.75E-04 patatin-like phospholipase domain containing 6 [Source:MGI Symbol;Acc:MGI:1354723]
199 Nap1l1 1.10 2.62E-02 1.14 5.83E-04 nucleosome assembly protein 1-like 1 [Source:MGI Symbol;Acc:MGI:1855693]
200 Hsf1 -1.15 4.54E-02 -1.22 6.18E-04 heat shock factor 1 [Source:MGI Symbol;Acc:MGI:96238]
201 Fam193b -1.20 3.26E-03 -1.22 6.22E-04 family with sequence similarity 193, member B [Source:MGI Symbol;Acc:MGI:2385851]
202 Paqr8 -1.18 6.00E-04 -1.17 6.26E-04 progestin and adipoQ receptor family member VIII [Source:MGI Symbol;Acc:MGI:1921479]
203 Arc -1.22 1.11E-02 -1.27 6.55E-04 activity regulated cytoskeletal-associated protein [Source:MGI Symbol;Acc:MGI:88067]
204 Kcnc1 -1.11 1.52E-02 -1.14 6.63E-04
potassium voltage gated channel, Shaw-related 
subfamily, member 1 [Source:MGI 
Symbol;Acc:MGI:96667]
205 Lrrc45 -1.25 4.84E-04 -1.23 6.73E-04 leucine rich repeat containing 45 [Source:MGI Symbol;Acc:MGI:2387183]
206 Shank1 -1.13 2.42E-02 -1.18 7.17E-04 SH3 and multiple ankyrin repeat domains 1 [Source:MGI Symbol;Acc:MGI:3613677]
207 Plekho1 -1.34 3.65E-06 -1.25 7.18E-04 pleckstrin homology domain containing, family O member 1 [Source:MGI Symbol;Acc:MGI:1914470]
208 Noc3l -1.23 1.30E-02 -1.29 7.39E-04 NOC3 like DNA replication regulator [Source:MGI Symbol;Acc:MGI:1932610]
209 Actr1b -1.12 3.95E-03 -1.13 7.48E-04 ARP1 actin-related protein 1B, centractin beta [Source:MGI Symbol;Acc:MGI:1917446]
210 Ik 1.13 2.12E-02 1.18 7.48E-04 IK cytokine [Source:MGI Symbol;Acc:MGI:1345142]
211 Rpl22 1.14 9.93E-03 1.17 7.50E-04 ribosomal protein L22 [Source:MGI Symbol;Acc:MGI:99262]
212 Usp14 1.12 3.44E-03 1.13 7.55E-04 ubiquitin specific peptidase 14 [Source:MGI Symbol;Acc:MGI:1928898]
213 Snrpd3 1.19 7.54E-03 1.23 7.59E-04 small nuclear ribonucleoprotein D3 [Source:MGI Symbol;Acc:MGI:1914582]
214 Rpl24 1.19 1.63E-03 1.19 7.66E-04 ribosomal protein L24 [Source:MGI Symbol;Acc:MGI:1915443]
215 Uqcrb 1.15 3.17E-02 1.21 7.79E-04 ubiquinol-cytochrome c reductase binding protein [Source:MGI Symbol;Acc:MGI:1914780]
216 Man2a2 -1.12 1.86E-02 -1.15 7.79E-04 mannosidase 2, alpha 2 [Source:MGI Symbol;Acc:MGI:2150656]
217 Utp3 1.16 4.02E-02 1.23 7.84E-04 UTP3 small subunit processome component [Source:MGI Symbol;Acc:MGI:1919230]
218 Clec16a -1.11 2.44E-02 -1.15 8.45E-04 C-type lectin domain family 16, member A [Source:MGI Symbol;Acc:MGI:1921624]
219 Armcx5 1.28 1.96E-03 1.29 8.45E-04 armadillo repeat containing, X-linked 5 [Source:MGI Symbol;Acc:MGI:2148026]
220 Pou3f3 -1.13 4.90E-02 -1.19 8.47E-04 POU domain, class 3, transcription factor 3 [Source:MGI Symbol;Acc:MGI:102564]
221 Rprm 1.29 1.81E-03 1.30 8.47E-04 reprimo, TP53 dependent G2 arrest mediator candidate [Source:MGI Symbol;Acc:MGI:1915124]
222 Ufd1l 1.13 2.46E-02 1.17 8.62E-04 NA
223 Kif5b 1.14 1.99E-02 1.18 8.69E-04 kinesin family member 5B [Source:MGI Symbol;Acc:MGI:1098268]
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224 S100a16 1.25 1.64E-04 1.22 8.70E-04 S100 calcium binding protein A16 [Source:MGI Symbol;Acc:MGI:1915110]
225 Ndst4 -1.25 9.70E-03 -1.29 8.86E-04
N-deacetylase/N-sulfotransferase (heparin 
glucosaminyl) 4 [Source:MGI 
Symbol;Acc:MGI:1932545]
226 Tubgcp4 -1.24 2.55E-04 -1.21 8.89E-04 tubulin, gamma complex associated protein 4 [Source:MGI Symbol;Acc:MGI:1196293]
227 Tsn 1.15 1.86E-03 1.15 8.98E-04 translin [Source:MGI Symbol;Acc:MGI:109263]
228 Hebp1 1.27 4.80E-03 1.30 9.01E-04 heme binding protein 1 [Source:MGI Symbol;Acc:MGI:1333880]
229 Pxk -1.16 2.60E-03 -1.17 9.03E-04 PX domain containing serine/threonine kinase [Source:MGI Symbol;Acc:MGI:1289230]
230 Rpl15 1.14 1.38E-02 1.17 9.03E-04 ribosomal protein L15 [Source:MGI Symbol;Acc:MGI:1913730]
231 Mfn1 -1.18 5.21E-04 -1.16 9.03E-04 mitofusin 1 [Source:MGI Symbol;Acc:MGI:1914664]
232 Lgi2 -1.19 2.09E-02 -1.25 9.03E-04 leucine-rich repeat LGI family, member 2 [Source:MGI Symbol;Acc:MGI:2180196]
233 Ralgapb -1.14 2.59E-02 -1.18 9.22E-04 Ral GTPase activating protein, beta subunit (non-catalytic) [Source:MGI Symbol;Acc:MGI:2444531]
234 Grb14 1.18 2.11E-02 1.23 1.02E-03 growth factor receptor bound protein 14 [Source:MGI Symbol;Acc:MGI:1355324]
235 Ptch1 -1.20 1.36E-02 -1.25 1.05E-03 patched 1 [Source:MGI Symbol;Acc:MGI:105373]
236 Zgpat -1.19 1.40E-02 -1.24 1.06E-03 zinc finger, CCCH-type with G patch domain [Source:MGI Symbol;Acc:MGI:2449939]
237 Eif3e 1.18 2.49E-03 1.19 1.08E-03 eukaryotic translation initiation factor 3, subunit E [Source:MGI Symbol;Acc:MGI:99257]
238 Hspb1 -1.38 6.44E-05 -1.31 1.09E-03 heat shock protein 1 [Source:MGI Symbol;Acc:MGI:96240]
239 Atp2a2 -1.14 3.38E-03 -1.14 1.10E-03 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 [Source:MGI Symbol;Acc:MGI:88110]
240 Lingo2 1.25 2.42E-03 1.25 1.12E-03 leucine rich repeat and Ig domain containing 2 [Source:MGI Symbol;Acc:MGI:2442298]
241 Nucks1 1.11 4.50E-02 1.16 1.13E-03 nuclear casein kinase and cyclin-dependent kinase substrate 1 [Source:MGI Symbol;Acc:MGI:1934811]
242 Enpp2 1.17 3.92E-04 1.15 1.13E-03 ectonucleotide pyrophosphatase/phosphodiesterase 2 [Source:MGI Symbol;Acc:MGI:1321390]
243 Dbi 1.12 4.83E-02 1.17 1.14E-03 diazepam binding inhibitor [Source:MGI Symbol;Acc:MGI:94865]
244 Fan1 1.29 1.12E-03 1.28 1.14E-03 FANCD2/FANCI-associated nuclease 1 [Source:MGI Symbol;Acc:MGI:3045266]
245 Rac1 1.12 1.96E-03 1.12 1.15E-03 Rac family small GTPase 1 [Source:MGI Symbol;Acc:MGI:97845]
246 Crmp1 1.12 1.36E-02 1.14 1.16E-03 collapsin response mediator protein 1 [Source:MGI Symbol;Acc:MGI:107793]
247 Ypel3 -1.16 2.60E-03 -1.16 1.17E-03 yippee like 3 [Source:MGI Symbol;Acc:MGI:1913340]
248 Rimklb 1.15 3.66E-02 1.20 1.20E-03 ribosomal modification protein rimK-like family member B [Source:MGI Symbol;Acc:MGI:1918325]
249 Rps7 1.17 8.07E-03 1.20 1.21E-03 ribosomal protein S7 [Source:MGI Symbol;Acc:MGI:1333818]
250 Eny2 1.15 1.95E-02 1.19 1.21E-03 ENY2 transcription and export complex 2 subunit [Source:MGI Symbol;Acc:MGI:1919286]
251 Rps3a1 1.20 6.18E-04 1.19 1.21E-03 ribosomal protein S3A1 [Source:MGI Symbol;Acc:MGI:1202063]
252 Limk2 -1.15 1.06E-03 -1.14 1.21E-03 LIM motif-containing protein kinase 2 [Source:MGI Symbol;Acc:MGI:1197517]
253 Mef2d -1.14 4.10E-02 -1.20 1.23E-03 myocyte enhancer factor 2D [Source:MGI Symbol;Acc:MGI:99533]
254 Cttnbp2 -1.21 1.95E-03 -1.21 1.23E-03 cortactin binding protein 2 [Source:MGI Symbol;Acc:MGI:1353467]
255 Rbl2 -1.12 2.59E-02 -1.16 1.23E-03 RB transcriptional corepressor like 2 [Source:MGI Symbol;Acc:MGI:105085]
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256 Exosc9 1.19 1.92E-02 1.24 1.24E-03 exosome component 9 [Source:MGI Symbol;Acc:MGI:1355319]
257 Dmp1 -1.49 4.74E-09 -1.27 1.26E-03 dentin matrix protein 1 [Source:MGI Symbol;Acc:MGI:94910]
258 Cacna1g -1.21 3.57E-03 -1.22 1.27E-03 calcium channel, voltage-dependent, T type, alpha 1G subunit [Source:MGI Symbol;Acc:MGI:1201678]
259 Atp2b2 -1.13 1.02E-02 -1.15 1.30E-03 ATPase, Ca++ transporting, plasma membrane 2 [Source:MGI Symbol;Acc:MGI:105368]
260 Scara3 1.27 1.77E-03 1.27 1.35E-03 scavenger receptor class A, member 3 [Source:MGI Symbol;Acc:MGI:2444418]
261 Slc4a3 -1.12 7.17E-03 -1.13 1.37E-03 solute carrier family 4 (anion exchanger), member 3 [Source:MGI Symbol;Acc:MGI:109350]
262 Zbtb7a -1.14 1.23E-02 -1.17 1.41E-03 zinc finger and BTB domain containing 7a [Source:MGI Symbol;Acc:MGI:1335091]
263 Rasal1 1.28 4.60E-03 1.30 1.42E-03 RAS protein activator like 1 (GAP1 like) [Source:MGI Symbol;Acc:MGI:1330842]
264 Csdc2 -1.09 3.31E-02 -1.12 1.43E-03 cold shock domain containing C2, RNA binding [Source:MGI Symbol;Acc:MGI:2146027]
265 Ift172 -1.14 2.52E-02 -1.18 1.44E-03 intraflagellar transport 172 [Source:MGI Symbol;Acc:MGI:2682064]
266 Cnrip1 1.19 3.18E-03 1.19 1.45E-03 cannabinoid receptor interacting protein 1 [Source:MGI Symbol;Acc:MGI:1917505]
267 Susd2 -1.17 3.41E-02 -1.22 1.49E-03 sushi domain containing 2 [Source:MGI Symbol;Acc:MGI:1918983]
268 Slc38a1 -1.11 9.24E-03 -1.12 1.52E-03 solute carrier family 38, member 1 [Source:MGI Symbol;Acc:MGI:2145895]
269 Ephx1 1.15 4.30E-02 1.21 1.59E-03 epoxide hydrolase 1, microsomal [Source:MGI Symbol;Acc:MGI:95405]
270 Gigyf2 -1.16 8.16E-03 -1.18 1.62E-03 GRB10 interacting GYF protein 2 [Source:MGI Symbol;Acc:MGI:2138584]
271 Xrcc3 1.20 3.09E-02 1.26 1.69E-03 X-ray repair complementing defective repair in Chinese hamster cells 3 [Source:MGI Symbol;Acc:MGI:1921585]
272 Ociad1 1.11 6.92E-03 1.12 1.69E-03 OCIA domain containing 1 [Source:MGI Symbol;Acc:MGI:1915345]
273 Zdhhc5 -1.14 1.66E-02 -1.17 1.70E-03 zinc finger, DHHC domain containing 5 [Source:MGI Symbol;Acc:MGI:1923573]
274 Gls -1.14 4.07E-03 -1.14 1.70E-03 glutaminase [Source:MGI Symbol;Acc:MGI:95752]
275 Set 1.12 2.59E-02 1.16 1.71E-03 SET nuclear oncogene [Source:MGI Symbol;Acc:MGI:1860267]
276 Vstm2b -1.18 3.72E-02 -1.24 1.71E-03 V-set and transmembrane domain containing 2B [Source:MGI Symbol;Acc:MGI:1914525]
277 Fam163b -1.17 4.49E-02 -1.24 1.72E-03 family with sequence similarity 163, member B [Source:MGI Symbol;Acc:MGI:1926106]
278 Mcts1 1.17 1.63E-02 1.20 1.73E-03 malignant T cell amplified sequence 1 [Source:MGI Symbol;Acc:MGI:1916245]
279 Bzrap1 -1.17 2.76E-03 -1.17 1.79E-03 NA
280 Rims4 -1.23 1.18E-02 -1.26 1.80E-03 regulating synaptic membrane exocytosis 4 [Source:MGI Symbol;Acc:MGI:2674366]
281 Actg1 1.13 8.22E-04 1.12 1.83E-03 actin, gamma, cytoplasmic 1 [Source:MGI Symbol;Acc:MGI:87906]
282 Rian -1.16 1.82E-05 -1.12 1.85E-03 RNA imprinted and accumulated in nucleus [Source:MGI Symbol;Acc:MGI:1922995]
283 Sfr1 1.18 2.60E-03 1.18 1.86E-03 SWI5 dependent recombination repair 1 [Source:MGI Symbol;Acc:MGI:1915038]
284 Cyp2j6 1.22 9.78E-04 1.20 1.86E-03 cytochrome P450, family 2, subfamily j, polypeptide 6 [Source:MGI Symbol;Acc:MGI:1270148]
285 Fam49b 1.11 4.47E-02 1.14 1.89E-03 family with sequence similarity 49, member B [Source:MGI Symbol;Acc:MGI:1923520]
286 Snx4 1.16 3.38E-02 1.21 1.96E-03 sorting nexin 4 [Source:MGI Symbol;Acc:MGI:1916400]
287 Kcnt1 -1.26 1.58E-04 -1.21 1.96E-03 potassium channel, subfamily T, member 1 [Source:MGI Symbol;Acc:MGI:1924627]
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288 Plcd4 -1.17 2.08E-02 -1.20 1.98E-03 phospholipase C, delta 4 [Source:MGI Symbol;Acc:MGI:107469]
289 Dnaja2 1.11 1.49E-02 1.12 1.98E-03 DnaJ heat shock protein family (Hsp40) member A2 [Source:MGI Symbol;Acc:MGI:1931882]
290 Syt7 -1.14 3.90E-03 -1.14 2.00E-03 synaptotagmin VII [Source:MGI Symbol;Acc:MGI:1859545]
291 Ptchd2 -1.17 5.00E-02 -1.23 2.00E-03 NA
292 Foxj1 -1.17 3.68E-02 -1.23 2.07E-03 forkhead box J1 [Source:MGI Symbol;Acc:MGI:1347474]
293 Efhd1 1.19 2.00E-03 1.18 2.15E-03 EF hand domain containing 1 [Source:MGI Symbol;Acc:MGI:1921607]
294 Klhl17 -1.22 4.00E-04 -1.19 2.18E-03 NA
295 Ap1b1 -1.08 3.71E-02 -1.11 2.21E-03 adaptor protein complex AP-1, beta 1 subunit [Source:MGI Symbol;Acc:MGI:1096368]
296 Tmem25 -1.21 1.63E-04 -1.17 2.25E-03 transmembrane protein 25 [Source:MGI Symbol;Acc:MGI:1918937]
297 Rab14 1.13 3.37E-04 1.11 2.26E-03 RAB14, member RAS oncogene family [Source:MGI Symbol;Acc:MGI:1915615]
298 Nap1l5 1.11 1.40E-02 1.12 2.29E-03 nucleosome assembly protein 1-like 5 [Source:MGI Symbol;Acc:MGI:1923555]
299 St8sia1 -1.11 2.62E-02 -1.14 2.30E-03
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 1 [Source:MGI 
Symbol;Acc:MGI:106011]
300 Lars 1.17 1.95E-02 1.20 2.45E-03 leucyl-tRNA synthetase [Source:MGI Symbol;Acc:MGI:1913808]
301 Rasl10b -1.13 1.28E-02 -1.14 2.53E-03 RAS-like, family 10, member B [Source:MGI Symbol;Acc:MGI:2685575]
302 Rpsa 1.15 1.09E-02 1.17 2.54E-03 ribosomal protein SA [Source:MGI Symbol;Acc:MGI:105381]
303 Kcnn2 -1.16 2.81E-02 -1.19 2.59E-03
potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 2 [Source:MGI 
Symbol;Acc:MGI:2153182]
304 Ddrgk1 1.15 1.89E-02 1.18 2.62E-03 DDRGK domain containing 1 [Source:MGI Symbol;Acc:MGI:1924256]
305 Snrk -1.19 1.78E-04 -1.15 2.66E-03 SNF related kinase [Source:MGI Symbol;Acc:MGI:108104]
306 Pcsk1 -1.28 6.44E-05 -1.21 2.70E-03 proprotein convertase subtilisin/kexin type 1 [Source:MGI Symbol;Acc:MGI:97511]
307 Psip1 1.10 3.12E-02 1.12 2.70E-03 PC4 and SFRS1 interacting protein 1 [Source:MGI Symbol;Acc:MGI:2142116]
308 Nabp2 1.18 2.76E-03 1.18 2.70E-03 nucleic acid binding protein 2 [Source:MGI Symbol;Acc:MGI:1917167]
309 Cerk -1.24 2.47E-05 -1.17 2.71E-03 ceramide kinase [Source:MGI Symbol;Acc:MGI:2386052]
310 Gtpbp4 1.16 1.35E-02 1.18 2.73E-03 GTP binding protein 4 [Source:MGI Symbol;Acc:MGI:1916487]
311 Zfp385a -1.14 3.85E-03 -1.14 2.74E-03 zinc finger protein 385A [Source:MGI Symbol;Acc:MGI:1352495]
312 Pqbp1 1.15 8.20E-03 1.16 2.76E-03 polyglutamine binding protein 1 [Source:MGI Symbol;Acc:MGI:1859638]
313 Nckipsd -1.17 3.25E-04 -1.14 2.90E-03 NCK interacting protein with SH3 domain [Source:MGI Symbol;Acc:MGI:1931834]
314 Tnni1 1.30 1.96E-03 1.28 2.91E-03 troponin I, skeletal, slow 1 [Source:MGI Symbol;Acc:MGI:105073]
315 Zswim4 -1.19 1.78E-02 -1.22 2.96E-03 zinc finger SWIM-type containing 4 [Source:MGI Symbol;Acc:MGI:2443726]
316 Aebp1 1.22 5.16E-03 1.22 3.03E-03 AE binding protein 1 [Source:MGI Symbol;Acc:MGI:1197012]
317 Coro6 -1.29 3.87E-04 -1.24 3.05E-03 coronin 6 [Source:MGI Symbol;Acc:MGI:2183448]
318 Gpr137c -1.25 2.03E-03 -1.23 3.09E-03 G protein-coupled receptor 137C [Source:MGI Symbol;Acc:MGI:1917963]
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319 Fyttd1 1.11 3.96E-02 1.14 3.12E-03 forty-two-three domain containing 1 [Source:MGI Symbol;Acc:MGI:1917955]
320 Rhobtb2 -1.17 5.52E-04 -1.14 3.14E-03 Rho-related BTB domain containing 2 [Source:MGI Symbol;Acc:MGI:2180557]
321 Pitpnm1 -1.12 4.60E-03 -1.12 3.16E-03 phosphatidylinositol transfer protein, membrane-associated 1 [Source:MGI Symbol;Acc:MGI:1197524]
322 Kpna6 -1.12 4.97E-03 -1.12 3.17E-03 karyopherin (importin) alpha 6 [Source:MGI Symbol;Acc:MGI:1100836]
323 Mtdh -1.19 2.16E-04 -1.16 3.23E-03 metadherin [Source:MGI Symbol;Acc:MGI:1914404]
324 Plekhm2 -1.13 2.87E-03 -1.12 3.25E-03
pleckstrin homology domain containing, family M (with 
RUN domain) member 2 [Source:MGI 
Symbol;Acc:MGI:1916832]
325 Cetn3 1.17 3.33E-02 1.22 3.28E-03 centrin 3 [Source:MGI Symbol;Acc:MGI:1097706]
326 Fam213a 1.13 1.22E-02 1.14 3.28E-03 family with sequence similarity 213, member A [Source:MGI Symbol;Acc:MGI:1917814]
327 Zbtb40 -1.24 1.62E-02 -1.27 3.29E-03 zinc finger and BTB domain containing 40 [Source:MGI Symbol;Acc:MGI:2682254]
328 Slc35b2 1.19 1.11E-02 1.20 3.29E-03 solute carrier family 35, member B2 [Source:MGI Symbol;Acc:MGI:1921086]
329 Hexim1 -1.13 3.03E-02 -1.15 3.32E-03 hexamethylene bis-acetamide inducible 1 [Source:MGI Symbol;Acc:MGI:2385923]
330 Sf1 -1.15 7.07E-04 -1.13 3.33E-03 splicing factor 1 [Source:MGI Symbol;Acc:MGI:1095403]
331 Vwa5b2 -1.15 2.51E-02 -1.19 3.35E-03 von Willebrand factor A domain containing 5B2 [Source:MGI Symbol;Acc:MGI:2681859]
332 Dnajb1 -1.19 1.67E-02 -1.21 3.40E-03 DnaJ heat shock protein family (Hsp40) member B1 [Source:MGI Symbol;Acc:MGI:1931874]
333 Rpl32 1.13 3.80E-02 1.17 3.43E-03 ribosomal protein L32 [Source:MGI Symbol;Acc:MGI:98038]
334 Ogdh -1.09 6.72E-03 -1.10 3.46E-03 oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) [Source:MGI Symbol;Acc:MGI:1098267]
335 Cables2 -1.14 1.55E-02 -1.16 3.56E-03 CDK5 and Abl enzyme substrate 2 [Source:MGI Symbol;Acc:MGI:2182335]
336 Ppm1h -1.15 1.24E-02 -1.16 3.70E-03 protein phosphatase 1H (PP2C domain containing) [Source:MGI Symbol;Acc:MGI:2442087]
337 Zfp598 -1.19 4.23E-03 -1.19 3.73E-03 zinc finger protein 598 [Source:MGI Symbol;Acc:MGI:2670965]
338 Zyx -1.16 6.22E-03 -1.16 3.79E-03 zyxin [Source:MGI Symbol;Acc:MGI:103072]
339 Pdk2 -1.12 1.52E-02 -1.13 3.89E-03 pyruvate dehydrogenase kinase, isoenzyme 2 [Source:MGI Symbol;Acc:MGI:1343087]
340 Uba2 1.13 9.76E-03 1.13 3.91E-03 ubiquitin-like modifier activating enzyme 2 [Source:MGI Symbol;Acc:MGI:1858313]
341 Mfhas1 -1.15 1.38E-02 -1.17 3.91E-03 malignant fibrous histiocytoma amplified sequence 1 [Source:MGI Symbol;Acc:MGI:1098644]
342 Sema3f -1.21 1.46E-02 -1.23 3.97E-03
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3F [Source:MGI 
Symbol;Acc:MGI:1096347]
343 Impdh1 -1.15 1.72E-02 -1.17 4.04E-03 inosine monophosphate dehydrogenase 1 [Source:MGI Symbol;Acc:MGI:96567]
344 Prdm2 -1.15 1.91E-02 -1.17 4.04E-03 PR domain containing 2, with ZNF domain [Source:MGI Symbol;Acc:MGI:107628]
345 Ssh3 -1.29 2.16E-04 -1.23 4.05E-03 slingshot protein phosphatase 3 [Source:MGI Symbol;Acc:MGI:2683546]
346 Cdc42ep1 -1.20 2.22E-03 -1.18 4.06E-03 CDC42 effector protein (Rho GTPase binding) 1 [Source:MGI Symbol;Acc:MGI:1929763]
347 Map3k10 -1.11 3.34E-02 -1.14 4.07E-03 mitogen-activated protein kinase kinase kinase 10 [Source:MGI Symbol;Acc:MGI:1346879]
348 Cmpk1 1.12 2.14E-02 1.14 4.07E-03 cytidine monophosphate (UMP-CMP) kinase 1 [Source:MGI Symbol;Acc:MGI:1913838]
349 Clec2l -1.23 1.78E-04 -1.18 4.11E-03 C-type lectin domain family 2, member L [Source:MGI Symbol;Acc:MGI:2141402]
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350 Rraga 1.16 3.48E-04 1.13 4.12E-03 Ras-related GTP binding A [Source:MGI Symbol;Acc:MGI:1915691]
351 Ubfd1 -1.13 6.73E-03 -1.13 4.17E-03 ubiquitin family domain containing 1 [Source:MGI Symbol;Acc:MGI:107301]
352 Gba2 -1.13 1.24E-02 -1.14 4.18E-03 glucosidase beta 2 [Source:MGI Symbol;Acc:MGI:2654325]
353 Rabep1 -1.09 4.92E-02 -1.12 4.18E-03 rabaptin, RAB GTPase binding effector protein 1 [Source:MGI Symbol;Acc:MGI:1860236]
354 Maz -1.14 1.77E-03 -1.13 4.25E-03
MYC-associated zinc finger protein (purine-binding 
transcription factor) [Source:MGI 
Symbol;Acc:MGI:1338823]
355 Scg2 -1.12 2.07E-02 -1.14 4.26E-03 secretogranin II [Source:MGI Symbol;Acc:MGI:103033]
356 Erlec1 1.13 3.84E-02 1.16 4.34E-03 endoplasmic reticulum lectin 1 [Source:MGI Symbol;Acc:MGI:1914003]
357 Snapc1 1.15 3.92E-02 1.19 4.53E-03 small nuclear RNA activating complex, polypeptide 1 [Source:MGI Symbol;Acc:MGI:1922877]
358 Usp53 -1.25 1.10E-03 -1.21 4.78E-03 ubiquitin specific peptidase 53 [Source:MGI Symbol;Acc:MGI:2139607]
359 Hnrnpa3 1.13 3.08E-02 1.15 4.81E-03 heterogeneous nuclear ribonucleoprotein A3 [Source:MGI Symbol;Acc:MGI:1917171]
360 Stac2 -1.17 1.06E-02 -1.17 4.84E-03 SH3 and cysteine rich domain 2 [Source:MGI Symbol;Acc:MGI:2144518]
361 Adam23 -1.18 4.11E-03 -1.16 4.95E-03 a disintegrin and metallopeptidase domain 23 [Source:MGI Symbol;Acc:MGI:1345162]
362 6330403K07Rik 1.21 2.82E-04 1.17 4.95E-03 RIKEN cDNA 6330403K07 gene [Source:MGI Symbol;Acc:MGI:1918001]
363 Rpl5 1.14 2.80E-02 1.17 5.07E-03 ribosomal protein L5 [Source:MGI Symbol;Acc:MGI:102854]
364 Ypel5 1.18 1.07E-03 1.15 5.09E-03 yippee like 5 [Source:MGI Symbol;Acc:MGI:1916937]
365 Tspyl4 1.14 2.81E-05 1.10 5.31E-03 TSPY-like 4 [Source:MGI Symbol;Acc:MGI:106393]
366 Stxbp3a 1.19 1.52E-02 1.20 5.50E-03 NA
367 Creg2 1.20 9.01E-05 1.14 5.61E-03 cellular repressor of E1A-stimulated genes 2 [Source:MGI Symbol;Acc:MGI:1928333]
368 Camta2 -1.12 4.84E-02 -1.14 5.66E-03 calmodulin binding transcription activator 2 [Source:MGI Symbol;Acc:MGI:2135957]
369 Rps8 1.14 3.59E-02 1.17 5.73E-03 ribosomal protein S8 [Source:MGI Symbol;Acc:MGI:98166]
370 Tjap1 -1.23 6.43E-03 -1.22 5.77E-03 tight junction associated protein 1 [Source:MGI Symbol;Acc:MGI:1921344]
371 Polg -1.18 5.50E-03 -1.17 5.86E-03 polymerase (DNA directed), gamma [Source:MGI Symbol;Acc:MGI:1196389]
372 Rps6 1.14 3.71E-02 1.17 5.86E-03 ribosomal protein S6 [Source:MGI Symbol;Acc:MGI:98159]
373 Morf4l2 1.11 2.84E-02 1.12 5.91E-03 mortality factor 4 like 2 [Source:MGI Symbol;Acc:MGI:1927167]
374 Nxph4 -1.26 2.72E-04 -1.19 6.05E-03 neurexophilin 4 [Source:MGI Symbol;Acc:MGI:1336197]
375 Rab6a 1.12 6.54E-03 1.11 6.06E-03 RAB6A, member RAS oncogene family [Source:MGI Symbol;Acc:MGI:894313]
376 Vsnl1 1.08 4.95E-02 1.11 6.12E-03 visinin-like 1 [Source:MGI Symbol;Acc:MGI:1349453]
377 Ppp1r12c -1.11 3.16E-02 -1.13 6.12E-03 protein phosphatase 1, regulatory subunit 12C [Source:MGI Symbol;Acc:MGI:1924258]
378 Apeh -1.15 2.78E-02 -1.16 6.36E-03 acylpeptide hydrolase [Source:MGI Symbol;Acc:MGI:88041]
379 Sppl2b -1.16 3.55E-02 -1.19 6.44E-03 signal peptide peptidase like 2B [Source:MGI Symbol;Acc:MGI:1920468]
380 Rpl36 1.15 3.59E-02 1.18 6.46E-03 ribosomal protein L36 [Source:MGI Symbol;Acc:MGI:1860603]
381 Rpl4 1.13 1.22E-02 1.13 6.58E-03 ribosomal protein L4 [Source:MGI Symbol;Acc:MGI:1915141]
382 Dnajc19 1.22 9.12E-03 1.21 7.14E-03 DnaJ heat shock protein family (Hsp40) member C19 [Source:MGI Symbol;Acc:MGI:1914963]
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383 Srp9 1.15 8.78E-03 1.15 7.32E-03 signal recognition particle 9 [Source:MGI Symbol;Acc:MGI:1350930]
384 Tbc1d9 -1.10 3.30E-02 -1.12 7.33E-03 TBC1 domain family, member 9 [Source:MGI Symbol;Acc:MGI:1918560]
385 Adar 1.19 6.43E-07 1.11 7.55E-03 adenosine deaminase, RNA-specific [Source:MGI Symbol;Acc:MGI:1889575]
386 Btrc 1.16 1.29E-04 1.12 7.58E-03 beta-transducin repeat containing protein [Source:MGI Symbol;Acc:MGI:1338871]
387 Fgf13 1.18 1.29E-03 1.15 7.58E-03 fibroblast growth factor 13 [Source:MGI Symbol;Acc:MGI:109178]
388 Rnf145 -1.12 2.01E-02 -1.13 7.63E-03 ring finger protein 145 [Source:MGI Symbol;Acc:MGI:1921565]
389 Slc39a13 -1.24 4.83E-04 -1.18 7.63E-03 solute carrier family 39 (metal ion transporter), member 13 [Source:MGI Symbol;Acc:MGI:1915677]
390 Rpl19 1.13 4.95E-02 1.15 7.66E-03 ribosomal protein L19 [Source:MGI Symbol;Acc:MGI:98020]
391 Znrf1 -1.11 5.00E-02 -1.14 7.72E-03 zinc and ring finger 1 [Source:MGI Symbol;Acc:MGI:2177308]
392 Gdi2 1.11 2.08E-02 1.12 7.72E-03 guanosine diphosphate (GDP) dissociation inhibitor 2 [Source:MGI Symbol;Acc:MGI:99845]
393 Atg2a -1.12 4.44E-02 -1.15 7.77E-03 autophagy related 2A [Source:MGI Symbol;Acc:MGI:1916291]
394 Rps3 1.13 4.92E-02 1.16 7.86E-03 ribosomal protein S3 [Source:MGI Symbol;Acc:MGI:1350917]
395 Mrpl4 -1.21 8.08E-04 -1.16 8.25E-03 mitochondrial ribosomal protein L4 [Source:MGI Symbol;Acc:MGI:2137210]
396 Tacc1 -1.13 6.02E-03 -1.12 8.34E-03 transforming, acidic coiled-coil containing protein 1 [Source:MGI Symbol;Acc:MGI:2443510]
397 Arpc5 1.12 4.44E-02 1.15 8.41E-03 actin related protein 2/3 complex, subunit 5 [Source:MGI Symbol;Acc:MGI:1915021]
398 Pdpk1 -1.11 4.93E-02 -1.14 8.52E-03 3-phosphoinositide dependent protein kinase 1 [Source:MGI Symbol;Acc:MGI:1338068]
399 Epm2aip1 1.15 1.01E-03 1.12 8.66E-03 EPM2A (laforin) interacting protein 1 [Source:MGI Symbol;Acc:MGI:1925031]
400 Cd200 1.14 3.14E-03 1.13 8.71E-03 CD200 antigen [Source:MGI Symbol;Acc:MGI:1196990]
401 Tmem18 1.13 4.84E-02 1.16 8.75E-03 transmembrane protein 18 [Source:MGI Symbol;Acc:MGI:2387176]
402 Miat -1.17 1.74E-02 -1.17 8.93E-03 myocardial infarction associated transcript (non-protein coding) [Source:MGI Symbol;Acc:MGI:2444886]
403 Wdr6 1.19 1.70E-04 1.13 9.15E-03 WD repeat domain 6 [Source:MGI Symbol;Acc:MGI:1930140]
404 Erlin2 1.14 3.61E-02 1.16 9.28E-03 ER lipid raft associated 2 [Source:MGI Symbol;Acc:MGI:2387215]
405 Lpcat2 1.24 1.21E-02 1.24 9.36E-03 lysophosphatidylcholine acyltransferase 2 [Source:MGI Symbol;Acc:MGI:3606214]
406 Ndufaf7 1.15 4.70E-02 1.18 9.36E-03 NADH:ubiquinone oxidoreductase complex assembly factor 7 [Source:MGI Symbol;Acc:MGI:1920944]
407 Fez1 1.10 4.09E-02 1.12 9.39E-03 fasciculation and elongation protein zeta 1 (zygin I) [Source:MGI Symbol;Acc:MGI:2670976]
408 Eif3m 1.14 3.44E-02 1.16 9.41E-03 eukaryotic translation initiation factor 3, subunit M [Source:MGI Symbol;Acc:MGI:1351744]
409 Psmd14 1.13 3.60E-02 1.15 9.59E-03 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 [Source:MGI Symbol;Acc:MGI:1913284]
410 Maged2 1.18 4.33E-04 1.13 9.79E-03 melanoma antigen, family D, 2 [Source:MGI Symbol;Acc:MGI:1933391]
411 Marcksl1 1.22 1.35E-04 1.15 9.92E-03 MARCKS-like 1 [Source:MGI Symbol;Acc:MGI:97143]
412 Col11a1 -1.21 3.87E-02 -1.24 9.98E-03 collagen, type XI, alpha 1 [Source:MGI Symbol;Acc:MGI:88446]
413 Kank4 -1.18 9.62E-03 -1.17 9.98E-03 KN motif and ankyrin repeat domains 4 [Source:MGI Symbol;Acc:MGI:3043381]
414 Golga7b -1.17 3.12E-02 -1.19 1.01E-02 golgi autoantigen, golgin subfamily a, 7B [Source:MGI Symbol;Acc:MGI:1918396]
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415 Zmat4 1.25 5.32E-06 1.15 1.01E-02 zinc finger, matrin type 4 [Source:MGI Symbol;Acc:MGI:2443497]
416 Cdh8 1.19 2.31E-03 1.15 1.05E-02 cadherin 8 [Source:MGI Symbol;Acc:MGI:107434]
417 Snrpe 1.23 7.55E-03 1.21 1.06E-02 small nuclear ribonucleoprotein E [Source:MGI Symbol;Acc:MGI:98346]
418 2900052N01Rik 1.20 8.39E-03 1.19 1.06E-02 RIKEN cDNA 2900052N01 gene [Source:MGI Symbol;Acc:MGI:1920290]
419 Hrasls 1.21 4.05E-03 1.18 1.07E-02 HRAS-like suppressor [Source:MGI Symbol;Acc:MGI:1351473]
420 Zcchc12 1.18 9.45E-04 1.14 1.07E-02 zinc finger, CCHC domain containing 12 [Source:MGI Symbol;Acc:MGI:1919943]
421 2310057M21Rik 1.26 1.09E-03 1.20 1.08E-02 RIKEN cDNA 2310057M21 gene [Source:MGI Symbol;Acc:MGI:1915527]
422 Slc12a6 -1.11 3.96E-02 -1.13 1.09E-02 solute carrier family 12, member 6 [Source:MGI Symbol;Acc:MGI:2135960]
423 Eif5a 1.11 2.07E-02 1.11 1.12E-02 eukaryotic translation initiation factor 5A [Source:MGI Symbol;Acc:MGI:106248]
424 Parp6 -1.13 1.94E-02 -1.13 1.13E-02 poly (ADP-ribose) polymerase family, member 6 [Source:MGI Symbol;Acc:MGI:1914537]
425 Rgs7 1.14 2.56E-02 1.15 1.14E-02 regulator of G protein signaling 7 [Source:MGI Symbol;Acc:MGI:1346089]
426 Wls 1.14 2.21E-02 1.15 1.15E-02 wntless WNT ligand secretion mediator [Source:MGI Symbol;Acc:MGI:1915401]
427 Hltf -1.16 2.52E-02 -1.17 1.17E-02 helicase-like transcription factor [Source:MGI Symbol;Acc:MGI:1196437]
428 Ssu72 1.16 1.43E-02 1.15 1.22E-02 Ssu72 RNA polymerase II CTD phosphatase homolog (yeast) [Source:MGI Symbol;Acc:MGI:1916241]
429 Gfra1 1.20 2.82E-04 1.14 1.25E-02 glial cell line derived neurotrophic factor family receptor alpha 1 [Source:MGI Symbol;Acc:MGI:1100842]
430 Gltp 1.14 2.70E-02 1.14 1.25E-02 glycolipid transfer protein [Source:MGI Symbol;Acc:MGI:1929253]
431 Cacna2d2 -1.10 4.50E-02 -1.11 1.26E-02 calcium channel, voltage-dependent, alpha 2/delta subunit 2 [Source:MGI Symbol;Acc:MGI:1929813]
432 Ebpl 1.23 1.36E-02 1.22 1.27E-02 emopamil binding protein-like [Source:MGI Symbol;Acc:MGI:1915427]
433 Ypel4 -1.19 7.12E-03 -1.16 1.28E-02 yippee like 4 [Source:MGI Symbol;Acc:MGI:3605071]
434 Eef1b2 1.13 3.98E-02 1.14 1.28E-02 eukaryotic translation elongation factor 1 beta 2 [Source:MGI Symbol;Acc:MGI:1929520]
435 Uhrf2 -1.17 1.91E-02 -1.16 1.28E-02 ubiquitin-like, containing PHD and RING finger domains 2 [Source:MGI Symbol;Acc:MGI:1923718]
436 Cdh22 -1.15 1.70E-02 -1.15 1.28E-02 cadherin 22 [Source:MGI Symbol;Acc:MGI:1341843]
437 Khdrbs2 1.21 4.55E-02 1.24 1.29E-02 KH domain containing, RNA binding, signal transduction associated 2 [Source:MGI Symbol;Acc:MGI:2159649]
438 2310067B10Rik -1.15 1.82E-02 -1.14 1.29E-02 NA
439 Cacul1 1.29 1.77E-08 1.13 1.31E-02 CDK2 associated, cullin domain 1 [Source:MGI Symbol;Acc:MGI:1926082]
440 Kcnj11 -1.15 1.82E-02 -1.14 1.36E-02 potassium inwardly rectifying channel, subfamily J, member 11 [Source:MGI Symbol;Acc:MGI:107501]
441 Prpsap2 1.16 1.90E-02 1.16 1.36E-02 phosphoribosyl pyrophosphate synthetase-associated protein 2 [Source:MGI Symbol;Acc:MGI:2384838]
442 Arhgef19 -1.18 2.40E-02 -1.18 1.36E-02 Rho guanine nucleotide exchange factor (GEF) 19 [Source:MGI Symbol;Acc:MGI:1925912]
443 Mvd 1.25 3.37E-03 1.20 1.36E-02 mevalonate (diphospho) decarboxylase [Source:MGI Symbol;Acc:MGI:2179327]
444 Rabl6 -1.10 3.39E-02 -1.11 1.39E-02 RAB, member RAS oncogene family-like 6 [Source:MGI Symbol;Acc:MGI:2442633]
445 Rps19 1.15 3.88E-02 1.16 1.40E-02 ribosomal protein S19 [Source:MGI Symbol;Acc:MGI:1333780]
446 Cstf2t 1.12 2.07E-02 1.12 1.44E-02 cleavage stimulation factor, 3' pre-RNA subunit 2, tau [Source:MGI Symbol;Acc:MGI:1932622]
447 Psma6 1.14 2.65E-02 1.14 1.56E-02 proteasome (prosome, macropain) subunit, alpha type 6 [Source:MGI Symbol;Acc:MGI:1347006]
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448 Gatm 1.14 4.50E-02 1.15 1.57E-02
glycine amidinotransferase (L-arginine:glycine 
amidinotransferase) [Source:MGI 
Symbol;Acc:MGI:1914342]
449 Rplp1 1.13 3.33E-02 1.14 1.58E-02 ribosomal protein, large, P1 [Source:MGI Symbol;Acc:MGI:1927099]
450 Ispd 1.21 2.44E-02 1.21 1.59E-02 isoprenoid synthase domain containing [Source:MGI Symbol;Acc:MGI:1923097]
451 Epb4.1l2 1.16 1.77E-03 1.12 1.60E-02 NA
452 Glra2 1.21 2.94E-03 1.17 1.60E-02 glycine receptor, alpha 2 subunit [Source:MGI Symbol;Acc:MGI:95748]
453 Rwdd2a 1.20 2.62E-03 1.16 1.60E-02 RWD domain containing 2A [Source:MGI Symbol;Acc:MGI:1916769]
454 Arhgef1 -1.17 1.15E-02 -1.16 1.62E-02 Rho guanine nucleotide exchange factor (GEF) 1 [Source:MGI Symbol;Acc:MGI:1353510]
455 Card10 -1.18 2.62E-02 -1.19 1.63E-02 caspase recruitment domain family, member 10 [Source:MGI Symbol;Acc:MGI:2146012]
456 Ptprs -1.10 4.50E-02 -1.11 1.71E-02 protein tyrosine phosphatase, receptor type, S [Source:MGI Symbol;Acc:MGI:97815]
457 2610044O15Rik8 1.20 4.00E-02 1.21 1.74E-02
RIKEN cDNA 2610044O15 gene [Source:MGI 
Symbol;Acc:MGI:1919389]
458 Mfn2 1.10 1.06E-02 1.09 1.78E-02 mitofusin 2 [Source:MGI Symbol;Acc:MGI:2442230]
459 Cldn11 1.19 2.00E-03 1.14 1.78E-02 claudin 11 [Source:MGI Symbol;Acc:MGI:106925]
460 Pdlim7 -1.18 3.31E-02 -1.19 1.79E-02 PDZ and LIM domain 7 [Source:MGI Symbol;Acc:MGI:1914649]
461 Rbm14 -1.18 2.84E-02 -1.18 1.79E-02 RNA binding motif protein 14 [Source:MGI Symbol;Acc:MGI:1929092]
462 Map3k13 -1.20 2.83E-02 -1.20 1.80E-02 mitogen-activated protein kinase kinase kinase 13 [Source:MGI Symbol;Acc:MGI:2444243]
463 Fmnl1 -1.17 1.36E-02 -1.15 1.81E-02 formin-like 1 [Source:MGI Symbol;Acc:MGI:1888994]
464 Gas5 1.17 1.21E-02 1.16 1.84E-02 growth arrest specific 5 [Source:MGI Symbol;Acc:MGI:95659]
465 Kcnf1 1.24 1.36E-02 1.22 1.84E-02 potassium voltage-gated channel, subfamily F, member 1 [Source:MGI Symbol;Acc:MGI:2687399]
466 Ndst3 -1.42 2.21E-06 -1.21 1.90E-02
N-deacetylase/N-sulfotransferase (heparan 
glucosaminyl) 3 [Source:MGI 
Symbol;Acc:MGI:1932544]
467 Ccdc132 1.16 1.56E-02 1.14 1.92E-02 NA
468 Morf4l1 1.09 4.44E-02 1.10 1.92E-02 mortality factor 4 like 1 [Source:MGI Symbol;Acc:MGI:1096551]
469 Kcnk1 -1.15 2.08E-02 -1.14 1.93E-02 potassium channel, subfamily K, member 1 [Source:MGI Symbol;Acc:MGI:109322]
470 Sel1l3 -1.30 3.69E-04 -1.20 2.00E-02 sel-1 suppressor of lin-12-like 3 (C. elegans) [Source:MGI Symbol;Acc:MGI:1916941]
471 Mapre2 -1.09 3.57E-02 -1.09 2.01E-02 microtubule-associated protein, RP/EB family, member 2 [Source:MGI Symbol;Acc:MGI:106271]
472 Deaf1 1.15 2.75E-02 1.15 2.06E-02 DEAF1, transcription factor [Source:MGI Symbol;Acc:MGI:1858496]
473 Zfp622 1.18 1.16E-02 1.16 2.07E-02 zinc finger protein 622 [Source:MGI Symbol;Acc:MGI:1289282]
474 Palm -1.12 2.96E-02 -1.12 2.08E-02 paralemmin [Source:MGI Symbol;Acc:MGI:1261814]
475 Pip5k1c -1.13 1.36E-02 -1.11 2.10E-02 phosphatidylinositol-4-phosphate 5-kinase, type 1 gamma [Source:MGI Symbol;Acc:MGI:1298224]
476 Rpl7a 1.13 1.95E-02 1.12 2.10E-02 ribosomal protein L7A [Source:MGI Symbol;Acc:MGI:1353472]
477 Dusp11 -1.19 1.64E-02 -1.17 2.11E-02 dual specificity phosphatase 11 (RNA/RNP complex 1-interacting) [Source:MGI Symbol;Acc:MGI:1919352]
478 Mgat5b -1.15 3.35E-02 -1.15 2.17E-02 mannoside acetylglucosaminyltransferase 5, isoenzyme B [Source:MGI Symbol;Acc:MGI:3606200]
479 Mcfd2 1.15 6.48E-03 1.13 2.19E-02 multiple coagulation factor deficiency 2 [Source:MGI Symbol;Acc:MGI:2183439]
480 Cog6 -1.16 8.78E-03 -1.13 2.22E-02 component of oligomeric golgi complex 6 [Source:MGI Symbol;Acc:MGI:1914792]
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481 Ppfia4 -1.15 7.56E-03 -1.13 2.23E-02
protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein (liprin), alpha 4 
[Source:MGI Symbol;Acc:MGI:1915757]
482 Slc25a36 -1.15 3.67E-02 -1.15 2.24E-02 solute carrier family 25, member 36 [Source:MGI Symbol;Acc:MGI:1924909]
483 Zrsr2 1.17 1.60E-02 1.15 2.26E-02 zinc finger (CCCH type), RNA binding motif and serine/arginine rich 2 [Source:MGI Symbol;Acc:MGI:103287]
484 Bche 1.26 9.16E-03 1.22 2.31E-02 butyrylcholinesterase [Source:MGI Symbol;Acc:MGI:894278]
485 Nfic -1.12 4.92E-02 -1.13 2.31E-02 nuclear factor I/C [Source:MGI Symbol;Acc:MGI:109591]
486 Rps9 1.14 1.91E-02 1.13 2.32E-02 ribosomal protein S9 [Source:MGI Symbol;Acc:MGI:1924096]
487 Kcng4 -1.35 1.18E-05 -1.19 2.32E-02 potassium voltage-gated channel, subfamily G, member 4 [Source:MGI Symbol;Acc:MGI:1913983]
488 Rps5 1.13 1.51E-02 1.11 2.32E-02 ribosomal protein S5 [Source:MGI Symbol;Acc:MGI:1097682]
489 Cpne4 1.23 1.74E-03 1.16 2.32E-02 copine IV [Source:MGI Symbol;Acc:MGI:1921270]
490 Nrg2 -1.21 4.33E-02 -1.22 2.32E-02 neuregulin 2 [Source:MGI Symbol;Acc:MGI:1098246]
491 Adamtsl5 -1.23 2.10E-02 -1.21 2.35E-02 ADAMTS-like 5 [Source:MGI Symbol;Acc:MGI:1913798]
492 Eif4h 1.10 1.38E-02 1.09 2.35E-02 eukaryotic translation initiation factor 4H [Source:MGI Symbol;Acc:MGI:1341822]
493 Rgs11 -1.30 1.10E-03 -1.21 2.37E-02 regulator of G-protein signaling 11 [Source:MGI Symbol;Acc:MGI:1354739]
494 Eln 1.24 1.70E-02 1.22 2.38E-02 elastin [Source:MGI Symbol;Acc:MGI:95317]
495 Atxn10 1.09 4.88E-02 1.09 2.39E-02 ataxin 10 [Source:MGI Symbol;Acc:MGI:1859293]
496 Acot9 1.18 3.82E-02 1.18 2.40E-02 acyl-CoA thioesterase 9 [Source:MGI Symbol;Acc:MGI:1928939]
497 Zak -1.21 1.80E-02 -1.19 2.45E-02 NA
498 Ccdc117 -1.20 9.96E-03 -1.17 2.47E-02 coiled-coil domain containing 117 [Source:MGI Symbol;Acc:MGI:2144383]
499 Islr2 1.32 1.05E-03 1.22 2.47E-02 immunoglobulin superfamily containing leucine-rich repeat 2 [Source:MGI Symbol;Acc:MGI:2444277]
500 Cryzl1 1.13 4.83E-02 1.14 2.47E-02 crystallin, zeta (quinone reductase)-like 1 [Source:MGI Symbol;Acc:MGI:1913859]
501 Rcn1 1.18 1.95E-02 1.17 2.49E-02 reticulocalbin 1 [Source:MGI Symbol;Acc:MGI:104559]
502 Cacng7 -1.17 1.68E-03 -1.12 2.49E-02 calcium channel, voltage-dependent, gamma subunit 7 [Source:MGI Symbol;Acc:MGI:1932374]
503 Lrp8 -1.16 4.06E-02 -1.16 2.53E-02
low density lipoprotein receptor-related protein 8, 
apolipoprotein e receptor [Source:MGI 
Symbol;Acc:MGI:1340044]
504 Cops5 1.12 4.00E-02 1.12 2.56E-02 COP9 signalosome subunit 5 [Source:MGI Symbol;Acc:MGI:1349415]
505 Stmn4 1.17 4.29E-03 1.13 2.56E-02 stathmin-like 4 [Source:MGI Symbol;Acc:MGI:1931224]
506 Omg 1.11 2.30E-02 1.11 2.57E-02 oligodendrocyte myelin glycoprotein [Source:MGI Symbol;Acc:MGI:106586]
507 Serpind1 1.21 2.35E-02 1.20 2.57E-02 serine (or cysteine) peptidase inhibitor, clade D, member 1 [Source:MGI Symbol;Acc:MGI:96051]
508 Rundc3b 1.17 8.12E-03 1.14 2.62E-02 RUN domain containing 3B [Source:MGI Symbol;Acc:MGI:2685286]
509 Maged1 1.09 2.37E-02 1.08 2.62E-02 melanoma antigen, family D, 1 [Source:MGI Symbol;Acc:MGI:1930187]
510 Polr3e 1.18 2.48E-02 1.17 2.62E-02 polymerase (RNA) III (DNA directed) polypeptide E [Source:MGI Symbol;Acc:MGI:1349452]
511 Atf4 1.12 3.17E-02 1.11 2.72E-02 activating transcription factor 4 [Source:MGI Symbol;Acc:MGI:88096]
512 Uimc1 -1.20 2.62E-02 -1.19 2.75E-02 ubiquitin interaction motif containing 1 [Source:MGI Symbol;Acc:MGI:103185]
513 Tmem143 -1.19 1.95E-02 -1.17 2.78E-02 transmembrane protein 143 [Source:MGI Symbol;Acc:MGI:1917459]
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514 Atp1b1 -1.09 1.40E-02 -1.07 2.81E-02 ATPase, Na+/K+ transporting, beta 1 polypeptide [Source:MGI Symbol;Acc:MGI:88108]
515 Zfp335 -1.20 8.20E-03 -1.16 2.82E-02 zinc finger protein 335 [Source:MGI Symbol;Acc:MGI:2682313]
516 Ddx42 1.11 4.85E-02 1.12 2.84E-02 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 [Source:MGI Symbol;Acc:MGI:1919297]
517 Rasd2 -1.15 4.36E-02 -1.16 2.85E-02 RASD family, member 2 [Source:MGI Symbol;Acc:MGI:1922391]
518 P4ha2 -1.23 1.67E-02 -1.20 2.89E-02
procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha II polypeptide 
[Source:MGI Symbol;Acc:MGI:894286]
519 Eif3d 1.12 4.98E-02 1.13 2.89E-02 eukaryotic translation initiation factor 3, subunit D [Source:MGI Symbol;Acc:MGI:1933181]
520 Fkbp4 -1.12 1.48E-02 -1.11 2.91E-02 FK506 binding protein 4 [Source:MGI Symbol;Acc:MGI:95543]
521 Fxyd6 1.16 8.62E-03 1.13 2.91E-02 FXYD domain-containing ion transport regulator 6 [Source:MGI Symbol;Acc:MGI:1890226]
522 Rpl27 1.15 1.85E-02 1.13 2.91E-02 ribosomal protein L27 [Source:MGI Symbol;Acc:MGI:98036]
523 Osbpl6 -1.14 3.58E-02 -1.13 2.91E-02 oxysterol binding protein-like 6 [Source:MGI Symbol;Acc:MGI:2139014]
524 Zmat1 1.20 1.99E-02 1.17 2.91E-02 zinc finger, matrin type 1 [Source:MGI Symbol;Acc:MGI:2442284]
525 Lrrk2 -1.18 4.44E-02 -1.18 2.93E-02 leucine-rich repeat kinase 2 [Source:MGI Symbol;Acc:MGI:1913975]
526 Cog4 -1.12 2.85E-02 -1.11 2.93E-02 component of oligomeric golgi complex 4 [Source:MGI Symbol;Acc:MGI:2142808]
527 App 1.08 1.36E-02 1.06 2.93E-02 amyloid beta (A4) precursor protein [Source:MGI Symbol;Acc:MGI:88059]
528 Tpra1 -1.15 4.37E-02 -1.15 2.95E-02 transmembrane protein, adipocyte asscociated 1 [Source:MGI Symbol;Acc:MGI:1345190]
529 Ppp2r2a 1.12 1.72E-02 1.11 3.04E-02 protein phosphatase 2, regulatory subunit B, alpha [Source:MGI Symbol;Acc:MGI:1919228]
530 Tspan6 1.21 6.55E-03 1.17 3.05E-02 tetraspanin 6 [Source:MGI Symbol;Acc:MGI:1926264]
531 Agpat4 1.20 1.64E-03 1.14 3.07E-02
1-acylglycerol-3-phosphate O-acyltransferase 4 
(lysophosphatidic acid acyltransferase, delta) 
[Source:MGI Symbol;Acc:MGI:1915512]
532 Cxxc5 -1.13 1.36E-02 -1.11 3.08E-02 CXXC finger 5 [Source:MGI Symbol;Acc:MGI:1914643]
533 Tmem229b -1.19 8.39E-03 -1.15 3.09E-02 transmembrane protein 229B [Source:MGI Symbol;Acc:MGI:2444389]
534 Hnrnpul2 1.08 3.63E-02 1.08 3.09E-02 heterogeneous nuclear ribonucleoprotein U-like 2 [Source:MGI Symbol;Acc:MGI:1915943]
535 Hps4 -1.19 4.31E-02 -1.19 3.14E-02 HPS4, biogenesis of lysosomal organelles complex 3 subunit 2 [Source:MGI Symbol;Acc:MGI:2177742]
536 Dhcr7 1.16 2.04E-02 1.14 3.17E-02 7-dehydrocholesterol reductase [Source:MGI Symbol;Acc:MGI:1298378]
537 Bub3 1.12 3.97E-02 1.11 3.18E-02 BUB3 mitotic checkpoint protein [Source:MGI Symbol;Acc:MGI:1343463]
538 Lpgat1 -1.11 3.97E-02 -1.10 3.19E-02 lysophosphatidylglycerol acyltransferase 1 [Source:MGI Symbol;Acc:MGI:2446186]
539 Tmem88b 1.15 1.48E-02 1.13 3.19E-02 transmembrane protein 88B [Source:MGI Symbol;Acc:MGI:2444329]
540 Mal 1.22 2.34E-04 1.13 3.22E-02 myelin and lymphocyte protein, T cell differentiation protein [Source:MGI Symbol;Acc:MGI:892970]
541 Dusp1 -1.23 2.53E-02 -1.20 3.24E-02 dual specificity phosphatase 1 [Source:MGI Symbol;Acc:MGI:105120]
542 Tipin 1.24 1.63E-02 1.20 3.26E-02 timeless interacting protein [Source:MGI Symbol;Acc:MGI:1921571]
543 Rps10 1.15 3.56E-02 1.14 3.30E-02 ribosomal protein S10 [Source:MGI Symbol;Acc:MGI:1914347]
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MB Specific 
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544 Cebpzos 1.20 2.81E-02 1.18 3.33E-02
CCAAT/enhancer binding protein (C/EBP), zeta, 
opposite strand [Source:MGI 
Symbol;Acc:MGI:1915804]
545 Gng3 -1.11 4.03E-02 -1.11 3.33E-02 guanine nucleotide binding protein (G protein), gamma 3 [Source:MGI Symbol;Acc:MGI:102704]
546 Terf2ip 1.12 4.43E-02 1.12 3.43E-02 telomeric repeat binding factor 2, interacting protein [Source:MGI Symbol;Acc:MGI:1929871]
547 Lman2 -1.13 9.06E-03 -1.11 3.43E-02 lectin, mannose-binding 2 [Source:MGI Symbol;Acc:MGI:1914140]
548 1110008P14Rik -1.19 4.19E-03 -1.14 3.43E-02 RIKEN cDNA 1110008P14 gene [Source:MGI Symbol;Acc:MGI:1920987]
549 1700001L19Rik 1.21 4.67E-02 1.20 3.45E-02 RIKEN cDNA 1700001L19 gene [Source:MGI Symbol;Acc:MGI:1916565]
550 Pcdhgc3 -1.18 8.69E-03 -1.14 3.48E-02 protocadherin gamma subfamily C, 3 [Source:MGI Symbol;Acc:MGI:1935201]
551 Ano10 1.20 3.86E-03 1.14 3.50E-02 anoctamin 10 [Source:MGI Symbol;Acc:MGI:2143103]
552 Wfs1 -1.15 3.55E-02 -1.14 3.51E-02 wolframin ER transmembrane glycoprotein [Source:MGI Symbol;Acc:MGI:1328355]
553 Suco 1.17 1.40E-02 1.14 3.53E-02 SUN domain containing ossification factor [Source:MGI Symbol;Acc:MGI:2138346]
554 B3gnt1 1.12 4.41E-02 1.11 3.57E-02 NA
555 Pop5 -1.16 1.43E-02 -1.14 3.57E-02 processing of precursor 5, ribonuclease P/MRP family (S. cerevisiae) [Source:MGI Symbol;Acc:MGI:2151221]
556 2310022B05Rik 1.20 1.33E-03 1.13 3.57E-02 RIKEN cDNA 2310022B05 gene [Source:MGI Symbol;Acc:MGI:1916801]
557 Atxn2l -1.13 4.95E-02 -1.13 3.59E-02 ataxin 2-like [Source:MGI Symbol;Acc:MGI:2446242]
558 Tpd52l1 1.23 7.25E-03 1.17 3.66E-02 tumor protein D52-like 1 [Source:MGI Symbol;Acc:MGI:1298386]
559 Bin1 1.11 3.16E-02 1.10 3.70E-02 bridging integrator 1 [Source:MGI Symbol;Acc:MGI:108092]
560 Apoe 1.12 2.62E-02 1.11 3.72E-02 apolipoprotein E [Source:MGI Symbol;Acc:MGI:88057]
561 Cpxm1 1.23 2.12E-02 1.20 3.75E-02 carboxypeptidase X 1 (M14 family) [Source:MGI Symbol;Acc:MGI:1934569]
562 Tmeff1 1.14 9.67E-03 1.11 3.76E-02
transmembrane protein with EGF-like and two 
follistatin-like domains 1 [Source:MGI 
Symbol;Acc:MGI:1926810]
563 Map3k12 -1.14 4.44E-03 -1.10 3.78E-02 mitogen-activated protein kinase kinase kinase 12 [Source:MGI Symbol;Acc:MGI:1346881]
564 Slc25a42 -1.16 3.73E-02 -1.15 3.81E-02 solute carrier family 25, member 42 [Source:MGI Symbol;Acc:MGI:1920345]
565 Hes5 1.23 2.53E-02 1.20 3.86E-02 hes family bHLH transcription factor 5 [Source:MGI Symbol;Acc:MGI:104876]
566 Hyou1 -1.13 1.36E-02 -1.11 3.95E-02 hypoxia up-regulated 1 [Source:MGI Symbol;Acc:MGI:108030]
567 Coro1c 1.10 4.46E-02 1.09 4.04E-02 coronin, actin binding protein 1C [Source:MGI Symbol;Acc:MGI:1345964]
568 Diras2 -1.26 6.44E-05 -1.14 4.05E-02 DIRAS family, GTP-binding RAS-like 2 [Source:MGI Symbol;Acc:MGI:1915453]
569 Atp11b -1.16 2.77E-02 -1.14 4.09E-02 ATPase, class VI, type 11B [Source:MGI Symbol;Acc:MGI:1923545]
570 Rhot2 -1.11 4.83E-02 -1.11 4.15E-02 ras homolog family member T2 [Source:MGI Symbol;Acc:MGI:2384892]
571 Snhg11 -1.26 6.73E-03 -1.19 4.27E-02 small nucleolar RNA host gene 11 [Source:MGI Symbol;Acc:MGI:2441845]
572 Atg4d -1.15 2.72E-02 -1.13 4.30E-02 autophagy related 4D, cysteine peptidase [Source:MGI Symbol;Acc:MGI:2444308]
573 Cdk5rap3 1.16 4.95E-02 1.15 4.31E-02 CDK5 regulatory subunit associated protein 3 [Source:MGI Symbol;Acc:MGI:1933126]
574 Smim18 1.24 1.69E-02 1.19 4.33E-02 small integral membrane protein 18 [Source:MGI Symbol;Acc:MGI:1919882]
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575 Pithd1 1.14 4.00E-02 1.12 4.38E-02
PITH (C-terminal proteasome-interacting domain of 
thioredoxin-like) domain containing 1 [Source:MGI 
Symbol;Acc:MGI:1913443]
576 Plekha8 -1.22 7.02E-03 -1.16 4.48E-02
pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 8 
[Source:MGI Symbol;Acc:MGI:2681164]
577 Irf2bpl -1.15 2.84E-02 -1.13 4.49E-02 interferon regulatory factor 2 binding protein-like [Source:MGI Symbol;Acc:MGI:2442463]
578 Fam20a -1.24 8.20E-03 -1.18 4.68E-02 family with sequence similarity 20, member A [Source:MGI Symbol;Acc:MGI:2388266]
579 E030003E18Rik -1.16 2.32E-02 -1.14 4.80E-02 NA
580 Taldo1 1.15 1.11E-02 1.11 4.87E-02 transaldolase 1 [Source:MGI Symbol;Acc:MGI:1274789]
581 Rundc3a -1.11 1.16E-02 -1.08 4.91E-02 RUN domain containing 3A [Source:MGI Symbol;Acc:MGI:1858752]
582 Zfp941 1.25 9.66E-04 1.15 4.93E-02 zinc finger protein 941 [Source:MGI Symbol;Acc:MGI:3039601]
Gene ID
MB Specific 
Gene NameWT vs. KO I172M vs. KO
FC in KO P Adj FC in KO P Adj




Gene NameWT vs. KO I172M vs. KO
FC in KO P Adj FC in KO P Adj
1 Ccng1 -1.17 4.17E-02 -1.44 7.33E-12 cyclin G1 [Source:MGI Symbol;Acc:MGI:102890]
2 Slc5a3 -1.36 7.70E-05 -1.56 7.59E-11 solute carrier family 5 (inositol transporters), member 3 [Source:MGI Symbol;Acc:MGI:1858226]
3 Glp2r 1.81 3.04E-11 1.78 1.44E-10 glucagon-like peptide 2 receptor [Source:MGI Symbol;Acc:MGI:2136733]
4 Itpka 1.36 6.94E-05 1.52 4.41E-10 inositol 1,4,5-trisphosphate 3-kinase A [Source:MGI Symbol;Acc:MGI:1333822]
5 Alox12b 1.50 9.78E-05 1.69 1.91E-08 arachidonate 12-lipoxygenase, 12R type [Source:MGI Symbol;Acc:MGI:1274782]
6 Srek1 -1.18 4.78E-02 -1.37 1.96E-07 splicing regulatory glutamine/lysine-rich protein 1 [Source:MGI Symbol;Acc:MGI:2145245]
7 Zmym1 -1.37 1.32E-04 -1.46 4.90E-07 zinc finger, MYM domain containing 1 [Source:MGI Symbol;Acc:MGI:1915560]
8 Calr -1.36 3.84E-06 -1.37 1.34E-06 calreticulin [Source:MGI Symbol;Acc:MGI:88252]
9 Papola -1.22 8.50E-04 -1.28 2.53E-06 poly (A) polymerase alpha [Source:MGI Symbol;Acc:MGI:109301]
10 Dnajc3 -1.31 8.27E-06 -1.31 3.31E-06 DnaJ heat shock protein family (Hsp40) member C3 [Source:MGI Symbol;Acc:MGI:107373]
11 Calb1 -1.29 2.65E-03 -1.40 5.28E-06 calbindin 1 [Source:MGI Symbol;Acc:MGI:88248]
12 Shisa7 -1.17 4.87E-03 -1.23 8.13E-06 shisa family member 7 [Source:MGI Symbol;Acc:MGI:3605641]
13 Eml2 1.22 4.36E-02 1.40 9.11E-06 echinoderm microtubule associated protein like 2 [Source:MGI Symbol;Acc:MGI:1919455]
14 Hrk -1.33 1.62E-04 -1.36 1.32E-05 harakiri, BCL2 interacting protein (contains only BH3 domain) [Source:MGI Symbol;Acc:MGI:1201608]
15 Stc1 -1.46 1.40E-04 -1.51 1.45E-05 stanniocalcin 1 [Source:MGI Symbol;Acc:MGI:109131]
16 Bbx -1.21 1.51E-02 -1.32 1.82E-05 bobby sox HMG box containing [Source:MGI Symbol;Acc:MGI:1917758]
17 Chordc1 -1.25 2.80E-02 -1.41 2.23E-05
cysteine and histidine-rich domain (CHORD)-containing, 
zinc-binding protein 1 [Source:MGI 
Symbol;Acc:MGI:1914167]
18 Ephb1 1.26 4.56E-03 1.35 2.51E-05 Eph receptor B1 [Source:MGI Symbol;Acc:MGI:1096337]
19 Crtac1 1.25 7.88E-03 1.35 2.76E-05 cartilage acidic protein 1 [Source:MGI Symbol;Acc:MGI:1920082]
20 Kdr -1.36 6.04E-04 -1.41 3.10E-05 kinase insert domain protein receptor [Source:MGI Symbol;Acc:MGI:96683]
21 Pdia3 -1.30 4.15E-04 -1.32 7.31E-05 protein disulfide isomerase associated 3 [Source:MGI Symbol;Acc:MGI:95834]
22 Hsp90b1 -1.28 2.37E-03 -1.33 8.83E-05 heat shock protein 90, beta (Grp94), member 1 [Source:MGI Symbol;Acc:MGI:98817]
23 Greb1l -1.38 4.28E-03 -1.48 1.04E-04 growth regulation by estrogen in breast cancer-like [Source:MGI Symbol;Acc:MGI:3576497]
24 Tia1 -1.23 2.70E-02 -1.34 1.37E-04 cytotoxic granule-associated RNA binding protein 1 [Source:MGI Symbol;Acc:MGI:107914]
25 Pcdhgc5 1.18 2.89E-02 1.27 1.46E-04 protocadherin gamma subfamily C, 5 [Source:MGI Symbol;Acc:MGI:1935205]
26 Trib2 -1.26 1.72E-03 -1.28 2.07E-04 tribbles pseudokinase 2 [Source:MGI Symbol;Acc:MGI:2145021]
27 Adamts2 -1.27 4.71E-02 -1.41 2.27E-04
a disintegrin-like and metallopeptidase (reprolysin type) 
with thrombospondin type 1 motif, 2 [Source:MGI 
Symbol;Acc:MGI:1347356]
28 Emx2 -1.22 4.78E-02 -1.32 4.04E-04 empty spiracles homeobox 2 [Source:MGI Symbol;Acc:MGI:95388]
29 E330013P04Rik -1.38 6.16E-03 -1.45 4.04E-04 RIKEN cDNA E330013P04 gene [Source:MGI Symbol;Acc:MGI:2147732]
30 Lrfn1 1.23 4.14E-02 1.33 4.04E-04 leucine rich repeat and fibronectin type III domain containing 1 [Source:MGI Symbol;Acc:MGI:2136810]
31 Grin2b 1.48 1.62E-11 1.26 4.29E-04 glutamate receptor, ionotropic, NMDA2B (epsilon 2) [Source:MGI Symbol;Acc:MGI:95821]
32 Larp6 1.22 1.59E-02 1.28 4.33E-04 La ribonucleoprotein domain family, member 6 [Source:MGI Symbol;Acc:MGI:1914807]
310
33 Rngtt -1.18 4.20E-02 -1.25 5.47E-04 RNA guanylyltransferase and 5'-phosphatase [Source:MGI Symbol;Acc:MGI:1329041]
34 Chac1 1.38 5.80E-03 1.44 5.48E-04 ChaC, cation transport regulator 1 [Source:MGI Symbol;Acc:MGI:1916315]
35 Hsd11b1 1.26 5.70E-03 1.29 5.58E-04 hydroxysteroid 11-beta dehydrogenase 1 [Source:MGI Symbol;Acc:MGI:103562]
36 Bcl6 -1.20 2.96E-02 -1.26 6.01E-04 B cell leukemia/lymphoma 6 [Source:MGI Symbol;Acc:MGI:107187]
37 Arglu1 -1.23 1.77E-02 -1.29 6.01E-04 arginine and glutamate rich 1 [Source:MGI Symbol;Acc:MGI:2442985]
38 Clk1 -1.35 3.69E-05 -1.29 6.25E-04 CDC-like kinase 1 [Source:MGI Symbol;Acc:MGI:107403]
39 Kcns1 1.36 5.24E-03 1.40 6.49E-04 K+ voltage-gated channel, subfamily S, 1 [Source:MGI Symbol;Acc:MGI:1197019]
40 Mbp 1.36 1.77E-04 1.31 6.62E-04 myelin basic protein [Source:MGI Symbol;Acc:MGI:96925]
41 Rgl1 -1.21 1.02E-03 -1.21 6.67E-04 ral guanine nucleotide dissociation stimulator,-like 1 [Source:MGI Symbol;Acc:MGI:107484]
42 Pacs2 1.24 2.39E-03 1.25 7.78E-04 phosphofurin acidic cluster sorting protein 2 [Source:MGI Symbol;Acc:MGI:1924399]
43 Efcab7 -1.38 7.05E-03 -1.42 8.27E-04 EF-hand calcium binding domain 7 [Source:MGI Symbol;Acc:MGI:2385199]
44 Zfp207 -1.16 4.48E-02 -1.22 8.36E-04 zinc finger protein 207 [Source:MGI Symbol;Acc:MGI:1340045]
45 Nptxr 1.35 1.05E-02 1.41 8.36E-04 neuronal pentraxin receptor [Source:MGI Symbol;Acc:MGI:1920590]
46 Mllt11 -1.16 3.20E-02 -1.21 8.57E-04
myeloid/lymphoid or mixed-lineage leukemia; 
translocated to, 11 [Source:MGI 
Symbol;Acc:MGI:1929671]
47 Myef2 -1.20 1.92E-02 -1.24 8.71E-04 myelin basic protein expression factor 2, repressor [Source:MGI Symbol;Acc:MGI:104592]
48 Plec 1.21 3.23E-02 1.27 9.79E-04 plectin [Source:MGI Symbol;Acc:MGI:1277961]
49 Fndc3a -1.20 1.88E-02 -1.24 1.20E-03 fibronectin type III domain containing 3A [Source:MGI Symbol;Acc:MGI:1196463]
50 Gucy2g 1.36 1.01E-02 1.41 1.28E-03 guanylate cyclase 2g [Source:MGI Symbol;Acc:MGI:106025]
51 Adssl1 1.42 7.46E-04 1.38 1.33E-03 adenylosuccinate synthetase like 1 [Source:MGI Symbol;Acc:MGI:87947]
52 Prr5l 1.32 1.07E-02 1.36 1.36E-03 proline rich 5 like [Source:MGI Symbol;Acc:MGI:1919696]
53 Zcchc7 -1.26 1.63E-02 -1.30 1.43E-03 zinc finger, CCHC domain containing 7 [Source:MGI Symbol;Acc:MGI:2442912]
54 Stip1 -1.19 1.63E-02 -1.22 1.60E-03 stress-induced phosphoprotein 1 [Source:MGI Symbol;Acc:MGI:109130]
55 Tra2a -1.24 1.54E-02 -1.27 1.61E-03 transformer 2 alpha [Source:MGI Symbol;Acc:MGI:1933972]
56 Srrm2 -1.15 4.71E-02 -1.19 1.61E-03 serine/arginine repetitive matrix 2 [Source:MGI Symbol;Acc:MGI:1923206]
57 Bmi1 -1.19 3.99E-02 -1.24 2.25E-03 Bmi1 polycomb ring finger oncogene [Source:MGI Symbol;Acc:MGI:88174]
58 Scand1 1.31 4.14E-02 1.39 2.32E-03 SCAN domain-containing 1 [Source:MGI Symbol;Acc:MGI:1343132]
59 A930011O12Rik -1.53 7.91E-07 -1.32 2.68E-03 NA
60 Snrpc 1.25 2.19E-02 1.28 2.72E-03 U1 small nuclear ribonucleoprotein C [Source:MGI Symbol;Acc:MGI:109489]
61 Myh8 -1.37 5.77E-03 -1.36 2.90E-03 myosin, heavy polypeptide 8, skeletal muscle, perinatal [Source:MGI Symbol;Acc:MGI:1339712]
62 St5 -1.24 2.19E-02 -1.27 3.03E-03 suppression of tumorigenicity 5 [Source:MGI Symbol;Acc:MGI:108517]
63 Fam178a -1.21 4.48E-02 -1.26 3.19E-03 NA
64 Bms1 -1.23 7.24E-03 -1.23 3.24E-03 BMS1, ribosome biogenesis factor [Source:MGI Symbol;Acc:MGI:2446132]
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65 Ubp1 -1.17 4.14E-02 -1.19 3.89E-03 upstream binding protein 1 [Source:MGI Symbol;Acc:MGI:104889]
66 Dusp6 -1.28 9.24E-04 -1.23 3.97E-03 dual specificity phosphatase 6 [Source:MGI Symbol;Acc:MGI:1914853]
67 L3mbtl3 -1.23 3.04E-02 -1.26 4.05E-03 L3MBTL3 histone methyl-lysine binding protein [Source:MGI Symbol;Acc:MGI:2143628]
68 Cflar -1.24 2.62E-02 -1.25 4.60E-03 CASP8 and FADD-like apoptosis regulator [Source:MGI Symbol;Acc:MGI:1336166]
69 Ptp4a1 -1.24 4.15E-02 -1.28 5.13E-03 protein tyrosine phosphatase 4a1 [Source:MGI Symbol;Acc:MGI:1277096]
70 Npy -1.23 4.56E-03 -1.21 5.58E-03 neuropeptide Y [Source:MGI Symbol;Acc:MGI:97374]
71 Pdp1 -1.19 2.05E-02 -1.20 6.15E-03 pyruvate dehyrogenase phosphatase catalytic subunit 1 [Source:MGI Symbol;Acc:MGI:2685870]
72 Thra 1.16 2.37E-02 1.16 6.40E-03 thyroid hormone receptor alpha [Source:MGI Symbol;Acc:MGI:98742]
73 Map3k5 -1.21 1.71E-02 -1.21 6.66E-03 mitogen-activated protein kinase kinase kinase 5 [Source:MGI Symbol;Acc:MGI:1346876]
74 Mtmr4 -1.21 4.42E-02 -1.23 7.11E-03 myotubularin related protein 4 [Source:MGI Symbol;Acc:MGI:2180699]
75 Extl1 1.26 7.77E-03 1.24 7.11E-03 exostoses (multiple)-like 1 [Source:MGI Symbol;Acc:MGI:1888742]
76 Fam46a -1.28 4.15E-02 -1.31 7.54E-03 NA
77 Fst -1.44 8.88E-04 -1.33 7.69E-03 follistatin [Source:MGI Symbol;Acc:MGI:95586]
78 Manf -1.42 2.52E-04 -1.29 7.75E-03 mesencephalic astrocyte-derived neurotrophic factor [Source:MGI Symbol;Acc:MGI:1922090]
79 Nrsn1 -1.21 3.53E-02 -1.22 8.03E-03 neurensin 1 [Source:MGI Symbol;Acc:MGI:894662]
80 Aim2 1.36 1.00E-02 1.33 8.05E-03 absent in melanoma 2 [Source:MGI Symbol;Acc:MGI:2686159]
81 Myof -1.32 1.30E-02 -1.30 8.05E-03 myoferlin [Source:MGI Symbol;Acc:MGI:1919192]
82 Lgi4 1.22 3.20E-02 1.23 8.71E-03 leucine-rich repeat LGI family, member 4 [Source:MGI Symbol;Acc:MGI:2180197]
83 Ttc14 -1.30 1.43E-02 -1.28 1.00E-02 tetratricopeptide repeat domain 14 [Source:MGI Symbol;Acc:MGI:1914370]
84 Kcnh7 1.26 3.73E-02 1.27 1.08E-02
potassium voltage-gated channel, subfamily H (eag-
related), member 7 [Source:MGI 
Symbol;Acc:MGI:2159566]
85 Tial1 -1.20 4.71E-02 -1.21 1.14E-02 Tia1 cytotoxic granule-associated RNA binding protein-like 1 [Source:MGI Symbol;Acc:MGI:107913]
86 Adam8 -1.36 1.05E-02 -1.32 1.17E-02 a disintegrin and metallopeptidase domain 8 [Source:MGI Symbol;Acc:MGI:107825]
87 Dhrs7 1.25 2.03E-02 1.24 1.18E-02 dehydrogenase/reductase (SDR family) member 7 [Source:MGI Symbol;Acc:MGI:1913625]
88 2810403A07Rik -1.19 2.96E-02 -1.18 1.27E-02 NA
89 Ptpn11 1.14 4.20E-02 1.14 1.28E-02 protein tyrosine phosphatase, non-receptor type 11 [Source:MGI Symbol;Acc:MGI:99511]
90 Kcnq3 1.26 7.05E-03 1.21 1.30E-02 potassium voltage-gated channel, subfamily Q, member 3 [Source:MGI Symbol;Acc:MGI:1336181]
91 Fndc1 -1.33 8.45E-03 -1.28 1.34E-02 fibronectin type III domain containing 1 [Source:MGI Symbol;Acc:MGI:1915905]
92 Rnpc3 -1.29 2.77E-02 -1.27 1.38E-02 RNA-binding region (RNP1, RRM) containing 3 [Source:MGI Symbol;Acc:MGI:1914475]
93 Mtus2 1.23 2.55E-03 1.18 1.46E-02 microtubule associated tumor suppressor candidate 2 [Source:MGI Symbol;Acc:MGI:1915388]
94 Fam206a -1.20 4.19E-02 -1.19 1.48E-02 family with sequence similarity 206, member A [Source:MGI Symbol;Acc:MGI:2677850]
95 Hs6st3 1.29 8.47E-03 1.24 1.49E-02 heparan sulfate 6-O-sulfotransferase 3 [Source:MGI Symbol;Acc:MGI:1354960]
96 Phldb1 1.24 2.26E-02 1.22 1.51E-02 pleckstrin homology like domain, family B, member 1 [Source:MGI Symbol;Acc:MGI:2143230]
97 Pdia6 -1.35 1.32E-03 -1.25 1.56E-02 protein disulfide isomerase associated 6 [Source:MGI Symbol;Acc:MGI:1919103]
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98 Rreb1 -1.41 5.47E-04 -1.27 1.61E-02 ras responsive element binding protein 1 [Source:MGI Symbol;Acc:MGI:2443664]
99 Ankrd29 1.29 5.80E-03 1.23 1.72E-02 ankyrin repeat domain 29 [Source:MGI Symbol;Acc:MGI:2687055]
100 Tmem55a -1.21 3.51E-03 -1.16 1.82E-02 NA
101 Rpap3 1.24 1.43E-02 1.20 1.86E-02 RNA polymerase II associated protein 3 [Source:MGI Symbol;Acc:MGI:1277218]
102 Grin2a 1.30 3.50E-03 1.22 1.90E-02 glutamate receptor, ionotropic, NMDA2A (epsilon 1) [Source:MGI Symbol;Acc:MGI:95820]
103 Thpo -1.37 7.05E-03 -1.29 2.07E-02 thrombopoietin [Source:MGI Symbol;Acc:MGI:101875]
104 Dnajb11 -1.21 1.54E-02 -1.18 2.07E-02 DnaJ heat shock protein family (Hsp40) member B11 [Source:MGI Symbol;Acc:MGI:1915088]
105 Ilvbl 1.30 1.63E-02 1.25 2.08E-02 ilvB (bacterial acetolactate synthase)-like [Source:MGI Symbol;Acc:MGI:1351911]
106 Cd180 1.38 6.95E-03 1.29 2.10E-02 CD180 antigen [Source:MGI Symbol;Acc:MGI:1194924]
107 Capn3 -1.23 4.71E-02 -1.22 2.20E-02 calpain 3 [Source:MGI Symbol;Acc:MGI:107437]
108 Nov 1.21 2.70E-02 1.18 2.42E-02 NA
109 Mid1 -1.41 3.13E-03 -1.29 2.43E-02 midline 1 [Source:MGI Symbol;Acc:MGI:1100537]
110 Zmym6 -1.25 2.73E-02 -1.22 2.43E-02 zinc finger, MYM-type 6 [Source:MGI Symbol;Acc:MGI:106505]
111 Sirt4 -1.31 1.92E-02 -1.26 2.57E-02 sirtuin 4 [Source:MGI Symbol;Acc:MGI:1922637]
112 Unc5b 1.34 6.74E-03 1.25 2.64E-02 unc-5 netrin receptor B [Source:MGI Symbol;Acc:MGI:894703]
113 Clk4 -1.26 2.32E-03 -1.18 2.70E-02 CDC like kinase 4 [Source:MGI Symbol;Acc:MGI:1098551]
114 Filip1 1.31 2.96E-02 1.27 2.70E-02 filamin A interacting protein 1 [Source:MGI Symbol;Acc:MGI:1917848]
115 C030029H02Rik 1.33 2.72E-02 1.28 2.75E-02 RIKEN cDNA C030029H02 gene [Source:MGI Symbol;Acc:MGI:1924633]
116 Npas3 1.29 1.23E-02 1.22 2.78E-02 neuronal PAS domain protein 3 [Source:MGI Symbol;Acc:MGI:1351610]
117 Rhog 1.29 7.80E-03 1.22 2.92E-02 ras homolog family member G [Source:MGI Symbol;Acc:MGI:1928370]
118 Atp7a -1.29 1.13E-02 -1.22 2.94E-02 ATPase, Cu++ transporting, alpha polypeptide [Source:MGI Symbol;Acc:MGI:99400]
119 Dsg2 -1.34 1.07E-02 -1.26 2.94E-02 desmoglein 2 [Source:MGI Symbol;Acc:MGI:1196466]
120 Arhgap42 -1.28 9.81E-03 -1.21 2.97E-02 Rho GTPase activating protein 42 [Source:MGI Symbol;Acc:MGI:1918794]
121 Iars2 1.16 3.42E-02 1.14 3.02E-02 isoleucine-tRNA synthetase 2, mitochondrial [Source:MGI Symbol;Acc:MGI:1919586]
122 Eogt -1.29 5.80E-03 -1.21 3.04E-02
EGF domain-specific O-linked N-acetylglucosamine 
(GlcNAc) transferase [Source:MGI 
Symbol;Acc:MGI:2141669]
123 Myh14 1.24 4.99E-02 1.21 3.15E-02 myosin, heavy polypeptide 14 [Source:MGI Symbol;Acc:MGI:1919210]
124 Ccnl2 -1.33 3.82E-05 -1.17 3.32E-02 cyclin L2 [Source:MGI Symbol;Acc:MGI:1927119]
125 Pdzd2 -1.25 1.19E-03 -1.15 3.98E-02 PDZ domain containing 2 [Source:MGI Symbol;Acc:MGI:1922394]
126 Hspa5 -1.30 4.71E-02 -1.26 4.01E-02 heat shock protein 5 [Source:MGI Symbol;Acc:MGI:95835]
127 Xbp1 -1.32 6.95E-03 -1.22 4.26E-02 X-box binding protein 1 [Source:MGI Symbol;Acc:MGI:98970]
128 Fam45a -1.35 2.08E-03 -1.21 4.50E-02 family with sequence similarity 45, member A [Source:MGI Symbol;Acc:MGI:1915144]
129 Lsamp 1.15 3.97E-02 1.12 4.52E-02 limbic system-associated membrane protein [Source:MGI Symbol;Acc:MGI:1261760]
130 Mobp 1.25 2.96E-02 1.20 4.81E-02 myelin-associated oligodendrocytic basic protein [Source:MGI Symbol;Acc:MGI:108511]
Gene ID
HPC Specific
Gene NameWT vs. KO I172M vs. KO
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































WT vs. KO I172M vs. KO Blakely Lab SIP Co-
IP Results for SERTs Gene NameMB HPC MB HPC
FC in KO P Adj FC in KO P Adj FC in KO P Adj FC in KO P Adj WT KO G56A
1 Kcnj10 -1.24 9.36E-09 -1.23 1.06E-08 -1.20 8.56E-03 Yes
potassium inwardly-rectifying 
channel, subfamily J, 
member 10 [Source:MGI 
Symbol;Acc:MGI:1194504]
2 Tph2 -1.27 7.02E-05 Yes
tryptophan hydroxylase 2 
[Source:MGI 
Symbol;Acc:MGI:2651811]
3 Srsf3 1.22 6.64E-06 1.36 4.63E-15 Yes
serine/arginine-rich splicing 
factor 3 [Source:MGI 
Symbol;Acc:MGI:98285]
4 Hsph1 -1.17 1.36E-02 -1.23 3.52E-03 -1.22 4.66E-04 -1.30 1.63E-05 Yes
heat shock 105kDa/110kDa 
protein 1 [Source:MGI 
Symbol;Acc:MGI:105053]




6 Clip3 -1.16 1.19E-05 -1.16 9.70E-06 -1.17 1.03E-02 Yes
CAP-GLY domain containing 
linker protein 3 [Source:MGI 
Symbol;Acc:MGI:1923936]
7 Diras2 -1.26 6.44E-05 -1.14 4.05E-02 Yes
DIRAS family, GTP-binding 
RAS-like 2 [Source:MGI 
Symbol;Acc:MGI:1915453]




9 Anks1b 1.13 1.94E-02 1.18 5.74E-04 Yes
ankyrin repeat and sterile 
alpha motif domain 
containing 1B [Source:MGI 
Symbol;Acc:MGI:1924781]
10 Cldn11 1.19 2.00E-03 1.28 2.09E-03 1.14 1.78E-02 Yes claudin 11 [Source:MGI Symbol;Acc:MGI:106925]
11 Cnrip1 1.19 3.18E-03 1.19 1.45E-03 Yes
cannabinoid receptor 
interacting protein 1 
[Source:MGI 
Symbol;Acc:MGI:1917505]




13 Erbb2ip 1.11 4.93E-02 Yes NA
14 Crmp1 1.12 1.36E-02 1.14 1.16E-03 Yes
collapsin response mediator 
protein 1 [Source:MGI 
Symbol;Acc:MGI:107793]
15 Rundc3a -1.11 1.16E-02 -1.08 4.91E-02 Yes
RUN domain containing 3A 
[Source:MGI 
Symbol;Acc:MGI:1858752]
16 Actr1b -1.12 3.95E-03 -1.13 7.48E-04 1.16 3.52E-02 Yes
ARP1 actin-related protein 
1B, centractin beta 
[Source:MGI 
Symbol;Acc:MGI:1917446]
17 Apc2 -1.11 1.46E-02 Yes
adenomatosis polyposis coli 
2 [Source:MGI 
Symbol;Acc:MGI:1346052]
18 Arl6 -1.25 5.62E-03 Yes
ADP-ribosylation factor-like 6 
[Source:MGI 
Symbol;Acc:MGI:1927136]
19 Herc2 1.16 4.30E-03 Yes
HECT and RLD domain 
containing E3 ubiquitin 
protein ligase 2 [Source:MGI 
Symbol;Acc:MGI:103234]
20 Clasp1 -1.11 3.70E-02 Yes
CLIP associating protein 1 
[Source:MGI 
Symbol;Acc:MGI:1923957]
21 Nlgn2 -1.10 1.39E-02 Yes neuroligin 2 [Source:MGI Symbol;Acc:MGI:2681835]
22 Acsbg1 1.15 4.45E-02 Yes
acyl-CoA synthetase 
bubblegum family member 1 
[Source:MGI 
Symbol;Acc:MGI:2385656]
23 Llgl1 1.21 3.04E-02 Yes




24 Ctnnd1 -1.13 4.00E-02 Yes
catenin (cadherin associated 
protein), delta 1 [Source:MGI 
Symbol;Acc:MGI:105100]
25 Acan -1.17 2.10E-02 Yes aggrecan [Source:MGI Symbol;Acc:MGI:99602]
26 Mast1 -1.10 4.29E-02 Yes
microtubule associated 
serine/threonine kinase 1 
[Source:MGI 
Symbol;Acc:MGI:1861901]
27 Dnm1l -1.18 2.71E-02 Yes dynamin 1-like [Source:MGI Symbol;Acc:MGI:1921256]
28 Prickle2 1.12 4.48E-02 Yes
prickle planar cell polarity 
protein 2 [Source:MGI 
Symbol;Acc:MGI:1925144]
29 Nfasc -1.14 6.38E-04 Yes neurofascin [Source:MGI Symbol;Acc:MGI:104753]
APPENDIX M. DEGs Coding for Proteins That Interact with WT, KO and G56A SERT.
329
Gene ID
WT vs. KO I172M vs. KO Blakely Lab SIP Co-
IP Results for SERTs Gene NameMB HPC MB HPC
FC in KO P Adj FC in KO P Adj FC in KO P Adj FC in KO P Adj WT KO G56A
30 Dagla -1.13 4.92E-02 Yes
diacylglycerol lipase, alpha 
[Source:MGI 
Symbol;Acc:MGI:2677061]
31 Csnk2a1 -1.15 4.30E-02 Yes
casein kinase 2, alpha 1 
polypeptide [Source:MGI 
Symbol;Acc:MGI:88543]
32 Wdr34 1.26 1.86E-02 Yes
WD repeat domain 34 
[Source:MGI 
Symbol;Acc:MGI:1919070]
33 Mapk8ip2 -1.09 8.92E-03 Yes
mitogen-activated protein 
kinase 8 interacting protein 2 
[Source:MGI 
Symbol;Acc:MGI:1926555]
34 Ago2 -1.18 2.85E-02 Yes
argonaute RISC catalytic 
subunit 2 [Source:MGI 
Symbol;Acc:MGI:2446632]
35 Ndufv1 1.26 8.18E-04 Yes
NADH:ubiquinone 
oxidoreductase core subunit 
V1 [Source:MGI 
Symbol;Acc:MGI:107851]
36 Hcn2 -1.13 7.50E-03 1.29 8.65E-04 Yes
hyperpolarization-activated, 
cyclic nucleotide-gated K+ 2 
[Source:MGI 
Symbol;Acc:MGI:1298210]
37 Ndufa9 1.13 3.61E-02 Yes
NADH:ubiquinone 
oxidoreductase subunit A9 
[Source:MGI 
Symbol;Acc:MGI:1913358]
38 Fkbp8 1.26 3.47E-03 Yes
FK506 binding protein 8 
[Source:MGI 
Symbol;Acc:MGI:1341070]
39 Serac1 -1.18 4.45E-02 Yes
serine active site containing 1 
[Source:MGI 
Symbol;Acc:MGI:2447813]
40 Amot -1.17 4.07E-02 Yes angiomotin [Source:MGI Symbol;Acc:MGI:108440]
41 Osbpl6 -1.14 3.58E-02 -1.13 2.91E-02 -1.17 9.32E-03 Yes
oxysterol binding protein-like 
6 [Source:MGI 
Symbol;Acc:MGI:2139014]
42 Flii -1.10 4.97E-02 Yes
flightless I actin binding 
protein [Source:MGI 
Symbol;Acc:MGI:1342286]
43 Pnpla8 -1.16 4.07E-02 Yes
patatin-like phospholipase 
domain containing 8 
[Source:MGI 
Symbol;Acc:MGI:1914702]
44 Nlgn3 -1.14 2.39E-02 Yes neuroligin 3 [Source:MGI Symbol;Acc:MGI:2444609]




46 Caskin1 -1.12 1.00E-02 Yes
CASK interacting protein 1 
[Source:MGI 
Symbol;Acc:MGI:2442952]
47 Mtss1l -1.11 2.01E-02 -1.18 1.24E-05 Yes
metastasis suppressor 1-like 
[Source:MGI 
Symbol;Acc:MGI:3039591]
48 Ndufs2 1.22 7.59E-04 Yes
NADH:ubiquinone 
oxidoreductase core subunit 
S2 [Source:MGI 
Symbol;Acc:MGI:2385112]
49 Dab2ip 1.20 2.33E-02 Yes
disabled 2 interacting protein 
[Source:MGI 
Symbol;Acc:MGI:1916851]
50 Sipa1l2 -1.18 4.97E-03 Yes
signal-induced proliferation-
associated 1 like 2 
[Source:MGI 
Symbol;Acc:MGI:2676970]
51 Phkg1 1.23 4.47E-03 1.25 2.98E-02 Yes
phosphorylase kinase 
gamma 1 [Source:MGI 
Symbol;Acc:MGI:97579]
52 Vps16 1.15 2.87E-02 Yes
VSP16 CORVET/HOPS core 
subunit [Source:MGI 
Symbol;Acc:MGI:2136772]




54 Bin1 1.11 3.16E-02 1.10 3.70E-02 Yes
bridging integrator 1 
[Source:MGI 
Symbol;Acc:MGI:108092]
55 Specc1 -1.13 1.12E-02 -1.15 3.92E-02 Yes
sperm antigen with calponin 
homology and coiled-coil 
domains 1 [Source:MGI 
Symbol;Acc:MGI:2442356]
56 Cdc42 1.10 2.09E-02 1.15 6.33E-05 Yes




57 Tmem160 1.29 2.06E-02 Yes
transmembrane protein 160 
[Source:MGI 
Symbol;Acc:MGI:1916344]
58 Gria4 -1.17 2.84E-02 Yes
glutamate receptor, 
ionotropic, AMPA4 (alpha 4) 
[Source:MGI 
Symbol;Acc:MGI:95811]
59 Fcho2 -1.22 1.11E-02 Yes
FCH domain only 2 
[Source:MGI 
Symbol;Acc:MGI:3505790]
60 Bdh1 1.19 2.95E-02 Yes
3-hydroxybutyrate 
dehydrogenase, type 1 
[Source:MGI 
Symbol;Acc:MGI:1919161]
61 Htra1 -1.18 4.18E-02 -1.17 3.42E-02 Yes
HtrA serine peptidase 1 
[Source:MGI 
Symbol;Acc:MGI:1929076]
62 Grin2a 1.30 3.50E-03 1.22 1.90E-02 Yes
glutamate receptor, 
ionotropic, NMDA2A (epsilon 
1) [Source:MGI 
Symbol;Acc:MGI:95820]
63 Tmcc3 1.14 2.46E-02 1.21 2.55E-03 Yes
transmembrane and coiled 
coil domains 3 [Source:MGI 
Symbol;Acc:MGI:2442900]
64 Baiap2 -1.19 1.67E-02 Yes
brain-specific angiogenesis 
inhibitor 1-associated protein 
2 [Source:MGI 
Symbol;Acc:MGI:2137336]










67 Actn1 -1.19 2.70E-02 Yes actinin, alpha 1 [Source:MGI Symbol;Acc:MGI:2137706]
68 Atp6v1b2 1.12 3.37E-02 Yes
ATPase, H+ transporting, 
lysosomal V1 subunit B2 
[Source:MGI 
Symbol;Acc:MGI:109618]
69 Rab18 1.10 1.41E-02 Yes




70 Arpc2 -1.14 1.89E-02 Yes
actin related protein 2/3 
complex, subunit 2 
[Source:MGI 
Symbol;Acc:MGI:1923959]
71 Dgkz 1.17 4.63E-02 Yes
diacylglycerol kinase zeta 
[Source:MGI 
Symbol;Acc:MGI:1278339]






73 Kcnq2 -1.14 9.62E-03 Yes
potassium voltage-gated 
channel, subfamily Q, 
member 2 [Source:MGI 
Symbol;Acc:MGI:1309503]
74 Mib2 -1.14 8.04E-03 Yes
mindbomb E3 ubiquitin 
protein ligase 2 [Source:MGI 
Symbol;Acc:MGI:2679684]
75 Kctd12 -1.20 6.27E-03 Yes
potassium channel 
tetramerisation domain 
containing 12 [Source:MGI 
Symbol;Acc:MGI:2145823]
76 Actr3 1.11 9.94E-03 Yes
ARP3 actin-related protein 3 
[Source:MGI 
Symbol;Acc:MGI:1921367]
77 Rph3a -1.15 3.08E-04 Yes rabphilin 3A [Source:MGI Symbol;Acc:MGI:102788]





79 Agap3 1.16 4.18E-02 Yes
ArfGAP with GTPase 
domain, ankyrin repeat and 
PH domain 3 [Source:MGI 
Symbol;Acc:MGI:2183446]





81 Arf3 1.14 2.94E-02 Yes




WT vs. KO I172M vs. KO Blakely Lab SIP Co-
IP Results for SERTs Gene NameMB HPC MB HPC
FC in KO P Adj FC in KO P Adj FC in KO P Adj FC in KO P Adj WT KO G56A
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82 Capza2 1.11 2.74E-02 Yes
capping protein (actin 
filament) muscle Z-line, alpha 
2 [Source:MGI 
Symbol;Acc:MGI:106222]
83 Ddr1 1.24 1.99E-02 Yes
discoidin domain receptor 
family, member 1 
[Source:MGI 
Symbol;Acc:MGI:99216]
84 Ap2s1 1.25 6.14E-03 Yes
adaptor-related protein 
complex 2, sigma 1 subunit 
[Source:MGI 
Symbol;Acc:MGI:2141861]
85 Uqcrq 1.33 8.27E-04 Yes
ubiquinol-cytochrome c 
reductase, complex III 
subunit VII [Source:MGI 
Symbol;Acc:MGI:107807]
86 Flot1 1.19 1.93E-02 Yes flotillin 1 [Source:MGI Symbol;Acc:MGI:1100500]
87 Slc6a4 -1.44 1.52E-10 4.65 1.20E-78 -1.22 2.52E-03 4.67 4.15E-79 Yes Yes Yes
solute carrier family 6 
(neurotransmitter transporter, 
serotonin), member 4 
[Source:MGI 
Symbol;Acc:MGI:96285]
88 Fxr1 -1.24 2.34E-03 Yes Yes Yes
fragile X mental retardation 
gene 1, autosomal homolog 
[Source:MGI 
Symbol;Acc:MGI:104860]
89 Agap1 -1.11 8.42E-03 Yes Yes Yes
ArfGAP with GTPase 
domain, ankyrin repeat and 
PH domain 1 [Source:MGI 
Symbol;Acc:MGI:2653690]
90 Coro1c 1.10 4.46E-02 1.09 4.04E-02 Yes Yes Yes
coronin, actin binding protein 
1C [Source:MGI 
Symbol;Acc:MGI:1345964]
91 Gabbr2 -1.15 1.69E-02 Yes Yes Yes
gamma-aminobutyric acid 
(GABA) B receptor, 2 
[Source:MGI 
Symbol;Acc:MGI:2386030]
92 Tpm3 1.10 4.56E-02 Yes Yes Yes
tropomyosin 3, gamma 
[Source:MGI 
Symbol;Acc:MGI:1890149]
93 Traf3 -1.17 5.71E-03 Yes Yes Yes
TNF receptor-associated 
factor 3 [Source:MGI 
Symbol;Acc:MGI:108041]
94 Ap1b1 -1.08 3.71E-02 -1.11 2.21E-03 Yes Yes Yes
adaptor protein complex 
AP-1, beta 1 subunit 
[Source:MGI 
Symbol;Acc:MGI:1096368]




96 Srgap3 -1.11 1.45E-02 -1.18 6.49E-04 Yes Yes Yes
SLIT-ROBO Rho GTPase 
activating protein 3 
[Source:MGI 
Symbol;Acc:MGI:2152938]
97 Dlgap3 1.24 1.63E-02 Yes Yes Yes
DLG associated protein 3 
[Source:MGI 
Symbol;Acc:MGI:3039563]
98 Iqsec1 -1.13 4.13E-04 Yes Yes Yes
IQ motif and Sec7 domain 1 
[Source:MGI 
Symbol;Acc:MGI:1196356]




100 Ap3b2 -1.09 2.54E-02 Yes Yes Yes
adaptor-related protein 
complex 3, beta 2 subunit 
[Source:MGI 
Symbol;Acc:MGI:1100869]
101 Eps15 1.08 4.19E-02 Yes Yes Yes
epidermal growth factor 
receptor pathway substrate 
15 [Source:MGI 
Symbol;Acc:MGI:104583]
102 Ap3d1 -1.11 8.37E-03 Yes Yes Yes
adaptor-related protein 
complex 3, delta 1 subunit 
[Source:MGI 
Symbol;Acc:MGI:107734]
103 Cntnap1 -1.12 1.59E-03 -1.16 7.88E-06 Yes Yes
contactin associated protein-
like 1 [Source:MGI 
Symbol;Acc:MGI:1858201]
104 Palm -1.12 2.96E-02 -1.12 2.08E-02 Yes Yes paralemmin [Source:MGI Symbol;Acc:MGI:1261814]
105 Arglu1 -1.23 1.77E-02 -1.29 6.01E-04 Yes Yes
arginine and glutamate rich 1 
[Source:MGI 
Symbol;Acc:MGI:2442985]
106 Luzp1 -1.15 3.71E-03 -1.26 9.88E-05 Yes Yes




WT vs. KO I172M vs. KO Blakely Lab SIP Co-
IP Results for SERTs Gene NameMB HPC MB HPC
FC in KO P Adj FC in KO P Adj FC in KO P Adj FC in KO P Adj WT KO G56A
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107 Upf1 -1.11 4.02E-02 Yes Yes
UPF1 regulator of nonsense 
transcripts homolog (yeast) 
[Source:MGI 
Symbol;Acc:MGI:107995]
108 Slc32a1 1.30 4.26E-03 Yes Yes
solute carrier family 32 
(GABA vesicular transporter), 
member 1 [Source:MGI 
Symbol;Acc:MGI:1194488]
109 Cep170b -1.11 5.54E-03 Yes Yes
centrosomal protein 170B 
[Source:MGI 
Symbol;Acc:MGI:2145043]
110 Atp9a 1.19 2.07E-02 Yes Yes
ATPase, class II, type 9A 
[Source:MGI 
Symbol;Acc:MGI:1330826]
111 Mapre2 -1.09 3.57E-02 -1.09 2.01E-02 Yes Yes
microtubule-associated 
protein, RP/EB family, 
member 2 [Source:MGI 
Symbol;Acc:MGI:106271]
112 Mtch1 1.16 4.39E-02 Yes Yes
mitochondrial carrier 1 
[Source:MGI 
Symbol;Acc:MGI:1929261]
113 Tnk2 -1.12 1.06E-03 Yes Yes
tyrosine kinase, non-receptor, 
2 [Source:MGI 
Symbol;Acc:MGI:1858308]
114 Fbxo41 -1.14 2.88E-02 Yes Yes
F-box protein 41 
[Source:MGI 
Symbol;Acc:MGI:1261912]
115 Bckdha 1.27 1.61E-02 Yes Yes
branched chain ketoacid 
dehydrogenase E1, alpha 
polypeptide [Source:MGI 
Symbol;Acc:MGI:107701]
116 Calcoco1 -1.15 2.65E-02 Yes Yes
calcium binding and coiled 
coil domain 1 [Source:MGI 
Symbol;Acc:MGI:1914738]
117 Slc25a25 -1.11 2.50E-02 Yes Yes
solute carrier family 25 
(mitochondrial carrier, 
phosphate carrier), member 
25 [Source:MGI 
Symbol;Acc:MGI:1915913]
118 Actr2 1.10 3.58E-02 Yes Yes
ARP2 actin-related protein 2 
[Source:MGI 
Symbol;Acc:MGI:1913963]




120 Hip1 -1.16 1.15E-02 Yes Yes
huntingtin interacting protein 
1 [Source:MGI 
Symbol;Acc:MGI:1099804]
121 Sorbs1 -1.22 2.11E-06 -1.24 2.65E-06 Yes Yes
sorbin and SH3 domain 
containing 1 [Source:MGI 
Symbol;Acc:MGI:700014]
122 Acsl6 1.13 3.21E-02 Yes Yes
acyl-CoA synthetase long-
chain family member 6 
[Source:MGI 
Symbol;Acc:MGI:894291]
123 Slc25a11 1.23 6.36E-03 Yes Yes
solute carrier family 25 
(mitochondrial carrier 
oxoglutarate carrier), 
member 11 [Source:MGI 
Symbol;Acc:MGI:1915113]
124 Eef2 1.16 2.78E-02 Yes Yes
eukaryotic translation 
elongation factor 2 
[Source:MGI 
Symbol;Acc:MGI:95288]
125 Gdap1 -1.23 2.61E-03 Yes Yes
ganglioside-induced 
differentiation-associated-
protein 1 [Source:MGI 
Symbol;Acc:MGI:1338002]
126 Map3k13 -1.20 2.83E-02 -1.20 1.80E-02 Yes Yes
mitogen-activated protein 
kinase kinase kinase 13 
[Source:MGI 
Symbol;Acc:MGI:2444243]
127 Homer3 -1.18 1.36E-02 Yes
homer scaffolding protein 3 
[Source:MGI 
Symbol;Acc:MGI:1347359]
128 Arhgap42 -1.28 9.81E-03 -1.21 2.97E-02 Yes
Rho GTPase activating 
protein 42 [Source:MGI 
Symbol;Acc:MGI:1918794]
129 Gstp1 1.28 1.06E-03 Yes
glutathione S-transferase, pi 
1 [Source:MGI 
Symbol;Acc:MGI:95865]
130 Hspa5 -1.30 4.71E-02 -1.26 4.01E-02 Yes
heat shock protein 5 
[Source:MGI 
Symbol;Acc:MGI:95835]
131 Prdx3 -1.29 9.32E-05 Yes peroxiredoxin 3 [Source:MGI Symbol;Acc:MGI:88034]
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protein, eta polypeptide 
[Source:MGI 
Symbol;Acc:MGI:109194]
133 Ralgapb -1.14 2.59E-02 -1.18 9.22E-04 -1.13 2.51E-02 Yes
Ral GTPase activating 
protein, beta subunit (non-
catalytic) [Source:MGI 
Symbol;Acc:MGI:2444531]
134 Prpf4b -1.22 9.30E-03 Yes
pre-mRNA processing factor 
4B [Source:MGI 
Symbol;Acc:MGI:109584]
135 Psd 1.33 7.96E-04 Yes
pleckstrin and Sec7 domain 
containing [Source:MGI 
Symbol;Acc:MGI:1920978]
136 Kcnn2 -1.16 2.81E-02 -1.19 2.59E-03 Yes
potassium intermediate/small 
conductance calcium-
activated channel, subfamily 
N, member 2 [Source:MGI 
Symbol;Acc:MGI:2153182]
* mRNA transcripts of Slc6a4 in the KO are truncated and lacks transcription of exon 2 containing the ATG start codon required for protein translation. Highlighted in RED: KO MB FC and P-adj values do not represent the 
true magnitude of SERT dysregulation (i.e. the absence of functional SERT). Highlighted in GREEN: KO HPC FC and P-adj values represent highly expressed ectopic trunc-mRNA Slc6a4 transcripts, likely resulting in 
aggregation of mis-folded SERTs.
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